



Registration of a Charge

Company Name: **JAZZ PHARMACEUTICALS RESEARCH UK LIMITED**

Company Number: **03107561**



Received for filing in Electronic Format on the: **23/01/2024**

XCVAQIU9

Details of Charge

Date of creation: **19/01/2024**

Charge code: **0310 7561 0003**

Persons entitled: **U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION AS COLLATERAL TRUSTEE**

Brief description: **UK PATENT REGISTRATION NUMBER GB2414933, UK PATENT REGISTRATION NUMBER GB2588457 AND THOSE ASSETS LISTED IN SCHEDULE 2 OF THIS INSTRUMENT. FOR MORE DETAILS, PLEASE REFER TO THE INSTRUMENT.**

Contains fixed charge(s).

Contains floating charge(s) (floating charge covers all the property or undertaking of the company).

Contains negative pledge.

Authentication of Form

This form was authorised by: **a person with an interest in the registration of the charge.**

Authentication of Instrument

Certification statement: **I CERTIFY THAT, SAVE FOR MATERIAL REDACTED PURSUANT TO S. 859G OF THE COMPANIES ACT 2006, THE ELECTRONIC COPY INSTRUMENT DELIVERED AS PART OF THIS APPLICATION**

**FOR REGISTRATION IS A CORRECT COPY OF THE ORIGINAL
INSTRUMENT.**

Certified by:

CAHILL GORDON & REINDEL (UK) LLP



CERTIFICATE OF THE REGISTRATION OF A CHARGE

Company number: 3107561

Charge code: 0310 7561 0003

The Registrar of Companies for England and Wales hereby certifies that a charge dated 19th January 2024 and created by JAZZ PHARMACEUTICALS RESEARCH UK LIMITED was delivered pursuant to Chapter A1 Part 25 of the Companies Act 2006 on 23rd January 2024 .

Given at Companies House, Cardiff on 24th January 2024

The above information was communicated by electronic means and authenticated by the Registrar of Companies under section 1115 of the Companies Act 2006



Companies House



**THE OFFICIAL SEAL OF THE
REGISTRAR OF COMPANIES**

ENGLISH CONFIRMATORY SECURITY AGREEMENT

19 January 2024

THE COMPANIES LISTED IN SCHEDULE 1
as Chargors

and

U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S.
BANK NATIONAL ASSOCIATION
as Collateral Trustee

relating to
an English law security agreement dated 5 May 2021
and
an English law accession deed dated 21 July 2021

This Deed is entered into subject to
the terms of the Collateral Trust Agreement

Cahill

Cahill Gordon & Reindel (UK) LLP

CONTENTS

| Clause | Page |
|---|----------|
| 1. INTERPRETATION..... | 2 |
| 2. CREATION OF SECURITY..... | 2 |
| 3. RESTRICTIONS ON DEALINGS..... | 6 |
| 4. INCORPORATION..... | 6 |
| 5. CONFIRMATION..... | 6 |
| 6. GOVERNING LAW..... | 6 |
| 7. JURISDICTION | 6 |
| SCHEDULE 1 CHARGORS | 8 |
| SCHEDULE 2 SECURITY ASSETS | 9 |
| Signatories | 17 |

THIS DEED is dated 19 January 2024 and is made

BETWEEN:

- (1) **THE COMPANIES LISTED IN SCHEDULE 1** (each a “Chargor” and together, the “Chargors”); and
- (2) **U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION** as collateral trustee for the Secured Parties (the “Collateral Trustee”).

BACKGROUND:

- (A) We refer to the credit agreement dated 5 May 2021, between, among others, Jazz Pharmaceuticals Public Limited Company as the Parent and an Irish Borrower, Jazz Pharmaceuticals UK Holdings Limited as a UK Borrower, Bank of America, N.A. as Administrative Agent, U.S. Bank Trust Company, National Association, as successor to U.S. Bank National Association, as Collateral Trustee and other parties from time to time party thereto (the “Credit Agreement”).
- (B) Pursuant to an English law security agreement dated 5 May 2021 between, among others, the Original Chargor as defined therein and listed in Schedule 1 beneath the heading “Chargors” (the “Original Chargor”) and the Collateral Trustee (the “Original Security Agreement”), the Original Chargor created Security over certain of its respective assets as security for, among other things, payment of all the Obligations (as defined below).
- (C) Pursuant to an accession deed dated 21 July 2021 between, among others, the Additional Chargors as defined therein and listed in Schedule 1 beneath the heading “Chargors” (the “Additional Chargors”) and the Collateral Trustee (the “Security Accession Deed”, and together with the Original Security Agreement, the “Security Agreements”), each Additional Chargor acceded to the Original Security Agreement and created Security over certain of its respective assets as security for, among other things, payment of all the Obligations (as defined below).
- (D) On or about the date of this Deed, an amendment no. 1 (“Amendment Agreement (No. 1)”) in respect of the Credit Agreement (as amended by Amendment Agreement (No. 1), the “Amended Credit Agreement”) has been entered into between, among others, Jazz Pharmaceuticals Public Limited Company as the Parent, Jazz Pharmaceuticals UK Holdings Limited as a UK Borrower, the Additional Tranche B-1 Dollar Term Lender (as defined in the Amended Credit Agreement), Bank of America, N.A. as Administrative Agent and U.S. Bank Trust Company, National Association, as successor to U.S. Bank National Association as Collateral Trustee in connection with, amongst other things, the refinancing in full of the Initial Dollar Term Loans (as defined in the Amended Credit Agreement) with new Tranche B-1 Dollar Term Loans (as defined in the Amended Credit Agreement) pursuant to the terms of the Amended Credit Agreement.
- (E) The Chargors and the Collateral Trustee consider that the Security created by the Chargors under each Security Agreement secures payment of the Obligations (as defined below), but enter into this Deed in case they do not.
- (F) This Deed is supplemental to the Security Agreements.
- (G) It is intended that this document takes effect as a deed notwithstanding the fact that a party may only execute this document under hand.

IT IS AGREED as follows:

1. INTERPRETATION

- (a) In this Deed, “Obligations” has the meaning given to the term “Senior Lien Obligations” in the Collateral Trust Agreement, including as modified by Amendment Agreement (No. 1) and those obligations and liabilities arising under and in relation to the Tranche B-1 Dollar Term Loans (as defined in the Amended Credit Agreement).
- (b) Capitalised terms defined in or incorporated by reference to the Original Security Agreement or Security Accession Deed (whether directly or by reference to the Credit Agreement or Collateral Trust Agreement) have, unless expressly defined in this Deed, the same meaning in this Deed.
- (c) The provisions of clause 1 (*Interpretation*) of the Original Security Agreement apply to this Deed as though they were set out in full in this Deed except that references to the Original Security Agreement will be construed as references to this Deed and references therein and in this Deed to the Credit Agreement shall be deemed to be references to the Amended Credit Agreement.

1.2 Third party rights

A person who is not a party to this Deed has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce or to enjoy the benefit of any term of this Deed.

1.3 Loan Document

This Deed is a Loan Document.

2. CREATION OF SECURITY

2.1 General

- (a) All the security created under this Deed:
 - (i) is created in favour of the Collateral Trustee;
 - (ii) is created over present and future assets of each Chargor;
 - (iii) is security for the payment, discharge and performance of all the Obligations; and
 - (iv) is made with full title guarantee in accordance with the Law of Property (Miscellaneous Provisions) Act 1994.
- (b) The Collateral Trustee holds the benefit of this Deed on trust for the Secured Parties.
- (c) All the security created under this Deed:
 - (i) is created in case the security created by each Security Agreement does not secure all of the Obligations; and
 - (ii) is created in addition to and does not affect the security created by the Security Agreements.
- (d) Where this Deed purports to create a first fixed Security, that Security will be a second ranking Security ranking subject to the equivalent Security created by the Security Agreements until such time as the Security created by the Security Agreements ceases

to have effect.

- (e) Where a right or asset has been assigned (subject to a proviso for re-assignment on redemption) under the Security Agreements and the same asset or right is purported to be assigned (subject to a proviso for re-assignment on redemption) again under this Deed, that second assignment will take effect as a fixed charge over that right or asset and will only take effect as an assignment if the relevant Security created by the Security Agreements ceases to have effect at a time when this Deed still has effect.
- (f) It is agreed and acknowledged that the security created or purported to be created pursuant to this Deed shall be supplemental and without prejudice to the security created or purported to be created pursuant to the Security Agreements and accordingly such security created or purported to be created pursuant to the Security Agreements shall remain in full force and effect.
- (g) Notwithstanding any other provisions of this Deed, the terms, rights, obligations and security interests created or purported to be created pursuant to this Deed shall at all times be subject to the terms and security interests created by the Security Agreements until such time as the security interests created by or pursuant to the Security Agreements have no, or cease to have, effect and no default or event of default (howsoever defined) under the Senior Lien Documents (as defined in the Collateral Trust Agreement) shall result solely from the execution of this Deed or from the existence of the Deed at the same time as the Security Agreements and such terms of this Deed shall be construed accordingly.
- (h) Where in circumstances where the security interests constituted by the Security Agreements remains in full force and effect, any reference in this Deed to an asset secured under the Security Agreements being assigned or the security over any asset secured under the Security Agreements being first ranking or secured with full title guarantee, shall be construed accordingly.
- (i) If the Chargor is in compliance with the terms of the Security Agreements (including without limitation, any obligation to deliver or deposit any deeds document of title, certificates, evidence of ownership or related documentation) then to the extent that the terms of this Deed are the same and apply in respect of the same assets, then the Chargor will be deemed to have complied with the respective terms of this Deed.
- (j) Notwithstanding that the Security created by this Deed will be second ranking Security subject to the Security created by the Security Agreements until such time as the Security created by the Security Agreements ceases to have effect, all amounts received or recovered by the Collateral Trustee or any Receiver pursuant to this Deed shall (subject to the claims of any person having prior rights thereto) be applied in the order and manner specified by section 3.4 (*Application of Proceeds*) of the Collateral Trust Agreement notwithstanding any purported appropriation by any Chargor.

2.2 Covenant to Pay

Each Chargor, as a principal obligor and not merely as a surety, covenants with the Collateral Trustee (as Collateral Trustee for itself and on behalf of the other Secured Parties) that it shall on demand of the Collateral Trustee pay or discharge each of the Obligations when they fall due in the manner provided for in the Senior Lien Documents.

2.3 Fixed Security

Each Chargor, as continuing security for the full payment of the Obligations, charges in favour of the Collateral Trustee (for itself and on behalf of the Secured Parties) with full title guarantee the following assets, both present and future, from time to time owned by it or in which it has

an interest:

- (a) by way of first legal mortgage all Real Property in England or Wales now belonging to or vested in it;
- (b) by way of first fixed charge:
 - (i) all its Shares and all corresponding Related Rights;
 - (ii) (to the extent that they are not the subject of a mortgage under paragraph (a) above) Real Property in England or Wales now belonging to or vested in it;
 - (iii) all of its rights in respect of any Account, any amount standing to the credit of any Account and the debt represented by it;
 - (iv) (to the extent that they are not the subject of an assignment under paragraph (a) of Clause 2.4 (*Security Assignment*) below) all Receivables and Insurance Policies and, in each case, all rights and claims against third parties or the relevant member of the Group in respect thereof;
 - (v) all of its rights in respect of any Intellectual Property;
 - (vi) all amounts payable to it under or in connection with each of its Insurances Policies and all of its rights and claims in connection with those amounts (other than all amounts received or receivable under or in connection with any third party liability insurance and required to settle a liability of an Obligor to a third party);
 - (vii) all Tangible Moveable Property owned by it and its interest in any Tangible Moveable Property in its possession; and
 - (viii) its goodwill and uncalled capital.

2.4 Security Assignment

- (a) Each Chargor assigns absolutely, subject to a proviso for reassignment on redemption, with full title guarantee to the Collateral Trustee (for itself and on behalf of the Secured Parties) as security for the payment and discharge of the Obligations all of its right, title and interests from time to time and to the proceeds of:
 - (i) the Receivables; and
 - (ii) the Insurance Policies.
- (b) To the extent that any right described in paragraph (a) above is not assignable or capable of assignment, the assignment of that right purported to be effected by paragraph (a) shall operate as an assignment of any damages, compensation, remuneration, profit, rent or income which that Chargor may derive from that right or be awarded or entitled to in respect of that right.

2.5 Floating Charge

- (a) Each Chargor charges by way of a first floating charge all of its present and future assets, undertakings and rights whatsoever and wheresoever not otherwise effectively mortgaged, charged or assigned under this Deed.

- (b) Except as provided below, the Collateral Trustee may by written notice to a Chargor convert the floating charge created by that Chargor under this Deed into a fixed charge as regards any of that Chargor's assets specified in that notice if:
 - (i) an Enforcement Event is continuing; or
 - (ii) the Collateral Trustee considers (acting reasonably) those assets to be in danger of being seized or sold under any form of distress, attachment, execution or other legal process or to be otherwise in jeopardy.
- (c) The floating charge created under this Deed may not be converted into a fixed charge solely by reason of:
 - (i) the obtaining of a moratorium; or
 - (ii) anything done with a view to obtaining a moratorium,under section 1A to the Insolvency Act 1986.
- (d) The floating charge created under this Deed will (in addition to the circumstances in which the same will occur under general law) automatically convert into a fixed charge over all of a Chargor's assets:
 - (i) if an administrator is appointed or the Collateral Trustee receives notice of an intention to appoint an administrator in respect of that Chargor; or
 - (ii) on the convening of any meeting of the members of that Chargor to consider a resolution to wind that Chargor up (or not to wind that Chargor up);
 - (iii) if in respect of that Chargor, a resolution is passed or any order is made in England and Wales for the winding-up, dissolution, administration or re-organisation of that Chargor;
 - (iv) any person levies or attempts to levy any distress, execution or other legal process against any of the assets of that Chargor subject to the floating charge (provided that only the assets the subject of such process shall become subject to a fixed charge); or
 - (v) if that Chargor is, or is deemed to be or is declared for the purposes of any applicable law to be, unable or admits inability to pay its debts as they fall due, suspends making payments on any of its debts or, by reason of actual or anticipated financial difficulties, commences negotiations with its creditors generally or any class of them (other than the Secured Parties) for the rescheduling of any of its financial indebtedness.
- (e) The floating charge created under this Deed is a **qualifying floating charge** for the purpose of paragraph 14 of Schedule B1 to the Insolvency Act 1986.
- (f) The giving by the Collateral Trustee of a notice under paragraph (b) above in relation to any asset of a Chargor will not be construed as a waiver or abandonment of the Collateral Trustee's rights to give any other notice in respect of any other asset or of any other right of any other Secured Parties under this Deed or any other Senior Lien Document.

3. RESTRICTIONS ON DEALINGS

No Chargor may during the Security Period:

- (a) create or agree to create or permit or allow to exist any Security or Quasi-Security over all or any part of the Security Assets; or
- (b) either in a single transaction or in a series of transactions and whether related or not and whether voluntarily or involuntarily sell, transfer, licence or lease or otherwise dispose of all or any part of its assets or the right to receive or to be paid the proceeds arising on disposal of the same; or agree or attempt to do so,

unless permitted or not prohibited under the Senior Lien Documents.

4. INCORPORATION

- (a) The provisions of clause 5 (*Representations and Undertakings*) to clause 20 (*Failure to Execute*) (inclusive) of the Original Security Agreement are deemed to be incorporated into this Deed with all necessary modifications as if they were set out in full in this Deed (including references to the Original Security Agreement shall be deemed to be references to this Deed and references to the Credit Agreement shall be deemed to be references to the Amended Credit Agreement).
- (b) Each Chargor shall procure that each member of the Group which accedes to the Original Security Agreement shall, substantially simultaneously with any such accession, also accede to this Deed by delivering a duly executed and completed deed of accession to the Collateral Trustee substantially in the form set out in schedule 5 (Form of Security Accession Deed) to the Original Security Agreement.

5. CONFIRMATION

Each Chargor acknowledges and agrees:

- (a) that the Security Agreements secured the payment, discharge and performance of the Obligations including, without limitation, the "Obligations" as defined under the Amended Credit Agreement as amended, varied, novated, supplemented, extended, restated (however fundamental and whether or not more onerous) or replaced including, without limitation, any change in the purpose of, any extension of, or increase in any facility or the addition of any new facility under any Senior Lien Documents, Senior Lien Security Document (as defined in the Collateral Trust Agreement) or other document or security from time to time; and
- (b) that the Security Agreements continue to have full force and effect in accordance with its respective terms and to secure the payment, discharge and performance of the Obligations including, without limitation, the "Obligations" as defined under the Amended Credit Agreement in favour of the applicable Secured Parties on the terms set out therein.

6. GOVERNING LAW

This Deed and any non-contractual obligations arising out of or in connection with it are governed by English law.

7. JURISDICTION

- (a) The courts of England have exclusive jurisdiction to settle any dispute including a dispute relating to non-contractual obligations arising out of or in connection with this

Deed (including a dispute regarding the existence, validity or termination of this Deed) (a “Dispute”).

- (b) The Parties agree that the courts of England are the most appropriate and convenient courts to settle Disputes and accordingly no Party will argue to the contrary.
- (c) This Clause 7 is for the benefit of the Secured Parties only. As a result, no Secured Party shall be prevented from taking proceedings relating to a Dispute in any other courts with jurisdiction. To the extent allowed by law, the Secured Parties may take concurrent proceedings in any number of jurisdictions.

THIS DEED has been entered into as a deed on the date stated at the beginning of this Deed.

SCHEDULE 1

CHARGORS

| Name of Chargor | Jurisdiction | Registration Number |
|--|-----------------|---------------------|
| Jazz Pharmaceuticals UK Holdings Limited | England & Wales | 13150429 |
| GW Pharmaceuticals Limited | England & Wales | 04160917 |
| GW Global Services (International) Limited | England & Wales | 12286307 |
| GW Pharma Limited | England & Wales | 03704998 |
| Jazz Pharmaceuticals Research UK Limited (formerly known as GW Research Limited) | England & Wales | 03107561 |
| GW UK Services Limited | England & Wales | 04383125 |

SCHEDULE 2**SECURITY ASSETS****PART 1****SHARES**

| Chargor | Name of company in which shares are held | Class of shares held | Number of shares held |
|--|--|-----------------------------|------------------------------|
| GW Pharmaceuticals Limited | GW Global Services (International) Limited | Ordinary shares | 100 |
| GW Pharmaceuticals Limited | GW Pharma Limited | Ordinary shares | 1 |
| GW Pharmaceuticals Limited | Jazz Pharmaceuticals Research UK Limited (formerly known as GW Research Limited) | Ordinary shares | 1 |
| GW Pharma Limited | GW UK Services Limited | Ordinary shares | 2 |
| Jazz Pharmaceuticals UK Holdings Limited | GW Pharmaceuticals Limited | Ordinary shares | 2 |

PART 2

DEPOSITARY RECEIPTS

None at the date of this deed.

PART 3

ACCOUNTS

| Chargor | Account Bank name and address | Account number | IBAN | Swift Code |
|--|--|----------------|-----------------|------------|
| Jazz Pharmaceuticals UK Holdings Limited | JPMorgan Chase Bank, N.A. – London Branch | ██████████1435 | ██████████1435 | CHASGB2L |
| GW Pharmaceuticals Limited | JPMorgan Chase Bank, N.A. – London branch | ██████████7708 | ██████████7708 | CHASGB2L |
| GW UK Services Limited | JPMorgan Chase Bank, N.A. – London branch | ██████████7924 | ██████████7924 | CHASGB2L |
| Jazz Pharmaceuticals Research UK Limited (formerly known as GW Research Limited) | JP Morgan Chase Bank, N.A. - London branch | ██████████7698 | ██████████7698 | CHASGB2L |
| | | ██████████7697 | ██████████7697 | CHASGB2L |
| | | ██████████7700 | ██████████7700 | CHASGB2L |
| GW Pharma Limited | HSBC Bank UK plc | ██████████5354 | ██████████53 54 | HBUKGB4B |
| | JP Morgan Chase Bank, N.A. - London branch | ██████████7701 | ██████████7701 | CHASGB2L |
| | | ██████████7702 | ██████████7702 | CHASGB2L |
| | | ██████████7704 | ██████████7704 | CHASGB2L |

PART 4

REAL PROPERTY

None at the date of this Deed.

PART 5

INTELLECTUAL PROPERTY

| OWNER | MARK | COUNTRY | STATUS | APPLICATION # | FILING DATE | REGISTRATION # | REGISTRATION DATE |
|-------------------|---------------------------------|---------|------------|---------------|-------------|----------------|-------------------|
| GW Pharma Limited | CANNGESIC | EM | Registered | 003477312 | 10/30/03 | 003477312 | 3/22/05 |
| GW Pharma Limited | CANNGESIC | GB | Registered | UK00903477312 | 10/30/03 | UK00903477312 | 3/22/05 |
| GW Pharma Limited | CEBEDEX | GB | Registered | UK00003009946 | 6/13/13 | UK00003009946 | 9/20/13 |
| GW Pharma Limited | EPIDIALOGUES | US | Allowed | 97921219 | 5/4/23 | | |
| GW Pharma Limited | EPIDIALOGUES | US | Registered | 97920978 | 5/4/23 | 7249414 | 12/19/23 |
| GW Pharma Limited | EPIDIALOGUES & Design | US | Allowed | 97921247 | 5/4/23 | | |
| GW Pharma Limited | EPIDIALOGUES & Design | US | Registered | 97921166 | 5/4/23 | 7249415 | 12/19/23 |
| GW Pharma Limited | GREENWICH | GB | Registered | UK00003272959 | 11/24/17 | UK00003272959 | 4/6/18 |
| GW Pharma Limited | GREENWICH | GB | Registered | UK00801414068 | 4/24/18 | UK00801414068 | 4/5/19 |
| GW Pharma Limited | GREENWICH | IB | Registered | 1414068 | 4/24/18 | 1414068 | 4/24/18 |
| GW Pharma Limited | GREENWICH ANIMAL HEALTH | GB | Registered | UK00003272956 | 11/24/17 | UK00003272956 | 4/6/18 |
| GW Pharma Limited | GREENWICH ANIMAL HEALTH | GB | Registered | UK00801415188 | 4/24/18 | UK00801415188 | 4/3/19 |
| GW Pharma Limited | GREENWICH ANIMAL HEALTH | IB | Registered | 1415188 | 4/24/18 | 1415188 | 4/24/18 |
| GW Pharma Limited | GREENWICH BIOSCIENCES | EM | Registered | 016140791 | 12/7/16 | 016140791 | 4/7/17 |
| GW Pharma Limited | GREENWICH BIOSCIENCES | GB | Registered | UK00916140791 | 12/7/16 | UK00916140791 | 4/7/17 |
| GW Pharma Limited | GREENWICH BIOSCIENCES | US | Registered | 87050601 | 5/26/16 | 5598310 | 11/6/18 |
| GW Pharma Limited | GREENWICH BIOSCIENCES | US | Registered | 87977676 | 5/26/16 | 5682224 | 2/19/19 |
| GW Pharma Limited | GREENWICH BIOSCIENCES | US | Registered | 87979127 | 5/26/16 | 5651696 | 1/8/19 |
| GW Pharma Limited | GREENWICH BOTANICALS | GB | Registered | UK00003272954 | 11/24/17 | UK00003272954 | 4/6/18 |
| GW Pharma Limited | GREENWICH BOTANICALS | GB | Registered | UK00801413521 | 4/24/18 | UK00801413521 | 5/8/19 |
| GW Pharma Limited | GREENWICH BOTANICALS | IB | Registered | 1413521 | 4/24/18 | 1413521 | 4/24/18 |
| GW Pharma Limited | GREENWICH in Chinese characters | CN | Registered | 48450780 | 7/28/20 | 48450780 | 4/7/21 |
| GW Pharma Limited | GREENWICH in Chinese characters | CN | Registered | 48472462 | 7/28/20 | 48472462 | 3/21/21 |
| GW Pharma Limited | GW ANIMAL HEALTH | GB | Registered | UK00003272953 | 11/24/17 | UK00003272953 | 3/23/18 |
| GW Pharma Limited | GW ANIMAL HEALTH | GB | Registered | UK00801419348 | 4/24/18 | UK00801419348 | 1/25/19 |
| GW Pharma Limited | GW ANIMAL HEALTH | IB | Registered | 1419348 | 4/24/18 | 1419348 | 4/24/18 |
| GW Pharma Limited | GW BOTANICALS | GB | Registered | UK00003272949 | 11/24/17 | UK00003272949 | 2/23/18 |
| GW Pharma Limited | GW BOTANICALS | GB | Registered | UK00801414095 | 4/24/18 | UK00801414095 | 12/21/18 |
| GW Pharma Limited | GW BOTANICALS | IB | Registered | 1414095 | 4/24/18 | 1414095 | 4/24/18 |
| GW Pharma Limited | GW PHARMA | AU | Registered | 1830933 | 3/9/17 | 1830933 | 3/9/17 |
| GW Pharma Limited | GW PHARMA | CA | Registered | 1826311 | 3/8/17 | 1086976 | 11/4/20 |
| GW Pharma Limited | GW PHARMA | CH | Registered | 10710/2020 | 7/30/20 | 776810 | 2/18/22 |
| GW Pharma Limited | GW PHARMA | EM | Registered | 016448201 | 3/8/17 | 016448201 | 6/30/17 |
| GW Pharma Limited | GW PHARMA | GB | Registered | UK00003573451 | 12/30/20 | UK00003573451 | 5/7/21 |
| GW Pharma Limited | GW PHARMA | GB | Registered | UK00916448201 | 3/8/17 | UK00916448201 | 6/30/17 |
| GW Pharma Limited | GW PHARMA | HK | Registered | 305347233 | 7/30/20 | 305347233 | 7/30/20 |
| GW Pharma Limited | GW PHARMA | IB | Registered | 1594926 | 1/29/21 | 1594926 | 1/29/21 |
| GW Pharma Limited | GW PHARMA | NO | Registered | 202009637 | 7/30/20 | 315691 | 5/21/21 |
| GW Pharma Limited | GW PHARMA | RS | Registered | 2020/1284 | 7/30/20 | 79799 | 2/19/21 |

| | | | | | | | |
|-------------------|---------------------------------------|----|------------|---------------|----------|---------------|----------|
| GW Pharma Limited | GW PHARMA | SG | Registered | 40202016090Y | 8/3/20 | 40202016090Y | 2/17/23 |
| GW Pharma Limited | GW PHARMA | TW | Registered | 110001705 | 1/8/21 | 02194722 | 1/1/22 |
| GW Pharma Limited | GW PHARMACEUTICALS | AE | Registered | 305768 | 2/5/19 | 305768 | 5/23/19 |
| GW Pharma Limited | GW PHARMACEUTICALS | AE | Registered | 305769 | 2/5/19 | 305769 | 5/23/19 |
| GW Pharma Limited | GW PHARMACEUTICALS | AR | Registered | 3761016 | 11/26/18 | 3071920 | 4/24/20 |
| GW Pharma Limited | GW PHARMACEUTICALS | AR | Registered | 3761017 | 11/26/18 | 3071921 | 4/24/20 |
| GW Pharma Limited | GW PHARMACEUTICALS | BR | Published | 916329380 | 11/28/18 | | |
| GW Pharma Limited | GW PHARMACEUTICALS | BR | Registered | 916329356 | 11/28/18 | 916329356 | 8/20/19 |
| GW Pharma Limited | GW PHARMACEUTICALS | CA | Registered | 1936407 | 12/17/18 | 1142330 | 9/20/22 |
| GW Pharma Limited | GW PHARMACEUTICALS | CH | Registered | 10707/2020 | 7/30/20 | 776806 | 2/18/22 |
| GW Pharma Limited | GW PHARMACEUTICALS | CL | Registered | 1312256 | 1/16/19 | 1316036 | 2/5/20 |
| GW Pharma Limited | GW PHARMACEUTICALS | CN | Registered | 37771593 | 4/25/19 | 37771593 | 6/14/22 |
| GW Pharma Limited | GW PHARMACEUTICALS | CN | Registered | 46083326 | 5/7/20 | 46083326 | 8/14/22 |
| GW Pharma Limited | GW PHARMACEUTICALS | GB | Registered | UK00003355223 | 11/21/18 | UK00003355223 | 2/8/19 |
| GW Pharma Limited | GW PHARMACEUTICALS | GB | Registered | UK00003573453 | 12/30/20 | UK00003573453 | 6/11/21 |
| GW Pharma Limited | GW PHARMACEUTICALS | GB | Registered | UK00801459268 | 2/28/19 | UK00801459268 | 9/10/19 |
| GW Pharma Limited | GW PHARMACEUTICALS | HK | Registered | 305347224 | 7/30/20 | 305347224 | 7/30/20 |
| GW Pharma Limited | GW PHARMACEUTICALS | IB | Registered | 1459268 | 2/28/19 | 1459268 | 2/28/19 |
| GW Pharma Limited | GW PHARMACEUTICALS | IB | Registered | 1593385 | 1/29/21 | 1593385 | 1/29/21 |
| GW Pharma Limited | GW PHARMACEUTICALS | NO | Registered | 202009635 | 7/30/20 | 315690 | 5/21/21 |
| GW Pharma Limited | GW PHARMACEUTICALS | RS | Registered | 2020/1283 | 7/30/20 | 79859 | 2/25/21 |
| GW Pharma Limited | GW PHARMACEUTICALS | SA | Registered | 170853 | 1/15/19 | 1440011920 | 1/15/19 |
| GW Pharma Limited | GW PHARMACEUTICALS | SA | Registered | 170855 | 1/15/19 | 1440011922 | 1/15/19 |
| GW Pharma Limited | GW PHARMACEUTICALS | SG | Registered | 40202016089W | 8/3/20 | 40202016089W | 8/3/22 |
| GW Pharma Limited | GW PHARMACEUTICALS | TW | Registered | 107083126 | 12/24/18 | 2015336 | 10/1/19 |
| GW Pharma Limited | GW PHARMACEUTICALS | TW | Registered | 110002772 | 1/14/21 | 02191326 | 12/16/21 |
| GW Pharma Limited | GW PHARMACEUTICALS | ZA | Registered | 2018/35259 | 11/26/18 | 201835259 | 6/21/22 |
| GW Pharma Limited | GW PHARMACEUTICALS | ZA | Registered | 2018/35260 | 11/26/18 | 201835260 | 6/21/22 |
| GW Pharma Limited | GW PHARMACEUTICALS & Design | US | Registered | 78354188 | 1/20/04 | 3910241 | 1/25/11 |
| GW Pharma Limited | GW PHARMACEUTICALS (CL 31) (47961741) | CN | Pending | 47961741 | 7/9/20 | | |
| GW Pharma Limited | GW PHARMACEUTICALS (CL 31) (56431404) | CN | Pending | 56431404 | 5/27/21 | | |
| GW Pharma Limited | GW Pharmaceuticals (Stylised) | AE | Registered | 305766 | 2/5/19 | 305766 | 5/23/19 |
| GW Pharma Limited | GW Pharmaceuticals (Stylised) | AE | Registered | 305767 | 2/5/19 | 305767 | 5/23/19 |
| GW Pharma Limited | GW Pharmaceuticals (Stylised) | AR | Registered | 3761014 | 11/26/18 | 3079709 | 5/22/20 |
| GW Pharma Limited | GW Pharmaceuticals (Stylised) | AR | Registered | 3761015 | 11/26/18 | 3071919 | 4/24/20 |
| GW Pharma Limited | GW Pharmaceuticals (Stylised) | CL | Registered | 1312260 | 1/16/19 | 1312230 | 12/17/19 |

| | | | | | | |
|-------------------|--|------------|-----------------|----------|---------------|----------|
| GW Pharma Limited | GW Pharmaceuticals (stylised) EM | Registered | 003477544 | 10/30/03 | 003477544 | 8/16/05 |
| GW Pharma Limited | GW Pharmaceuticals (Stylised) GB | Registered | UK00003355228 | 11/21/18 | UK00003355228 | 2/8/19 |
| GW Pharma Limited | GW Pharmaceuticals (stylised) GB | Registered | UK00903477544 | 10/30/03 | UK00903477544 | 8/16/05 |
| GW Pharma Limited | GW PHARMACEUTICALS HK (stylised) | Registered | 305347251 | 7/30/20 | 305347251 | 7/30/20 |
| GW Pharma Limited | GW Pharmaceuticals (Stylised) IB | Registered | 1462420 | 2/28/19 | 1462420 | 2/28/19 |
| GW Pharma Limited | GW Pharmaceuticals (stylised) IN | Registered | 1262692 | 1/22/04 | 1262692 | 1/22/04 |
| GW Pharma Limited | GW PHARMACEUTICALS NO (stylised) | Registered | 202009639 | 7/30/20 | 315694 | 5/21/21 |
| GW Pharma Limited | GW Pharmaceuticals (stylised) NZ | Registered | 707134 | 1/21/04 | 707134 | 7/22/04 |
| GW Pharma Limited | GW PHARMACEUTICALS RS (stylised) | Registered | 2020/1286 | 7/30/20 | 79801 | 2/19/21 |
| GW Pharma Limited | GW Pharmaceuticals (Stylised) SA | Registered | 170899 | 1/15/19 | 1440011966 | 1/16/19 |
| GW Pharma Limited | GW Pharmaceuticals (Stylised) SA | Registered | 170901 | 1/15/19 | 1440011968 | 1/16/19 |
| GW Pharma Limited | GW Pharmaceuticals (Stylised) TW | Registered | 107083125 | 12/24/18 | 2015335 | 10/1/19 |
| GW Pharma Limited | GW PHARMACEUTICALS (Stylized) BR | Published | 916329330 | 11/28/18 | | |
| GW Pharma Limited | GW PHARMACEUTICALS (Stylized) BR | Registered | 916329313 | 11/28/18 | 916329313 | 8/20/19 |
| GW Pharma Limited | GW PHARMACEUTICALS (Stylized) CH | Registered | 10716/2020 | 7/30/20 | 776808 | 2/18/22 |
| GW Pharma Limited | GW PHARMACEUTICALS (Stylized) CN | Registered | 37771591 | 4/25/19 | 37771591 | 6/14/22 |
| GW Pharma Limited | GW PHARMACEUTICALS (Stylized) KR | Published | 40-2022-0143115 | 8/2/22 | | |
| GW Pharma Limited | GW PHARMACEUTICALS (Stylized) SG | Registered | 40202016091T | 8/3/20 | 40202016091T | 12/14/23 |
| GW Pharma Limited | GW PHARMACEUTICALS (Stylized) & Design ZA | Registered | 2018/35258 | 11/26/18 | 201835258 | 6/21/22 |
| GW Pharma Limited | GW PHARMACEUTICALS (Stylized) & Design CA | Registered | 1936408 | 12/17/18 | 1142335 | 9/20/22 |
| GW Pharma Limited | GW PHARMACEUTICALS (Stylized) & Design ZA | Registered | 2018/35257 | 11/26/18 | 201835257 | 6/21/22 |
| GW Pharma Limited | GW PHARMACEUTICALS (Stylized) & Design (46069688) CN | Pending | 46069688 | 5/7/20 | | |

| | | | | | | | |
|-------------------|---|----|------------|---------------|----------|---------------|----------|
| GW Pharma Limited | GW PHARMACEUTICALS (Stylized) & Design (53412434) – China | CN | Registered | 53412434 | 1/29/21 | 53412434 | 8/14/22 |
| GW Pharma Limited | GW PHARMACEUTICALS (Stylized) & Design (CL 31) – China | CN | Pending | 47959707 | 7/9/20 | | |
| GW Pharma Limited | GW PHARMACEUTICALS in Chinese characters | CN | Registered | 48450798 | 7/28/20 | 48450798 | 4/7/21 |
| GW Pharma Limited | GW PHARMACEUTICALS in Chinese characters | CN | Registered | 48472469 | 7/28/20 | 48472469 | 3/14/21 |
| GW Pharma Limited | GWICH BIO | BX | Registered | 1402024 | 9/11/19 | 1402024 | 9/12/19 |
| GW Pharma Limited | GWP | GB | Registered | UK00801220878 | 6/25/14 | UK00801220878 | 9/1/15 |
| GW Pharma Limited | GWP | IB | Registered | 1220878 | 6/25/14 | 1220878 | 6/25/14 |
| GW Pharma Limited | GWPCARE | EM | Registered | 013172846 | 8/14/14 | 013172846 | 2/10/15 |
| GW Pharma Limited | GWPCARE | GB | Registered | UK00003068493 | 8/13/14 | UK00003068493 | 12/5/14 |
| GW Pharma Limited | GWPCARE | GB | Registered | UK00913172846 | 8/14/14 | UK00913172846 | 2/10/15 |
| GW Pharma Limited | GWPCARE CANNABIDIOL IN RESISTANT EPILEPSY & Design | EM | Registered | 13173075 | 8/14/14 | 013173075 | 2/10/15 |
| GW Pharma Limited | GWPCARE CANNABIDIOL IN RESISTANT EPILEPSY (Color) | GB | Registered | UK00913173075 | 8/14/14 | UK00913173075 | 2/10/15 |
| GW Pharma Limited | GWPCARE Logo (Series of 2) | GB | Registered | UK00003068496 | 8/13/14 | UK00003068496 | 11/21/14 |
| GW Pharma Limited | GWPHARM | CH | Registered | 10714/2020 | 7/30/20 | 776809 | 2/18/22 |
| GW Pharma Limited | GWPHARM | CN | Registered | 62999466 | 3/3/22 | 62999466 | 11/21/22 |
| GW Pharma Limited | GWPHARM | GB | Registered | UK00003038722 | 1/21/14 | UK00003038722 | 4/25/14 |
| GW Pharma Limited | GWPHARM | GB | Registered | UK00003573447 | 12/30/20 | UK00003573447 | 5/7/21 |
| GW Pharma Limited | GWPHARM | GB | Registered | UK00801220677 | 6/5/14 | UK00801220677 | 9/1/15 |
| GW Pharma Limited | GWPHARM | HK | Registered | 305347242 | 7/30/20 | 305347242 | 7/30/20 |
| GW Pharma Limited | GWPHARM | IB | Registered | 1220677 | 6/5/14 | 1220677 | 6/5/14 |
| GW Pharma Limited | GWPHARM | IB | Registered | 1628494 | 1/29/21 | 1628494 | 1/29/21 |
| GW Pharma Limited | GWPHARM | NO | Registered | 202009638 | 7/30/20 | 315693 | 5/21/21 |
| GW Pharma Limited | GWPHARM | RS | Registered | 2020/1285 | 7/30/20 | 79800 | 2/19/21 |
| GW Pharma Limited | GWPHARM | SG | Registered | 402020160925 | 8/3/20 | 402020160925 | 12/16/21 |
| GW Pharma Limited | GWPHARM | TW | Registered | 110001706 | 1/8/21 | 02191324 | 12/16/21 |
| GW Pharma Limited | GWPHARMA | CN | Pending | 62999475 | 3/3/22 | | |
| GW Pharma Limited | GWPHARMA | CN | Pending | 67643488 | 10/10/22 | | |
| GW Pharma Limited | GWPHARMA | CN | Registered | 62999475A | 3/3/22 | 62999475A | 10/21/22 |
| GW Pharma Limited | GWPHARMACEUTICALS | CN | Registered | 62989215 | 3/3/22 | 62989215 | 11/21/22 |
| GW Pharma Limited | MEVATYL | EM | Registered | 003530491 | 10/31/03 | 003530491 | 3/30/05 |
| GW Pharma Limited | MEVATYL | GB | Registered | 3530491 | 10/31/03 | 903530491 | 3/30/05 |
| GW Pharma Limited | MEVATYL | BR | Registered | 826332668 | 3/19/04 | 826332668 | 9/11/07 |
| GW Pharma Limited | MEVATYL | BR | Registered | 826332978 | 3/19/04 | 826332978 | 9/11/07 |
| GW Pharma Limited | MEVATYL | CL | Registered | 1133654 | 12/2/14 | 1169705 | 6/16/15 |
| GW Pharma Limited | MEVATYL | CO | Registered | 14272070 | 12/11/14 | 517554 | 4/22/15 |
| GW Pharma Limited | MEVATYL | CR | Registered | 2015-0002127 | 3/4/15 | 244149 | 6/1/15 |

| | | | | | | | |
|---------------------|--|----|------------|---------------|----------|----------------|----------|
| GW Pharma Limited | MEVATYL | EC | Registered | 201430330 | 12/8/14 | IEPI2015TI4537 | 9/30/15 |
| GW Pharma Limited | MEVATYL | FR | Registered | 043277551 | 3/4/04 | 043277551 | 3/4/04 |
| GW Pharma Limited | MEVATYL | FR | Registered | 217769 | 6/15/90 | 1597467 | 6/15/90 |
| GW Pharma Limited | MEVATYL | KR | Registered | 40-2004-11053 | 3/11/04 | 400641206 | 12/1/05 |
| GW Pharma Limited | MEVATYL | MX | Registered | 645927 | 3/9/04 | 836543 | 6/9/04 |
| GW Pharma Limited | MEVATYL | PA | Registered | 237108-01 | 12/12/14 | 23710801 | 12/12/14 |
| GW Pharma Limited | MEVATYL | PE | Registered | 600070 | 12/15/14 | 222427 | 3/20/15 |
| GW Pharma Limited | MEVATYL | TW | Registered | 093010491 | 3/11/04 | 01128457 | 11/16/04 |
| GW Pharma Limited | MEVATYL | VE | Registered | 20626-2014 | 12/26/14 | P355736 | 8/11/16 |
| GW Pharma Limited | MORE THAN | EM | Registered | 018189213 | 1/29/20 | 018189213 | 6/5/20 |
| GW Pharma Limited | MORE THAN | BR | Registered | 921402449 | 11/24/20 | 921402449 | 11/3/21 |
| GW Pharma Limited | MORE THAN | BR | Registered | 921402759 | 11/24/20 | 921402759 | 11/3/21 |
| GW Pharma Limited | MORE THAN | GB | Registered | UK00918189213 | 1/29/20 | UK00918189213 | 6/5/20 |
| GW Pharma Limited | MORE THAN | JP | Registered | 2020-145225 | 11/25/20 | 6486293 | 12/15/21 |
| GW Pharma Limited | MORE THAN | MX | Registered | 2458261 | 11/24/20 | 2202979 | 2/9/21 |
| GW Pharma Limited | MORE THAN | MX | Registered | 2458263 | 11/24/20 | 2323819 | 11/11/21 |
| GW Pharma Limited | SATIVEX | CL | Registered | 1463158 | 6/25/21 | 1365431 | 3/9/22 |
| GW Pharma Limited | SATIVEX | GB | Registered | UK00003573455 | 12/30/20 | UK00003573455 | 5/7/21 |
| GW Pharma Limited | SATIVEX | TW | Registered | 110000496 | 1/5/21 | 02184459 | 11/16/21 |
| GW Pharma Limited | SATIVEX in Chinese characters | CN | Registered | 48461866 | 7/28/20 | 48461866 | 3/14/21 |
| GW Pharma Limited | SATIVEX in Chinese characters | CN | Registered | 48466663 | 7/28/20 | 48466663 | 3/21/21 |
| GW Pharma Limited | Sativex Logo (Color) | CN | Registered | 47799225 | 7/3/20 | 47799225 | 2/21/21 |
| GW Pharma Limited | THERACANNEX | AE | Registered | 186707 | 2/12/13 | 186707 | 8/26/14 |
| GW Pharma Limited | UK Medicinal Cannabis Project (Device) | GB | Registered | UK00002213257 | 11/3/99 | UK00002213257 | 9/15/00 |
| GW Pharma Limited | VARINEX | GB | Registered | UK00002411358 | 1/18/06 | UK00002411358 | 9/22/06 |
| GW Pharma Limited | WE ARE MORE THAN | AU | Registered | 2137387 | 11/19/20 | 2137387 | 6/28/21 |
| GW Pharma Limited | WE ARE MORE THAN | BR | Registered | 921515049 | 12/4/20 | 921515049 | 11/30/21 |
| GW Pharma Limited | WE ARE MORE THAN | BR | Registered | 921515383 | 12/4/20 | 921515383 | 11/30/21 |
| GW Pharma Limited | WE ARE MORE THAN | CA | Pending | 2093642 | 3/22/21 | | |
| GW Pharma Limited | WE ARE MORE THAN | JP | Registered | 2020-145224 | 11/25/20 | 6486292 | 12/15/21 |
| GW Pharma Limited | WE ARE MORE THAN | MX | Registered | 2458264 | 11/24/20 | 2202980 | 2/9/21 |
| GW Pharma Limited | WE ARE MORE THAN | MX | Registered | 2458268 | 11/24/20 | 2202982 | 2/9/21 |
| GW Research Limited | ACESLY | US | Allowed | 90322048 | 11/16/20 | | |
| GW Research Limited | ALIGHT | EM | Registered | 018168689 | 12/17/19 | 018168689 | 5/22/20 |
| GW Research Limited | ALIGHT | GB | Registered | UK00918168689 | 12/17/19 | UK00918168689 | 5/22/20 |
| GW Research Limited | ALIGHT | RS | Registered | Z-2005/2019 | 12/17/19 | 78604 | 3/16/20 |
| GW Research Limited | ALIGHT | US | Registered | 88730506 | 12/17/19 | 6268010 | 2/9/21 |
| GW Research Limited | ASCELTA | AE | Registered | 313991 | 7/17/19 | 313991 | 11/4/19 |
| GW Research Limited | ASCELTA | AR | Registered | 3819778 | 7/15/19 | 3142572 | 2/17/21 |
| GW Research Limited | ASCELTA | BR | Registered | 917758102 | 7/18/19 | 917758102 | 8/3/21 |
| GW Research Limited | ASCELTA | CL | Registered | 1330052 | 7/17/19 | 1316071 | 2/5/20 |
| GW Research Limited | ASCELTA | CR | Registered | 2019-6437 | 7/17/19 | 286441 | 2/14/20 |

| | | | | | | | |
|---------------------|---------------------------|----|------------|-------------------|----------|------------------|----------|
| GW Research Limited | ASCELTA | EC | Registered | SENADI-2019-71879 | 10/2/19 | SENADI2020TI2909 | 12/27/19 |
| GW Research Limited | ASCELTA | EM | Registered | 018016661 | 1/29/19 | 018016661 | 6/1/19 |
| GW Research Limited | ASCELTA | GB | Registered | UK00003153773 | 3/8/16 | UK00003153773 | 6/3/16 |
| GW Research Limited | ASCELTA | GB | Registered | UK00918016661 | 1/29/19 | UK00918016661 | 6/1/19 |
| GW Research Limited | ASCELTA | IB | Registered | 1484201 | 7/12/19 | 1484201 | 7/12/19 |
| GW Research Limited | ASCELTA | KS | Registered | KS/M/2019/000955 | 7/16/19 | 27314 | 3/15/21 |
| GW Research Limited | ASCELTA | KW | Registered | 2019-7335 | 9/5/19 | 1616417 | 9/5/19 |
| GW Research Limited | ASCELTA | PA | Registered | 275039 | 7/18/19 | 275039 | 7/18/19 |
| GW Research Limited | ASCELTA | PE | Registered | 806897-2019 | 7/17/19 | P00288761 | 11/15/19 |
| GW Research Limited | ASCELTA | PY | Registered | 1958557 | 7/19/19 | 506955 | 8/13/20 |
| GW Research Limited | ASCELTA | QA | Registered | 133861 | 8/22/19 | 133861 | 2/28/21 |
| GW Research Limited | ASCELTA | SA | Registered | 195436 | 7/30/19 | 1440029305 | 7/31/19 |
| GW Research Limited | ASCELTA | TW | Registered | 108046924 | 7/19/19 | 2049533 | 4/1/20 |
| GW Research Limited | ASCELTA | UY | Registered | 506375 | 7/19/19 | 506375 | 10/20/21 |
| GW Research Limited | ASCELTA | VE | Published | 2019-008014 | 9/18/19 | | |
| GW Research Limited | ASCELTA | ZA | Registered | 2019/19694 | 7/16/19 | 201919694 | 11/25/20 |
| GW Research Limited | AVRULEY | US | Allowed | 90322063 | 11/16/20 | | |
| GW Research Limited | BEXUB | EM | Registered | 017012873 | 7/21/17 | 017012873 | 11/23/17 |
| GW Research Limited | BEXUB | GB | Registered | UK00917012873 | 7/21/17 | UK00917012873 | 11/23/17 |
| GW Research Limited | BICANNEX | GB | Registered | UK00002304383 | 7/4/02 | UK00002304383 | 6/13/03 |
| GW Research Limited | CANNABIDEX | GB | Registered | UK00002304389 | 7/4/02 | UK00002304389 | 5/30/03 |
| GW Research Limited | CANNABIDIOL ORAL SOLUTION | BX | Registered | 1413649 | 7/29/19 | 1413649 | 7/7/20 |
| GW Research Limited | CANNABIDIOL ORAL SOLUTION | CH | Registered | 02781/2020 | 2/28/20 | 766225 | 7/6/21 |
| GW Research Limited | CANNABIDIOL ORAL SOLUTION | DK | Registered | VA202000593 | 7/29/19 | VR202100989 | 5/10/21 |
| GW Research Limited | CANNABIDIOL ORAL SOLUTION | EM | Registered | 018100171 | 7/29/19 | 018100171 | 6/25/20 |
| GW Research Limited | CANNABIDIOL ORAL SOLUTION | FI | Registered | T202000016 | 7/29/19 | 278560 | 3/17/20 |
| GW Research Limited | CANNABIDIOL ORAL SOLUTION | GB | Registered | UK00918100171 | 7/29/19 | UK00918100171 | 6/25/20 |
| GW Research Limited | CANNABIDIOL ORAL SOLUTION | NO | Registered | 202003054 | 2/28/20 | 316670 | 7/19/21 |
| GW Research Limited | CANNABIDIOL ORAL SOLUTION | SE | Registered | 2020/01966 | 3/17/20 | 609499 | 8/3/20 |
| GW Research Limited | CANNABIDIOL OS | BX | Registered | 1413643 | 7/29/19 | 1413643 | 7/7/20 |
| GW Research Limited | CANNABIDIOL OS | CH | Registered | 02783/2020 | 2/28/20 | 750176 | 7/29/20 |
| GW Research Limited | CANNABIDIOL OS | DK | Registered | VA202000590 | 7/29/19 | VR202100019 | 12/28/20 |
| GW Research Limited | CANNABIDIOL OS | EM | Registered | 018100168 | 7/29/19 | 018100168 | 6/25/20 |
| GW Research Limited | CANNABIDIOL OS | FI | Registered | T202000015 | 7/29/19 | 277534 | 3/17/20 |
| GW Research Limited | CANNABIDIOL OS | GB | Registered | UK00918100168 | 7/29/19 | UK00918100168 | 6/25/20 |
| GW Research Limited | CANNABIDIOL OS | NO | Registered | 202003053 | 2/28/20 | 316669 | 7/19/21 |
| GW Research Limited | CANNABIDIOL OS | SE | Registered | 2020/01971 | 3/17/20 | 609500 | 8/3/20 |

| | | | | | | | |
|---------------------|--|----|------------|---------------|----------|---------------|----------|
| GW Research Limited | CANNABINEWS | CA | Pending | 2008256 | 1/27/20 | | |
| GW Research Limited | CANNABINEWS | US | Registered | 88774342 | 1/27/20 | 6667387 | 3/8/22 |
| GW Research Limited | CANNABINOID CLINICAL | US | Registered | 88791507 | 2/10/20 | 6623962 | 1/18/22 |
| GW Research Limited | Cannabinoid Education 360 | GB | Registered | UK00003523530 | 8/17/20 | UK00003523530 | 12/4/20 |
| GW Research Limited | Cannabinoid Education 360 (Device) | EM | Registered | 018292958 | 8/18/20 | 018292958 | 1/8/21 |
| GW Research Limited | Cannabinoid Education 360 (Series of 2) | GB | Registered | UK00003523527 | 8/17/20 | UK00003523527 | 12/4/20 |
| GW Research Limited | CANNABINOID EDUCATION 360° & Design | TW | Registered | 110010378 | 2/17/21 | 02194765 | 1/1/22 |
| GW Research Limited | CANNABINOID EDUCATION 360° (Stylized) & Design (Color) | IB | Registered | 1586002 | 2/17/21 | 1586002 | 2/17/21 |
| GW Research Limited | CANNABINOID EDUCATION WORKING GROUP | CA | Pending | 2009509 | 2/3/20 | | |
| GW Research Limited | CANNABINOID RESEARCH INSTITUTE | GB | Registered | UK00002304395 | 7/4/02 | UK00002304395 | 12/20/02 |
| GW Research Limited | CANNABINOID RESEARCH INSTITUTE | US | Registered | 87771739 | 1/26/18 | 5765928 | 5/28/19 |
| GW Research Limited | CANNABINOIDCLINICAL | CA | Pending | 2009508 | 2/3/20 | | |
| GW Research Limited | CANNAVAR | GB | Registered | UK00002304386 | 7/4/02 | UK00002304386 | 12/13/02 |
| GW Research Limited | CANNIVEX | GB | Registered | UK00002338253 | 7/21/03 | UK00002338253 | 12/19/03 |
| GW Research Limited | CANTIVEX | AE | Registered | 181113 | 10/24/12 | 181113 | 10/19/14 |
| GW Research Limited | CANTIVEX | EM | Registered | 003477346 | 10/30/03 | 003477346 | 3/4/05 |
| GW Research Limited | CANTIVEX | GB | Registered | UK00002338259 | 7/21/03 | UK00002338259 | 12/19/03 |
| GW Research Limited | CANTIVEX | GB | Registered | UK00903477346 | 10/30/03 | UK00903477346 | 3/4/05 |
| GW Research Limited | CANTIVEX | IB | Registered | 824459 | 1/20/04 | 824459 | 1/20/04 |
| GW Research Limited | CANTIVEX | KW | Registered | 134769 | 11/18/12 | 115573 | 11/18/12 |
| GW Research Limited | CANTIVEX | QA | Registered | 77784 | 11/12/12 | 77784 | 11/12/12 |
| GW Research Limited | CBD ORAL SOLUTION | BX | Registered | 1413647 | 7/29/19 | 1413647 | 7/7/20 |
| GW Research Limited | CBD ORAL SOLUTION | CH | Registered | 02780/2020 | 2/28/20 | 767016 | 7/22/21 |
| GW Research Limited | CBD ORAL SOLUTION | DK | Registered | VA202000592 | 7/29/19 | VR202100988 | 5/10/21 |
| GW Research Limited | CBD ORAL SOLUTION | EM | Registered | 018100167 | 7/29/19 | 018100167 | 6/25/20 |
| GW Research Limited | CBD ORAL SOLUTION | FI | Registered | T202000014 | 7/29/19 | 278561 | 3/17/20 |
| GW Research Limited | CBD ORAL SOLUTION | GB | Registered | UK00918100167 | 7/29/19 | UK00918100167 | 6/25/20 |
| GW Research Limited | CBD ORAL SOLUTION | NO | Registered | 202003052 | 2/28/20 | 321811 | 5/4/22 |
| GW Research Limited | CBD ORAL SOLUTION | SE | Registered | 2020/01968 | 3/17/20 | 609502 | 8/3/20 |
| GW Research Limited | CBD OS | BX | Registered | 1413635 | 7/29/19 | 1413635 | 7/7/20 |
| GW Research Limited | CBD OS | CH | Registered | 02778/2020 | 2/28/20 | 750177 | 7/29/20 |
| GW Research Limited | CBD OS | DK | Registered | VA202000591 | 7/29/19 | VR202100020 | 12/28/20 |
| GW Research Limited | CBD OS | EM | Registered | 018100165 | 7/29/19 | 018100165 | 6/25/20 |
| GW Research Limited | CBD OS | FI | Registered | T202000013 | 7/29/19 | 277533 | 3/17/20 |
| GW Research Limited | CBD OS | GB | Registered | UK00918100165 | 7/29/19 | UK00918100165 | 6/25/20 |
| GW Research Limited | CBD OS | NO | Registered | 202003051 | 2/28/20 | 321810 | 5/4/22 |
| GW Research Limited | CBD OS | SE | Registered | 2020/01974 | 3/17/20 | 609501 | 8/3/20 |

| | | | | | | | |
|---------------------|--------------------------------|----|------------|-------------------|----------|------------------|----------|
| GW Research Limited | CEPADEX | GB | Registered | UK00003009941 | 6/13/13 | UK00003009941 | 9/20/13 |
| GW Research Limited | CEWG | CA | Pending | 2009510 | 2/3/20 | | |
| GW Research Limited | CEWG | US | Allowed | 88791520 | 2/10/20 | | |
| GW Research Limited | COVERING CANNABINOIDS | US | Registered | 88747689 | 1/6/20 | 6609905 | 1/4/22 |
| GW Research Limited | COVERING CANNABINOIDS & Design | US | Registered | 88747694 | 1/6/20 | 6667366 | 3/8/22 |
| GW Research Limited | CRI | GB | Registered | UK00003274822 | 12/4/17 | UK00003274822 | 4/27/18 |
| GW Research Limited | DUCANNEX | EM | Registered | 003478054 | 10/30/03 | 003478054 | 3/4/05 |
| GW Research Limited | DUCANNEX | GB | Registered | UK00903478054 | 10/30/03 | UK00903478054 | 3/4/05 |
| GW Research Limited | EJOZY | EM | Registered | 017012881 | 7/21/17 | 017012881 | 11/23/17 |
| GW Research Limited | EJOZY | GB | Registered | UK00917012881 | 7/21/17 | UK00917012881 | 11/23/17 |
| GW Research Limited | ENBEILE (Chinese Characters) | CN | Published | 69308830 | 1/29/23 | | |
| GW Research Limited | ENBEILE (Chinese Characters) | CN | Registered | 69306010 | 1/29/23 | 69306010 | 9/28/23 |
| GW Research Limited | ENBEILE (Chinese Characters) | KR | Pending | 40-2022-0221426 | 12/1/22 | | |
| GW Research Limited | ENBEILE (Chinese Characters) | TW | Registered | 110057531 | 8/11/21 | 02217661 | 4/16/22 |
| GW Research Limited | EPI CAMPUS | DE | Registered | 30 2021 112 568.1 | 7/20/21 | 302021112568 | 11/3/21 |
| GW Research Limited | EPIDIOLEX | AE | Registered | 334152 | 8/18/20 | 334152 | 12/24/20 |
| GW Research Limited | EPIDIOLEX | AE | Registered | 334153 | 8/18/20 | 334153 | 12/24/20 |
| GW Research Limited | EPIDIOLEX | AR | Pending | 3728932 | 7/30/18 | | |
| GW Research Limited | EPIDIOLEX | AR | Registered | 3728929 | 7/30/18 | 3115147 | 10/1/20 |
| GW Research Limited | EPIDIOLEX | BR | Registered | 914114077 | 2/1/18 | 914114077 | 9/24/19 |
| GW Research Limited | EPIDIOLEX | BR | Registered | 914114107 | 2/1/18 | 914114107 | 3/26/19 |
| GW Research Limited | EPIDIOLEX | CA | Registered | 1818624 | 1/18/17 | TMA1067775 | 1/3/20 |
| GW Research Limited | EPIDIOLEX | CA | Registered | 1912786 | 8/1/18 | TMA1082388 | 9/30/20 |
| GW Research Limited | EPIDIOLEX | CL | Registered | 1295685 | 7/27/18 | 1298182 | 6/3/19 |
| GW Research Limited | EPIDIOLEX | CL | Registered | 1458810 | 6/22/21 | 1365427 | 3/9/22 |
| GW Research Limited | EPIDIOLEX | CN | Registered | 59841790 | 10/15/21 | 59841790 | 4/14/22 |
| GW Research Limited | EPIDIOLEX | CN | Registered | 59856132 | 10/15/21 | 59856132 | 4/14/22 |
| GW Research Limited | EPIDIOLEX | CN | Pending | 70496877 | 3/28/23 | | |
| GW Research Limited | EPIDIOLEX | CN | Registered | 70496877A | 3/28/23 | 70496877A | 10/7/23 |
| GW Research Limited | EPIDIOLEX | EC | Registered | 2018-57058 | 7/27/18 | SENADI2019TI5994 | 11/29/18 |
| GW Research Limited | EPIDIOLEX | EC | Registered | 2018-57061 | 7/27/18 | SENADI2020TI1009 | 11/29/18 |
| GW Research Limited | EPIDIOLEX | EM | Registered | 012639373 | 2/26/14 | 012639373 | 7/18/14 |
| GW Research Limited | EPIDIOLEX | GB | Registered | UK00003013236 | 7/9/13 | UK00003013236 | 10/11/13 |
| GW Research Limited | EPIDIOLEX | GB | Registered | UK00003068471 | 8/13/14 | UK00003068471 | 11/14/14 |
| GW Research Limited | EPIDIOLEX | GB | Registered | UK00003573458 | 12/30/20 | UK00003573458 | 5/7/21 |
| GW Research Limited | EPIDIOLEX | GB | Registered | UK00801226800 | 8/14/14 | UK00801226800 | 10/14/15 |
| GW Research Limited | EPIDIOLEX | GB | Registered | UK00912639373 | 2/26/14 | UK00912639373 | 7/18/14 |
| GW Research Limited | EPIDIOLEX | HK | Registered | 305271714 | 5/13/20 | 305271714 | 5/13/20 |
| GW Research Limited | EPIDIOLEX | IB | Registered | 1208519 | 3/18/14 | 1208519 | 3/18/14 |
| GW Research Limited | EPIDIOLEX | IB | Registered | 1226800 | 8/14/14 | 1226800 | 8/14/14 |
| GW Research Limited | EPIDIOLEX | IB | Registered | 1637670 | 6/23/21 | 1637670 | 6/23/21 |
| GW Research Limited | EPIDIOLEX | LB | Registered | 198372 | 9/22/20 | 198372 | 9/22/20 |
| GW Research Limited | EPIDIOLEX | PA | Registered | 267710 | 8/1/18 | 267710 | 8/1/18 |
| GW Research Limited | EPIDIOLEX | PE | Registered | 760008-2018 | 7/31/18 | T00021543 | 9/20/18 |

| | | | | | | | |
|---------------------|---|----|------------|---------------|----------|-----------------|----------|
| GW Research Limited | EPIDIOLEX | PR | Registered | 227938-05-0 | 7/30/18 | 224674 | 7/30/18 |
| GW Research Limited | EPIDIOLEX | PY | Registered | 1863078 | 8/1/18 | 2021530284 | 10/18/21 |
| GW Research Limited | EPIDIOLEX | PY | Registered | 1863081 | 8/1/18 | 486088 | 6/21/19 |
| GW Research Limited | EPIDIOLEX | SA | Registered | 239234 | 9/2/20 | 1442002182 | 12/27/20 |
| GW Research Limited | EPIDIOLEX | SA | Registered | 239236 | 9/2/20 | 1442002184 | 12/27/20 |
| GW Research Limited | EPIDIOLEX | TW | Registered | 108016022 | 3/18/19 | 2034077 | 1/1/20 |
| GW Research Limited | EPIDIOLEX | TW | Registered | 110044656 | 6/24/21 | 02223613 | 5/16/22 |
| GW Research Limited | EPIDIOLEX | US | Registered | 86007888 | 7/11/13 | 4484943 | 2/18/14 |
| GW Research Limited | EPIDIOLEX | ZA | Registered | 2019/27592 | 9/27/19 | 201927592 | 8/11/21 |
| GW Research Limited | EPIDIOLEX | ZA | Registered | 2019/27593 | 9/27/19 | 201927593 | 8/11/21 |
| GW Research Limited | EPIDIOLEX in Chinese characters | CN | Registered | 48752724 | 8/7/20 | 48752724 | 3/21/21 |
| GW Research Limited | EPIDIOLEX in Chinese characters | CN | Registered | 48768022 | 8/7/20 | 48768022 | 3/21/21 |
| GW Research Limited | EPIDIOLEX in traditional Chinese characters | TW | Registered | 110026695 | 4/16/21 | 02201561 | 2/1/22 |
| GW Research Limited | EPIDYOLEX | AE | Registered | 334155 | 8/18/20 | 334155 | 12/24/20 |
| GW Research Limited | EPIDYOLEX | AE | Registered | 334157 | 8/18/20 | 334157 | 12/24/20 |
| GW Research Limited | EPIDYOLEX | AR | Pending | 3684181 | 2/15/18 | | |
| GW Research Limited | EPIDYOLEX | AR | Registered | 3684182 | 2/15/18 | 3003150 | 8/28/19 |
| GW Research Limited | EPIDYOLEX | BR | Registered | 914355694 | 3/19/18 | 914355694 | 11/19/19 |
| GW Research Limited | EPIDYOLEX | BR | Registered | 914355880 | 3/19/18 | 914355880 | 4/16/19 |
| GW Research Limited | EPIDYOLEX | CA | Registered | 1882918 | 2/13/18 | TMA1097418 | 3/31/21 |
| GW Research Limited | EPIDYOLEX | CL | Registered | 1281963 | 3/8/18 | 1288564 | 12/27/18 |
| GW Research Limited | EPIDYOLEX | CL | Registered | 1458804 | 6/22/21 | 1365507 | 3/9/22 |
| GW Research Limited | EPIDYOLEX | EC | Registered | 2018-11113 | 2/14/18 | SENADI2020TI17 | 9/19/18 |
| GW Research Limited | EPIDYOLEX | EC | Registered | 2018-11117 | 2/14/18 | SENADI2020TI860 | 9/18/18 |
| GW Research Limited | EPIDYOLEX | EM | Registered | 016409179 | 2/27/17 | 016409179 | 10/12/17 |
| GW Research Limited | EPIDYOLEX | GB | Registered | UK00003289185 | 2/9/18 | UK00003289185 | 6/8/18 |
| GW Research Limited | EPIDYOLEX | GB | Registered | UK00003573459 | 12/30/20 | UK00003573459 | 5/7/21 |
| GW Research Limited | EPIDYOLEX | GB | Registered | UK00801421965 | 7/18/18 | UK00801421965 | 2/12/19 |
| GW Research Limited | EPIDYOLEX | GB | Registered | UK00916409179 | 2/27/17 | UK00916409179 | 10/12/17 |
| GW Research Limited | EPIDYOLEX | HK | Registered | 305271723 | 5/13/20 | 305271723 | 5/13/20 |
| GW Research Limited | EPIDYOLEX | IB | Registered | 1421965 | 7/18/18 | 1421965 | 7/18/18 |
| GW Research Limited | EPIDYOLEX | IB | Registered | 1637668 | 6/23/21 | 1637668 | 6/23/21 |
| GW Research Limited | EPIDYOLEX | LB | Registered | 198373 | 9/22/20 | 198373 | 9/22/20 |
| GW Research Limited | EPIDYOLEX | PA | Registered | 264147 | 2/19/18 | 264147 | 2/19/18 |
| GW Research Limited | EPIDYOLEX | PE | Registered | 738459-2018 | 2/15/18 | T00020715 | 6/18/18 |
| GW Research Limited | EPIDYOLEX | PR | Registered | 244362-05-0 | 6/22/21 | 227455 | 6/22/21 |
| GW Research Limited | EPIDYOLEX | PY | Registered | 1809956 | 2/16/18 | 2021527906 | 9/9/21 |
| GW Research Limited | EPIDYOLEX | PY | Registered | 1809957 | 2/16/18 | 482381 | 5/8/19 |
| GW Research Limited | EPIDYOLEX | SA | Registered | 239238 | 9/2/20 | 1442002186 | 12/27/20 |
| GW Research Limited | EPIDYOLEX | SA | Registered | 239242 | 9/2/20 | 1442002189 | 12/27/20 |
| GW Research Limited | EPIDYOLEX | TW | Registered | 108016023 | 3/18/19 | 2034078 | 1/1/20 |
| GW Research Limited | EPIDYOLEX | TW | Registered | 110044657 | 6/24/21 | 02223614 | 5/16/22 |

| | | | | | | | |
|---------------------|---|----|------------|-----------------|----------|---------------|----------|
| GW Research Limited | EPIDYOLEX | ZA | Registered | 2019/27591 | 9/27/19 | 201927591 | 8/10/22 |
| GW Research Limited | EPIDYOLEX | ZA | Registered | 2019/27594 | 9/27/19 | 201927594 | 1/19/23 |
| GW Research Limited | EPIDYOLEX (Japanese Characters) | JP | Registered | 2022-093577 | 8/12/22 | 6647384 | 12/1/22 |
| GW Research Limited | EPIDYOLEX (Japanese Characters) | JP | Registered | 2022-093578 | 8/12/22 | 6647385 | 12/1/22 |
| GW Research Limited | EPIDYOLEX (Korean Characters 1) | KR | Published | 40-2022-0202892 | 11/7/22 | | |
| GW Research Limited | EPIDYOLEX (Korean Characters 2) | KR | Published | 40-2022-0202893 | 11/7/22 | | |
| GW Research Limited | EPIDYOLEX in Chinese characters | CN | Registered | 48768031 | 8/7/20 | 48768031 | 3/21/21 |
| GW Research Limited | EPIDYOLEX in Chinese characters (2022) | CN | Registered | 63957208 | 4/13/22 | 63957208 | 10/14/22 |
| GW Research Limited | EPIDYOLEX in Chinese characters (2022) | CN | Registered | 63962625 | 4/13/22 | 63962625 | 10/7/22 |
| GW Research Limited | EPIDYOLEX in Chinese characters (2022) | KR | Pending | 40-2022-0186467 | 10/13/22 | | |
| GW Research Limited | EPIDYOLEX in traditional Chinese characters | TW | Registered | 110026694 | 4/16/21 | 02201560 | 2/1/22 |
| GW Research Limited | Epidyolex Logo | CA | Registered | 1928280 | 11/1/18 | TMA1097419 | 3/31/21 |
| GW Research Limited | Epidyolex Logo | GB | Registered | UK00801460321 | 2/1/19 | UK00801460321 | 9/13/19 |
| GW Research Limited | Epidyolex Logo | IB | Registered | 1460321 | 2/1/19 | 1460321 | 2/1/19 |
| GW Research Limited | Epidyolex Logo | IL | Registered | 315633 | 4/7/19 | 315633 | 6/1/20 |
| GW Research Limited | Epidyolex Logo (Series of 2) | AU | Registered | 2001371 | 4/5/19 | 2001371 | 4/5/19 |
| GW Research Limited | Epidyolex Logo (Series of 2) | GB | Registered | UK00003348532 | 10/25/18 | 3348532 | 1/11/19 |
| GW Research Limited | Epidyolex Logo (Series of 2) | NZ | Registered | 1117930 | 4/5/19 | 1117930 | 10/25/18 |
| GW Research Limited | EPINUKIA | GB | Registered | UK00003153774 | 3/8/16 | UK00003153774 | 6/3/16 |
| GW Research Limited | EPIVARINEX | GB | Registered | UK00003044567 | 2/28/14 | UK00003044567 | 6/6/14 |
| GW Research Limited | EPIVARINEX | GB | Registered | UK00801222832 | 6/18/14 | UK00801222832 | 9/22/15 |
| GW Research Limited | EPIVARINEX | IB | Registered | 1222832 | 6/18/14 | 1222832 | 6/18/14 |
| GW Research Limited | EPIX | US | Allowed | 90472235 | 1/18/21 | | |
| GW Research Limited | EPIX | US | Registered | 90978897 | 1/18/21 | 6997901 | 3/7/23 |
| GW Research Limited | EPIX (Stylized) & Design | US | Allowed | 90472233 | 1/18/21 | | |
| GW Research Limited | EPIX (Stylized) & Design | US | Registered | 90978896 | 1/18/21 | 6997900 | 3/7/23 |
| GW Research Limited | EPYDIOLEX | EM | Registered | 016409153 | 2/27/17 | 016409153 | 9/30/17 |
| GW Research Limited | EPYDIOLEX | GB | Registered | UK00916409153 | 2/27/17 | UK00916409153 | 9/30/17 |
| GW Research Limited | FEPURYX | EM | Registered | 017012725 | 7/21/17 | 017012725 | 11/23/17 |
| GW Research Limited | FEPURYX | GB | Registered | UK00917012725 | 7/21/17 | UK00917012725 | 11/23/17 |
| GW Research Limited | IABNI | EM | Registered | 017012824 | 7/21/17 | 017012824 | 11/23/17 |
| GW Research Limited | IABNI | GB | Registered | UK00917012824 | 7/21/17 | UK00917012824 | 11/23/17 |
| GW Research Limited | ILLUMINATE STUDY & Design (Color) | US | Registered | 90549385 | 2/26/21 | 7127825 | 8/1/23 |
| GW Research Limited | IMPACT | US | Registered | 88153003 | 10/12/18 | 6629505 | 1/25/22 |
| GW Research Limited | JESCABE | EM | Registered | 017012841 | 7/21/17 | 017012841 | 11/23/17 |

| | | | | | | | |
|---------------------|-------------|----|------------|-------------------|----------|------------------|----------|
| GW Research Limited | JESCABE | GB | Registered | UK00917012841 | 7/21/17 | UK00917012841 | 11/23/17 |
| GW Research Limited | KATEULIA | GB | Registered | UK00003153780 | 3/8/16 | UK00003153780 | 7/8/16 |
| GW Research Limited | KYNEUBIA | GB | Registered | UK00003153763 | 3/8/16 | UK00003153763 | 6/3/16 |
| GW Research Limited | KYTEUVIA | GB | Registered | UK00003153778 | 3/8/16 | UK00003153778 | 6/3/16 |
| GW Research Limited | LIBMUVO | US | Allowed | 90322070 | 11/16/20 | | |
| GW Research Limited | LIVING WITH | US | Allowed | 97561065 | 8/23/22 | | |
| GW Research Limited | MOFISCA | US | Allowed | 90322030 | 11/16/20 | | |
| GW Research Limited | MOTIVY | GB | Registered | UK00003683781 | 8/19/21 | UK00003683781 | 12/3/21 |
| GW Research Limited | MOTIVY | IB | Registered | 1663353 | 2/21/22 | 1663353 | 2/21/22 |
| GW Research Limited | MOTIVY | US | Allowed | 90322039 | 11/16/20 | | |
| GW Research Limited | MOVIMI | US | Allowed | 90322057 | 11/16/20 | | |
| GW Research Limited | NABIDIOLEX | CA | Registered | 1196173 | 11/6/03 | TMA676968 | 11/16/06 |
| GW Research Limited | NABIDIOLEX | EM | Registered | 003477353 | 10/30/03 | 003477353 | 3/22/05 |
| GW Research Limited | NABIDIOLEX | GB | Registered | UK00002331741 | 5/8/03 | UK00002331741 | 10/24/03 |
| GW Research Limited | NABIDIOLEX | GB | Registered | UK00903477353 | 10/30/03 | UK00903477353 | 3/22/05 |
| GW Research Limited | NABIDIOLEX | IB | Registered | 816176 | 11/6/03 | 816176 | 11/6/03 |
| GW Research Limited | NABIDIOLEX | IL | Registered | 167829 | 11/6/03 | 167829 | 4/5/06 |
| GW Research Limited | NABIDIOLEX | IN | Registered | 1248283 | 11/7/03 | 1248283 | 11/7/03 |
| GW Research Limited | NABIDIOLEX | NZ | Registered | 704224 | 11/10/03 | 704224 | 5/10/04 |
| GW Research Limited | NARULEO | US | Allowed | 90322163 | 11/16/20 | | |
| GW Research Limited | NATMUVO | US | Allowed | 90322007 | 11/16/20 | | |
| GW Research Limited | NEODIOL | GB | Registered | UK00002581189 | 5/13/11 | UK00002581189 | 8/12/11 |
| GW Research Limited | NEODIOLEX | GB | Registered | UK00002581191 | 5/13/11 | UK00002581191 | 8/12/11 |
| GW Research Limited | NEONABIDEX | GB | Registered | UK00002581192 | 5/13/11 | UK00002581192 | 8/12/11 |
| GW Research Limited | OPURFY | EM | Registered | 17012733 | 7/21/17 | 017012733 | 2/7/18 |
| GW Research Limited | OPURFY | GB | Registered | UK00917012733 | 7/21/17 | UK00917012733 | 2/7/18 |
| GW Research Limited | ORORA | EM | Registered | 17017237 | 7/21/17 | 017017237 | 11/23/17 |
| GW Research Limited | ORORA | GB | Registered | UK00917017237 | 7/21/17 | UK00917017237 | 11/23/17 |
| GW Research Limited | PACAMZO | EM | Registered | 17012782 | 7/21/17 | 017012782 | 11/23/17 |
| GW Research Limited | PACAMZO | GB | Registered | UK00917012782 | 7/21/17 | UK00917012782 | 11/23/17 |
| GW Research Limited | PEFYO | EM | Registered | 17012857 | 7/21/17 | 017012857 | 1/13/18 |
| GW Research Limited | PEFYO | GB | Registered | UK00917012857 | 7/21/17 | UK00917012857 | 1/13/18 |
| GW Research Limited | RIKLEMY | US | Allowed | 90322109 | 11/16/20 | | |
| GW Research Limited | RISILIO | US | Allowed | 90322013 | 11/16/20 | | |
| GW Research Limited | RYLEBI | US | Allowed | 90321899 | 11/16/20 | | |
| GW Research Limited | SATIV | AE | Registered | 318407 | 10/6/19 | 318407 | 1/26/20 |
| GW Research Limited | SATIV | AR | Registered | 3841012 | 10/3/19 | 3153905 | 3/19/21 |
| GW Research Limited | SATIV | BR | Published | 918389852 | 10/4/19 | | |
| GW Research Limited | SATIV | CL | Registered | 1338137 | 10/3/19 | 1321250 | 5/5/20 |
| GW Research Limited | SATIV | CR | Registered | 2019-9163 | 10/4/19 | 287739 | 4/27/20 |
| GW Research Limited | SATIV | EC | Registered | SENADI-2019-72167 | 10/3/19 | SENADI2020TI2907 | 12/27/19 |
| GW Research Limited | SATIV | GB | Registered | UK00003389714 | 4/4/19 | UK00003389714 | 8/16/19 |
| GW Research Limited | SATIV | GB | Registered | UK00801508059 | 10/3/19 | UK00801508059 | 6/25/20 |
| GW Research Limited | SATIV | IB | Registered | 1508059 | 10/3/19 | 1508059 | 10/3/19 |
| GW Research Limited | SATIV | KS | Registered | KS/M/2019/001283 | 10/4/19 | 26633 | 10/6/20 |

| | | | | | | | |
|---------------------|----------|----|------------|------------------|----------|---------------|----------|
| GW Research Limited | SATIV | KW | Registered | 2019-8276 | 10/6/19 | 1617527 | 10/6/19 |
| GW Research Limited | SATIV | PA | Registered | 276978 | 10/4/19 | 276978 | 10/4/19 |
| GW Research Limited | SATIV | PE | Registered | 820484-2019 | 10/4/19 | P00289136 | 1/9/20 |
| GW Research Limited | SATIV | PY | Registered | 1983220 | 10/4/19 | 508296 | 9/7/20 |
| GW Research Limited | SATIV | QA | Registered | 134830 | 10/6/19 | 134830 | 7/6/20 |
| GW Research Limited | SATIV | SA | Registered | 202454 | 10/6/19 | 1441003985 | 10/6/19 |
| GW Research Limited | SATIV | TW | Registered | 108065428 | 10/4/19 | 2061686 | 6/1/20 |
| GW Research Limited | SATIV | UY | Registered | 508710 | 10/4/19 | 508710 | 12/20/21 |
| GW Research Limited | SATIV | VE | Registered | 2019-008635 | 10/4/19 | P378554 | 2/8/21 |
| GW Research Limited | SATIV | ZA | Registered | 2019/28183 | 10/4/19 | 201928183 | 4/26/21 |
| GW Research Limited | SATIVECS | GB | Registered | UK00002655592 | 3/11/13 | UK00002655592 | 7/5/13 |
| GW Research Limited | SATIVEX | AE | Registered | 181114 | 10/24/12 | 181114 | 10/15/14 |
| GW Research Limited | SATIVEX | AR | Registered | 4120334 | 12/16/09 | 3316113 | 4/27/12 |
| GW Research Limited | SATIVEX | BR | Registered | 830480595 | 12/21/09 | 830480595 | 12/5/17 |
| GW Research Limited | SATIVEX | CA | Registered | 1163979 | 1/6/03 | TMA658137 | 2/6/06 |
| GW Research Limited | SATIVEX | CA | Registered | 1284363 | 12/22/05 | TMA817317 | 2/9/12 |
| GW Research Limited | SATIVEX | CL | Registered | 1133486 | 11/28/14 | 1197819 | 3/2/16 |
| GW Research Limited | SATIVEX | CN | Registered | 47788038 | 7/3/20 | 47788038 | 2/21/21 |
| GW Research Limited | SATIVEX | CO | Registered | 09-141935 | 12/11/09 | 407386 | 8/23/10 |
| GW Research Limited | SATIVEX | CR | Registered | 2014-010556 | 12/4/14 | 247278 | 10/16/15 |
| GW Research Limited | SATIVEX | EC | Registered | 2014-29270 | 11/28/14 | 2016002578 | 11/25/15 |
| GW Research Limited | SATIVEX | EM | Registered | 2993384 | 1/2/03 | 002993384 | 10/29/04 |
| GW Research Limited | SATIVEX | EM | Registered | 4800819 | 12/22/05 | 004800819 | 11/23/06 |
| GW Research Limited | SATIVEX | GB | Registered | UK00002304388 | 7/4/02 | UK00002304388 | 11/29/02 |
| GW Research Limited | SATIVEX | GB | Registered | UK00002395506 | 6/29/05 | UK00002395506 | 12/16/05 |
| GW Research Limited | SATIVEX | GB | Registered | UK00902993384 | 1/2/03 | UK00902993384 | 10/29/04 |
| GW Research Limited | SATIVEX | GB | Registered | UK00904800819 | 12/22/05 | UK00904800819 | 11/23/06 |
| GW Research Limited | SATIVEX | GB | Registered | UK00902993384 | 1/2/03 | UK00902993384 | 10/29/04 |
| GW Research Limited | SATIVEX | IB | Registered | 805396 | 1/3/03 | 805396 | 1/3/03 |
| GW Research Limited | SATIVEX | IB | Registered | 1594371 | 1/29/21 | 1594371 | 1/29/21 |
| GW Research Limited | SATIVEX | ID | Registered | D002010003768 | 2/1/10 | IDM000307614 | 5/25/11 |
| GW Research Limited | SATIVEX | IL | Registered | 162116 | 1/5/03 | 162116 | 7/4/04 |
| GW Research Limited | SATIVEX | IN | Registered | 1216859 | 7/23/03 | 1216859 | 7/23/03 |
| GW Research Limited | SATIVEX | KS | Registered | KS/M/2014/000395 | 4/30/14 | 18700 | 9/5/16 |
| GW Research Limited | SATIVEX | KW | Registered | 134770 | 11/18/12 | 117728 | 1/16/14 |
| GW Research Limited | SATIVEX | MX | Registered | 2319594 | 1/22/20 | 2110496 | 8/19/20 |
| GW Research Limited | SATIVEX | NZ | Registered | 678744 | 5/21/03 | 678744 | 11/27/03 |
| GW Research Limited | SATIVEX | PA | Registered | 2021-28970 | 12/2/14 | 236894 | 12/2/14 |
| GW Research Limited | SATIVEX | PE | Registered | 771683-2018 | 10/25/18 | P00281373 | 7/5/19 |
| GW Research Limited | SATIVEX | PY | Registered | 1502174 | 1/27/15 | 457088 | 4/19/18 |
| GW Research Limited | SATIVEX | QA | Registered | 77783 | 11/12/12 | 77783 | 11/12/12 |
| GW Research Limited | SATIVEX | SA | Registered | 162129 | 11/30/10 | 131319 | 11/30/10 |
| GW Research Limited | SATIVEX | TW | Registered | 99000643 | 1/7/10 | 1431842 | 10/1/10 |
| GW Research Limited | SATIVEX | UY | Registered | 488647 | 10/23/17 | 488647 | 10/24/19 |
| GW Research Limited | SATIVEX | VE | Registered | 2010-002277 | 2/17/10 | P318080 | 7/26/12 |

| | | | | | | | |
|---------------------|--------------------------------|----|------------|------------------|----------|---------------|----------|
| GW Research Limited | SATIVEX | ZA | Registered | 2009/25333 | 12/10/09 | 200925333 | 10/11/11 |
| GW Research Limited | Sativex design | ES | Registered | M2903919 | 12/3/09 | M2903919 | 3/17/10 |
| GW Research Limited | Sativex Design | GB | Registered | UK00801029836 | 12/17/09 | UK00801029836 | 12/17/09 |
| GW Research Limited | Sativex Design | IB | Registered | 1029836 | 12/17/09 | 1029836 | 12/17/09 |
| GW Research Limited | Sativex Design | KS | Registered | KS/M/2014/000394 | 4/30/14 | 18699 | 9/5/16 |
| GW Research Limited | Sativex Design | MX | Registered | 1262255 | 3/29/12 | 1306304 | 8/23/12 |
| GW Research Limited | SATORIVEX | GB | Registered | UK00002655595 | 3/11/13 | UK00002655595 | 7/5/13 |
| GW Research Limited | SEIZURES ARE SIGNS | US | Registered | 90402952 | 12/22/20 | 6775975 | 6/28/22 |
| GW Research Limited | SEIZURES ARE SIGNS & Design | US | Registered | 90402941 | 12/22/20 | 6775974 | 6/28/22 |
| GW Research Limited | SEMVICITY | US | Allowed | 90321961 | 11/16/20 | | |
| GW Research Limited | SESKYO | EM | Registered | 17012766 | 7/21/17 | 017012766 | 11/23/17 |
| GW Research Limited | SESKYO | GB | Registered | 3264780 | 10/19/17 | 3264780 | 1/12/18 |
| GW Research Limited | SESKYO | GB | Registered | UK00917012766 | 7/21/17 | UK00917012766 | 11/23/17 |
| GW Research Limited | SIMVICITY | US | Allowed | 90321970 | 11/16/20 | | |
| GW Research Limited | SISLEFIO | EM | Registered | 17012865 | 7/21/17 | 017012865 | 11/23/17 |
| GW Research Limited | SISLEFIO | GB | Registered | UK00917012865 | 7/21/17 | UK00917012865 | 11/23/17 |
| GW Research Limited | STRAIGHT FACTS ON CBD & Design | US | Allowed | 90667311 | 4/23/21 | | |
| GW Research Limited | STRAIGHT FACTS ON CBD & Design | US | Registered | 90978959 | 4/23/21 | 7001860 | 3/14/23 |
| GW Research Limited | TETRA V ARINEX | IN | Registered | 1506906 | 11/23/06 | 1506906 | 11/23/06 |
| GW Research Limited | TETTRANABINEX | CA | Registered | 1196172 | 11/6/03 | TMA677375 | 11/20/06 |
| GW Research Limited | TETTRANABINEX | EM | Registered | 3477387 | 10/30/03 | 003477387 | 4/1/05 |
| GW Research Limited | TETTRANABINEX | GB | Registered | UK00002331742 | 5/8/03 | UK00002331742 | 10/24/03 |
| GW Research Limited | TETTRANABINEX | GB | Registered | UK00903477387 | 10/30/03 | UK00903477387 | 4/1/05 |
| GW Research Limited | TETTRANABINEX | IB | Registered | 820250 | 11/6/03 | 820250 | 11/6/03 |
| GW Research Limited | TETTRANABINEX | IL | Registered | 167830 | 11/6/03 | 167830 | 4/5/06 |
| GW Research Limited | TETTRANABINEX | IN | Registered | 1248282 | 11/7/03 | 1248282 | 11/7/03 |
| GW Research Limited | TETTRANABINEX | NZ | Registered | 704223 | 11/10/03 | 704223 | 5/10/04 |
| GW Research Limited | TETRAVARINEX | GB | Registered | UK00002422557 | 5/23/06 | UK00002422557 | 4/6/07 |
| GW Research Limited | TETRAVARINEX | GB | Registered | UK00800918111 | 11/20/06 | UK00800918111 | 3/10/08 |
| GW Research Limited | TETRAVARINEX | IB | Registered | 918111 | 11/20/06 | 918111 | 11/20/06 |
| GW Research Limited | THERACANNEX | EM | Registered | 2993764 | 1/3/03 | 002993764 | 11/18/04 |
| GW Research Limited | THERACANNEX | GB | Registered | UK00002304371 | 7/4/02 | UK00002304371 | 7/25/03 |
| GW Research Limited | THERACANNEX | GB | Registered | UK00902993764 | 1/3/03 | UK00902993764 | 11/18/04 |
| GW Research Limited | THERACANNEX | IB | Registered | 1154748 | 2/9/13 | 1154748 | 2/9/13 |
| GW Research Limited | THERACANNEX | KW | Registered | 137289 | 2/11/13 | 119845 | 4/11/14 |
| GW Research Limited | THERACANNEX | QA | Registered | 79508 | 2/10/13 | 79508 | 2/10/13 |
| GW Research Limited | THERACANNEX | SA | Registered | 192148 | 2/11/13 | 143404275 | 4/17/13 |
| GW Research Limited | THERACANNOID | GB | Registered | UK00002304390 | 7/4/02 | UK00002304390 | 5/30/03 |
| GW Research Limited | THERACANNOL | GB | Registered | UK00002304373 | 7/4/02 | UK00002304373 | 6/27/03 |
| GW Research Limited | UCREDLA | EM | Registered | 17012808 | 7/21/17 | 017012808 | 11/23/17 |
| GW Research Limited | UCREDLA | GB | Registered | UK00917012808 | 7/21/17 | UK00917012808 | 11/23/17 |
| GW Research Limited | UNSPOKEN SYMPHONY | US | Allowed | 90402920 | 12/22/20 | | |

| | | | | | | | |
|---------------------|--|----|------------|---------------|----------|---------------|----------|
| GW Research Limited | UNSPOKEN SYMPHONY | US | Published | 98007274 | 5/22/23 | | |
| GW Research Limited | UNSPOKEN SYMPHONY | US | Registered | 97474891 | 6/24/22 | 7126129 | 8/1/23 |
| GW Research Limited | UNSPOKEN SYMPHONY & Design (B/W) | US | Published | 98007294 | 5/22/23 | | |
| GW Research Limited | UNSPOKEN SYMPHONY + Design (B&W) | US | Allowed | 90402896 | 12/22/20 | | |
| GW Research Limited | UNSPOKEN SYMPHONY + Design (B&W) | US | Registered | 97474905 | 6/24/22 | 7126130 | 8/1/23 |
| GW Research Limited | VARULEY | US | Allowed | 90322021 | 11/16/20 | | |
| GW Research Limited | VUCAVY | EM | Registered | 17012774 | 7/21/17 | 017012774 | 11/23/17 |
| GW Research Limited | VUCAVY | GB | Registered | UK00917012774 | 7/21/17 | UK00917012774 | 11/23/17 |
| GW Research Limited | XORVEN | EM | Registered | 17012907 | 7/21/17 | 017012907 | 11/23/17 |
| GW Research Limited | XORVEN | GB | Registered | UK00917012907 | 7/21/17 | UK00917012907 | 11/23/17 |
| GW Research Limited | ZATIVIX | GB | Registered | UK00002655593 | 3/11/13 | UK00002655593 | 7/5/13 |
| GW Research Limited | ZATTIVEX | GB | Registered | UK00002655590 | 3/11/13 | UK00002655590 | 7/5/13 |
| GW Research Limited | ZYTIVEX | GB | Registered | UK00002655587 | 3/11/13 | UK00002655587 | 7/5/13 |
| GW Research Limited | САТИВЕКС (SATIVEX in Cyrillic characters) | AL | Registered | ALT2014256 | 4/30/14 | 15864 | 4/30/14 |
| GW Research Limited | САТИВЕКС (SATIVEX in Cyrillic characters) | BG | Registered | 2014132359N | 4/29/14 | 90962 | 4/6/15 |
| GW Research Limited | САТИВЕКС (SATIVEX in Cyrillic characters) | KS | Registered | KS/M/2014/393 | 4/30/14 | 18714 | 4/30/14 |
| GW Research Limited | САТИВЕКС (SATIVEX in Cyrillic characters) | ME | Registered | Z-2014-178 | 4/30/14 | 12684 | 11/9/15 |
| GW Research Limited | САТИВЕКС (SATIVEX in Cyrillic characters) | RS | Registered | 2014/0641 | 4/30/14 | 68542 | 12/23/14 |

| Owner | Title | Country Name | Status | Application # | Date Filed | Local Date Filed | Patent # | Grant Date |
|-------------------|---|----------------|-----------|------------------|------------|------------------|------------|------------|
| GW Pharma Limited | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | US | Pending | 18/560,346 | 05/11/2022 | 11/10/2023 | | |
| GW Pharma Limited | (-)-cis tetrahydrocannabinol ((-)-cis-THC) for use as a medicament | Australia | Pending | 2020371994 | 10/23/2020 | 04/28/2022 | | |
| GW Pharma Limited | (-)-cis-THC First Medical Use | New Zealand | Published | 787691 | 10/23/2020 | 04/28/2022 | | |
| GW Pharma Limited | (-)-cis-THC First Medical Use | Mexico | Pending | MX/A/2022/004888 | 10/23/2020 | 04/28/2022 | | |
| GW Pharma Limited | (+)-CIS TETRAHYDROCANNABINOL ((+)-CIS-THC) FOR USE AS A MEDICAMENT | Canada | Pending | 3155390 | 10/23/2020 | 04/20/2022 | | |
| GW Pharma Limited | (-)-CIS TETRAHYDROCANNABINOL ((-)-CIS-THC) FOR USE AS A MEDICAMENT | Canada | Pending | 3155386 | 10/23/2020 | 04/20/2022 | | |
| GW Pharma Limited | (+)-cis tetrahydrocannabinol ((+)-cis-THC) for use as a medicament | Australia | Pending | 2020371267 | 10/23/2020 | 04/28/2022 | | |
| GW Pharma Limited | (+)-cis-THC First Medical Use | New Zealand | Published | 787676 | 10/23/2020 | 04/28/2022 | | |
| GW Pharma Limited | (+)-cis-THC First Medical Use | Mexico | Pending | MX/A/2022/004767 | 10/23/2020 | 04/20/2022 | | |
| GW Pharma Limited | (+)-trans-THC First Medical Use | New Zealand | Published | 787668 | 10/23/2020 | 04/28/2022 | | |
| GW Pharma Limited | (+)-trans-THC First Medical Use | Mexico | Pending | MX/A/2022/004935 | 10/23/2020 | 04/22/2022 | | |
| GW Pharma Limited | (+)-trans-THC First Medical Use | Canada | Pending | 3155393 | 10/23/2020 | 04/20/2022 | | |
| GW Pharma Limited | (+)-trans-THC First Medical Use | Australia | Pending | 2020370116 | 10/23/2020 | 04/28/2022 | | |
| GW Pharma Limited | A NOVEL REFERENCE PLANT, A METHOD FOR ITS PRODUCTION, EXTRACTS OBTAINED THEREFROM AND THEIR USE | United Kingdom | Issued | 08750728.1 | 05/30/2008 | 12/28/2009 | EP2162144 | 04/28/2021 |
| GW Pharma Limited | A NOVEL REFERENCE PLANT, A METHOD FOR ITS PRODUCTION, EXTRACTS OBTAINED THEREFROM AND THEIR USE | Spain | Issued | 08750728.1 | 05/30/2008 | 12/28/2009 | EP2162144 | 04/28/2021 |
| GW Pharma Limited | A NOVEL REFERENCE PLANT, A METHOD FOR ITS PRODUCTION, EXTRACTS OBTAINED THEREFROM AND THEIR USE | Netherlands | Issued | 08750728.1 | 05/30/2008 | 12/28/2009 | EP2162144 | 04/28/2021 |
| GW Pharma Limited | A NOVEL REFERENCE PLANT, A METHOD FOR ITS PRODUCTION, EXTRACTS OBTAINED THEREFROM AND THEIR USE | France | Issued | 08750728.1 | 05/30/2008 | 12/28/2009 | EP2162144 | 04/28/2021 |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | South Africa | Issued | 2014/02207 | 09/14/2012 | 03/25/2014 | 2014/02207 | 12/23/2014 |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Taiwan | Issued | 101134706 | 09/21/2012 | | I577373 | 04/11/2017 |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Singapore | Published | 10202103035Y | 09/14/2012 | 03/24/2021 | | |

| | | | | | | | | |
|-------------------|---|-------------------|-----------|------------------|------------|------------|--------------|------------|
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | New Zealand | Issued | 622424 | 09/14/2012 | 03/19/2014 | 622424 | 02/02/2016 |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Mexico | Issued | MX/A/2014/003310 | 09/14/2012 | | 367758 | 09/05/2019 |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Republic of Korea | Issued | 2014-7009091 | 09/14/2012 | 04/04/2014 | 2107715 | 04/28/2020 |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Japan | Issued | 2014-532465 | 09/14/2012 | 03/27/2014 | 6326695 | 04/27/2018 |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Israel | Issued | 280294 | 09/14/2012 | 01/19/2021 | 280294 | 04/03/2023 |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Israel | Issued | 231701 | 09/14/2012 | 03/25/2014 | 231701 | 06/02/2021 |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Hong Kong | Published | 42021031950.5 | 05/28/2021 | 05/28/2021 | | |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | United Kingdom | Issued | 1116789.7 | 09/29/2011 | | GB2495118 | 05/18/2016 |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Canada | Issued | 2845677 | 09/14/2012 | 02/18/2014 | 2845677 | 08/18/2020 |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Australia | Issued | 2012314129 | 09/14/2012 | 03/04/2014 | 2012314129 | 12/18/2017 |
| GW Pharma Limited | Absence Seizures | Germany | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | 602015010466 | 04/25/2018 |

| | | | | | | | | |
|-------------------|--|-------------------|-----------|------------------|------------|------------|---------------|------------|
| GW Pharma Limited | Absence Seizures | Austria | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | 992122 | 04/25/2018 |
| GW Pharma Limited | Antitumor effects of cannabinoid combinations | Japan | Issued | 2011-512222 | 06/04/2009 | 12/01/2010 | 5611196 | 09/12/2014 |
| GW Pharma Limited | Anti-tumoural effects of cannabinoid combinations | Philippines | Issued | 1-2010-502652 | 06/04/2009 | 11/25/2010 | 1-2010-502652 | 08/24/2016 |
| GW Pharma Limited | Anti-tumoural effects of cannabinoid combinations | New Zealand | Issued | 589228 | 06/04/2009 | 11/11/2010 | 589228 | 09/03/2013 |
| GW Pharma Limited | Anti-tumoural effects of cannabinoid combinations | Republic of Korea | Issued | 10-2011-7000057 | 06/04/2009 | 01/03/2011 | 10-1801639 | 11/21/2017 |
| GW Pharma Limited | Anti-tumoural effects of cannabinoid combinations | Israel | Issued | 209738 | 06/04/2009 | 12/02/2010 | 209738 | 02/01/2019 |
| GW Pharma Limited | Anti-tumoural effects of cannabinoid combinations | United Kingdom | Issued | 1107850.8 | 06/04/2008 | 05/11/2011 | G82478074 | 12/26/2012 |
| GW Pharma Limited | Anti-tumoural effects of cannabinoid combinations | United Kingdom | Issued | 1105991.2 | 06/04/2008 | 04/08/2011 | G82478072 | 12/26/2012 |
| GW Pharma Limited | Anti-tumoural effects of cannabinoid combinations | United Kingdom | Issued | 0810195.8 | 06/04/2008 | 06/04/2008 | G82471987 | 02/22/2012 |
| GW Pharma Limited | Anti-tumoural effects of cannabinoid combinations | Australia | Issued | 2009254936 | 06/04/2009 | 11/26/2010 | 2009254936 | 07/02/2015 |
| GW Pharma Limited | Anti-tumoural effects of cannabinoid combinations | Taiwan | Issued | 98118351 | 06/03/2009 | | 1445531 | 07/21/2014 |
| GW Pharma Limited | Anti-tumoural effects of cannabinoid combinations with non-cannabinoid CANNABIDIOL-TYPE CANNABINOID COMPOUND | New Zealand | Pending | 787943 | 11/18/2020 | 05/05/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | New Zealand | Pending | 787949 | 11/18/2020 | 05/05/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | New Zealand | Pending | 788926 | 11/18/2020 | 05/13/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | New Zealand | Pending | 788850 | 11/18/2020 | 05/30/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Mexico | Pending | MX/A/2022/006046 | 11/18/2020 | 05/18/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Mexico | Pending | MX/A/2022/005995 | 11/18/2020 | 05/17/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Japan | Pending | 2022-529670 | 11/18/2020 | 05/20/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Japan | Published | 2022-529060 | 11/18/2020 | 05/18/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Japan | Published | 2022-529679 | 11/18/2020 | 05/20/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Israel | Pending | 293035 | 11/18/2020 | 05/16/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Israel | Pending | 293033 | 11/18/2020 | 05/16/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | China | Published | 202080079590.5 | 11/18/2020 | 05/16/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Canada | Pending | 3156764 | 11/18/2020 | 04/29/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Canada | Pending | 3156758 | 11/18/2020 | 04/29/2022 | | |

| | | | | | | | | |
|-------------------|---|----------------|---------|------------------|------------|------------|-----------|------------|
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Canada | Pending | 3158182 | 11/18/2020 | 05/12/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Canada | Pending | 3158192 | 11/18/2020 | 05/12/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Brazil | Pending | BR112022009580.5 | 11/18/2020 | 05/17/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Australia | Pending | 2020388277 | 11/18/2020 | 05/05/2022 | | |
| GW Pharma Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Australia | Pending | 2020385666 | 11/18/2020 | 05/05/2022 | | |
| GW Pharma Limited | Cannabinoid extracts as neuroprotectants | Romania | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Pharma Limited | Cannabinoid extracts as neuroprotectants | Poland | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Pharma Limited | Cannabinoid extracts as neuroprotectants | Monaco | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Pharma Limited | Cannabinoid extracts as neuroprotectants | Hungary | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Pharma Limited | Cannabinoid extracts as neuroprotectants | Czechia | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Pharma Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Romania | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Pharma Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Poland | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Pharma Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Monaco | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Pharma Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Hungary | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Pharma Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Denmark | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Pharma Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Czechia | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Pharma Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Austria | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Pharma Limited | CANNABINOID-CONTAINING PLANT EXTRACTS FOR THE TREATMENT OF PROSTATE CANCER | Hong Kong | Issued | 10106725.7 | 07/12/2010 | 07/12/2010 | 1139877B | 01/31/2020 |
| GW Pharma Limited | CANNABINOID-CONTAINING PLANT EXTRACTS FOR THE TREATMENT OF PROSTATE CANCER | United Kingdom | Issued | 08737019.3 | 04/17/2008 | 11/17/2009 | EP2146731 | 01/16/2019 |
| GW Pharma Limited | CANNABINOIDS (THC:CBD RATIO) IN COMBINATION WITH AN ALKYLATING AGENT FOR USE IN TREATING BRAIN TUMOUR | Netherlands | Issued | 16201983.0 | 06/04/2009 | 12/02/2016 | EP3213748 | 08/18/2021 |

| | | | | | | | | |
|-------------------|--|----------------|-----------|-------------|------------|------------|-----------|------------|
| GW Pharma Limited | CANNABINOIDS (THC:CBD RATIO) IN COMBINATION WITH AN ALKYLATING AGENT FOR USE IN TREATING BRAIN TUMOUR | Italy | Issued | 16201983.0 | 06/04/2009 | 12/02/2016 | EP3213748 | 08/18/2021 |
| GW Pharma Limited | CANNABINOIDS (THC:CBD RATIO) IN COMBINATION WITH AN ALKYLATING AGENT FOR USE IN TREATING BRAIN TUMOUR | United Kingdom | Issued | 16201983.0 | 06/04/2009 | | EP3213748 | 08/18/2021 |
| GW Pharma Limited | CANNABINOIDS (THC:CBD RATIO) IN COMBINATION WITH AN ALKYLATING AGENT FOR USE IN TREATING BRAIN TUMOUR | France | Issued | 16201983.0 | 06/04/2009 | 12/02/2016 | EP3213748 | 08/18/2021 |
| GW Pharma Limited | CANNABINOIDS (THC:CBD RATIO) IN COMBINATION WITH AN ALKYLATING AGENT FOR USE IN TREATING BRAIN TUMOUR | Spain | Issued | 16201983.0 | 06/04/2009 | 12/02/2016 | EP3213748 | 08/18/2021 |
| GW Pharma Limited | Cannabinoids for the treatment of neuropathic pain | Japan | Issued | 2009-517376 | 06/21/2007 | 12/24/2008 | 539898 | 11/01/2013 |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | US | Published | 17/585,415 | 01/26/2022 | | | |
| GW Pharma Limited | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders | Italy | Issued | 12731151.2 | 06/29/2012 | 06/29/2012 | EP2726069 | 05/01/2019 |
| GW Pharma Limited | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders | United Kingdom | Issued | 1211639.8 | 06/29/2012 | 06/29/2012 | G82492487 | 09/16/2015 |
| GW Pharma Limited | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders | United Kingdom | Issued | 12731151.2 | 06/29/2012 | 06/29/2012 | EP2726069 | 05/01/2019 |
| GW Pharma Limited | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders | France | Issued | 12731151.2 | 06/29/2012 | 06/29/2012 | EP2726069 | 05/01/2019 |
| GW Pharma Limited | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders | Spain | Issued | 12731151.2 | 06/29/2012 | 06/29/2012 | EP2726069 | 05/01/2019 |
| GW Pharma Limited | PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | US | Published | 17/576,868 | 01/14/2022 | | | |
| GW Pharma Limited | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders | Germany | Issued | 12731151.2 | 06/29/2012 | 06/29/2012 | EP2726069 | 05/01/2019 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | New Zealand | Issued | 618246 | 05/18/2012 | 11/28/2013 | 618246 | 05/03/2016 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Japan | Issued | 2014-510885 | 05/18/2012 | 11/15/2013 | 6147249 | 05/26/2017 |

| | | | | | | | | |
|-------------------|---|----------------|--------|------------|------------|------------|------------------|------------|
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Israel | Issued | 229474 | 05/18/2012 | 11/17/2013 | 229474 | 03/01/2019 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | United Kingdom | Issued | 1512357.3 | 05/20/2011 | 07/15/2015 | GB2524689 | 01/27/2016 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | United Kingdom | Issued | 1108506.5 | 05/20/2011 | 05/20/2011 | GB2491118 | 12/30/2015 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | United Kingdom | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | EP2709604 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Turkey | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | TR 2017 06225 T4 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Switzerland | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | EP2709604 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Sweden | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | EP2709604 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Spain | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | EP2709604 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Portugal | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | EP2709604 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Netherlands | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | EP2709604 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Italy | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | 502017000046585 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Ireland | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | EP2709604 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Germany | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | 602012028260 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | France | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | EP2709604 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Denmark | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | EP2709604 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Belgium | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | EP2709604 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Austria | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | 864972 | 02/01/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Canada | Issued | 2833099 | 05/18/2012 | 10/11/2013 | 2833099 | 11/03/2020 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Australia | Issued | 2012260611 | 05/18/2012 | 11/21/2013 | 2012260611 | 09/28/2017 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Poland | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | 2037902 | 07/03/2013 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | United Kingdom | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | EP2037902 | 07/03/2013 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Switzerland | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | 2037902 | 07/03/2013 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Sweden | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | 2037902 | 07/03/2013 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Spain | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | 2037902 | 07/03/2013 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Netherlands | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | EP2037902 | 07/03/2013 |

| | | | | | | | | |
|-------------------|---|----------------|--------|----------------|------------|------------|-----------------|------------|
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Italy | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | 502013902195752 | 07/03/2013 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Ireland | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | 2037902 | 07/03/2013 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Germany | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | 602007031391 | 07/03/2013 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | France | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | 2037902 | 07/03/2013 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Belgium | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | EP2037902 | 07/03/2013 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Austria | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | 619300 | 07/03/2013 |
| GW Pharma Limited | Cannabinoids for use in the treatment of neuropathic pain (High CBD extract) | Canada | Issued | 2656698 | 06/21/2007 | 12/18/2008 | 2656698 | 10/13/2015 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON -CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | New Zealand | Issued | 589373 | 06/04/2009 | 11/18/2010 | 589373 | 09/03/2013 |
| GW Pharma Limited | Cannabinoids in combination with non -cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents) | China | Issued | 200980120573.5 | 06/04/2009 | 12/03/2010 | 1663502 | 05/13/2015 |
| GW Pharma Limited | Cannabinoids in combination with non -cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents) | Australia | Issued | 2009254935 | 06/04/2009 | 11/29/2010 | 2009254935 | 07/02/2015 |
| GW Pharma Limited | Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators | United Kingdom | Issued | 1101072.5 | 06/04/2008 | 01/21/2011 | GB2475183 | 11/23/2011 |
| GW Pharma Limited | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents | Taiwan | Issued | 98118352 | 06/03/2009 | | 1469777 | 01/21/2015 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | South Africa | Issued | 2010/08558 | 06/04/2009 | 11/29/2010 | 2010/08558 | 11/26/2014 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Turkey | Issued | 09757810.8 | 06/04/2009 | | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Sweden | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Portugal | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Netherlands | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 2320881 | 09/20/2017 |

| | | | | | | | | |
|-------------------|---|----------------|--------|------------|------------|------------|--------------|------------|
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Luxembourg | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Italy | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Ireland | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | United Kingdom | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | EP2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | France | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Finland | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Spain | Issued | 09757810.8 | 06/04/2009 | | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Denmark | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Germany | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 602009048453 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Czechia | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Switzerland | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Canada | Issued | 2726257 | 06/04/2009 | 11/29/2010 | 2726257 | 09/13/2016 |

| | | | | | | | | |
|-------------------|---|--------------------|-----------|-------------------|------------|------------|----------------|------------|
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Belgium | Issued | 09757810.8 | 06/04/2009 | 06/04/2009 | 2320881 | 09/20/2017 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS) | Austria | Issued | 09757810.8 | 06/04/2009 | | 2320881 | 09/20/2017 |
| GW Pharma Limited | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (eg SERM or alkylating agents) | Japan | Issued | 2011-512221 | 06/04/2009 | 12/01/2010 | JP5674649 | 01/09/2015 |
| GW Pharma Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (FOR INSTANCE, SERMS OR ALKYLATING AGENTS) | Russian Federation | Issued | 2010154672 | 06/04/2009 | 12/30/2010 | 2543034 | 02/27/2015 |
| GW Pharma Limited | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents | United Kingdom | Issued | 0810203.0 | 06/04/2008 | 06/04/2008 | GB2460672 | 01/04/2012 |
| GW Pharma Limited | CANNABINOIDS IN SKIN INFLAMMATION | Germany | Issued | 60 2016 046 314.8 | 09/29/2016 | 09/29/2016 | 602016046314.8 | 10/21/2020 |
| GW Pharma Limited | Cannabionoids for use in the treatment of neuro-degenerative diseases or disorders | Hong Kong | Issued | 14111255.1 | 11/06/2014 | 11/06/2014 | 11978063 | 05/15/2020 |
| GW Pharma Limited | CBD / SAED'S combination | Israel | Issued | 227298 | 01/03/2012 | 07/02/2013 | 227298 | 03/01/2018 |
| GW Pharma Limited | CBD / SAED'S combination | Republic of Korea | Issued | 2013-7020543 | 01/03/2012 | 08/02/2013 | 1853634 | 04/25/2018 |
| GW Pharma Limited | CBD / SAED'S combination | Japan | Issued | 2013-546766 | 01/03/2012 | 06/28/2013 | 6076259 | 01/20/2017 |
| GW Pharma Limited | CBD / SAED'S combination | Hong Kong | Published | 42021038677.7 | 09/10/2021 | 09/10/2021 | | |
| GW Pharma Limited | CBD / SAED'S combination | Denmark | Issued | 12700294.7 | 01/03/2012 | 01/03/2012 | EP2661263 | 04/14/2021 |
| GW Pharma Limited | CBD / SAED'S combination | Germany | Issued | 12700294.7 | 01/03/2012 | | 602012075202.5 | 04/14/2021 |
| GW Pharma Limited | CBD / SAED'S combination | Czechia | Issued | 12700294.7 | 01/03/2012 | 01/03/2012 | EP2661263 | 04/14/2021 |
| GW Pharma Limited | CBD / SAED'S combination | Belgium | Issued | 12700294.7 | 01/03/2012 | 01/03/2012 | EP2661263 | 04/14/2021 |
| GW Pharma Limited | CBD / SAED'S combination | Austria | Issued | 12700294.7 | 01/03/2012 | 01/03/2012 | EP2661263 | 04/14/2021 |
| GW Pharma Limited | CBDa for use in epilepsy | New Zealand | Published | 777608 | 07/29/2016 | 06/29/2021 | | |
| GW Pharma Limited | CBDa for use in epilepsy | New Zealand | Pending | 739200 | 07/29/2016 | 01/17/2018 | | |
| GW Pharma Limited | CBDV EPILEPSY | South Africa | Issued | 2012/08141 | 03/30/2011 | 10/29/2012 | 2012/08141 | 06/26/2013 |
| GW Pharma Limited | CBDV EPILEPSY | Taiwan | Issued | 100108735 | 03/15/2011 | | 1583374 | 05/21/2017 |
| GW Pharma Limited | CBDV EPILEPSY | New Zealand | Issued | 602925 | 03/30/2011 | | 602925 | 03/03/2015 |
| GW Pharma Limited | CBDV EPILEPSY | Mexico | Issued | MX/A/2012/011033 | 03/30/2011 | | 330328 | 05/27/2015 |
| GW Pharma Limited | CBDV EPILEPSY | Republic of Korea | Issued | 10-2012-7028091 | 03/30/2011 | 10/26/2012 | 10-1849703 | 04/11/2018 |
| GW Pharma Limited | CBDV EPILEPSY | Japan | Issued | 2013-501945 | 03/30/2011 | 09/07/2012 | 5918748 | 04/15/2016 |
| GW Pharma Limited | CBDV EPILEPSY | Israel | Issued | 222132 | 03/30/2011 | 09/24/2012 | 222132 | 07/31/2018 |
| GW Pharma Limited | CBDV EPILEPSY | Hong Kong | Published | 42021033922.2 | 06/29/2021 | 06/29/2021 | | |
| GW Pharma Limited | CBDV EPILEPSY | United Kingdom | Issued | 1005364.3 | 03/30/2010 | | GB2479153 | 03/19/2014 |
| GW Pharma Limited | CBDV EPILEPSY | Canada | Issued | 2794620 | 03/30/2011 | 09/26/2012 | 2794620 | 03/13/2018 |
| GW Pharma Limited | Chemotherapeutic Agents | Singapore | Issued | 201009655-0 | 06/04/2009 | 12/28/2010 | 167613 | 07/15/2013 |
| GW Pharma Limited | Chemotherapeutic Agents | Philippines | Issued | 1-2010-502950 | 06/04/2009 | 12/29/2010 | 1-2010-502950 | 06/17/2015 |
| GW Pharma Limited | Chemotherapeutic Agents | Germany | Issued | 16201983.0 | 06/04/2009 | 06/04/2009 | EP3213748 | 08/18/2021 |
| GW Pharma Limited | Inhibition of tumor cell migration | Japan | Issued | 2014-215666 | 09/30/2005 | 10/22/2014 | JP6280489 | 01/26/2018 |
| GW Pharma Limited | INHIBITION OF TUMOUR CELL MIGRATION | Canada | Issued | 2582289 | 09/30/2005 | 03/28/2007 | 2582289 | 10/14/2014 |

| | | | | | | | | |
|-------------------|---|----------------|--------|-----------------|------------|------------|-----------------|------------|
| GW Pharma Limited | Method if extracting cannabichromene and its acid from Cannabis sativa plant material | United Kingdom | Issued | 0806553.4 | 04/10/2008 | 04/10/2008 | GB2459125 | 01/02/2013 |
| GW Pharma Limited | New pharmaceutical formulation | United Kingdom | Issued | 0713175.8 | 07/06/2007 | 07/06/2007 | GB2450753 | 07/18/2012 |
| GW Pharma Limited | NEW USE FOR CANNABINOID | India | Issued | 4431/DELNP/2007 | 11/15/2005 | 06/11/2007 | 264549 | 01/05/2015 |
| GW Pharma Limited | New use for cannabinoid | United Kingdom | Issued | 0515704.5 | 07/29/2005 | 07/29/2005 | GB2434097 | 05/19/2010 |
| GW Pharma Limited | New use for cannabinoid-containing plant extract (TRP channels) | Japan | Issued | 2010-503587 | 04/17/2008 | 10/19/2009 | 5775300 | 07/10/2015 |
| GW Pharma Limited | New use for cannabinoid-containing plant extract (TRP channels) | Italy | Issued | EP08737019.3 | 11/17/2009 | 11/17/2009 | EP2146731 | 01/16/2019 |
| GW Pharma Limited | New use for cannabinoid-containing plant extract (TRP channels) | France | Issued | EP08737019.3 | 11/17/2009 | 11/17/2009 | EP2146731 | 01/16/2019 |
| GW Pharma Limited | New use for cannabinoid-containing plant extract (TRP channels) | Spain | Issued | EP08737019.3 | 11/17/2009 | 11/17/2009 | EP2146731 | 01/16/2019 |
| GW Pharma Limited | New use for cannabinoid-containing plant extract (TRP channels) | Germany | Issued | EP08737019.3 | 11/17/2009 | 11/17/2009 | 602008058773 | 01/16/2019 |
| GW Pharma Limited | New use for cannabinoid-containing plant extracts | United Kingdom | Issued | 08762489.6 | 02/05/2010 | 02/05/2010 | EP2182940 | 03/12/2014 |
| GW Pharma Limited | New use for cannabinoid-containing plant extracts | Spain | Issued | 08762489.6 | 02/05/2010 | 02/05/2010 | 2182940 | 03/12/2014 |
| GW Pharma Limited | New use for cannabinoid-containing plant extracts | Italy | Issued | 08762489.6 | 02/05/2010 | 02/05/2010 | 502014902267436 | 03/12/2014 |
| GW Pharma Limited | New use for cannabinoid-containing plant extracts | Germany | Issued | 08762489.6 | 02/05/2010 | 02/05/2010 | 602008030842 | 03/12/2014 |
| GW Pharma Limited | New use for cannabinoid-containing plant extracts | France | Issued | 08762489.6 | 02/05/2010 | 02/05/2010 | 2182940 | 03/12/2014 |
| GW Pharma Limited | New use for cannabinoids | United Kingdom | Issued | 0801051.4 | 01/21/2008 | 01/21/2008 | GB2459637 | 06/06/2012 |
| GW Pharma Limited | PHARMACEUTICAL COMPOSITIONS | Norway | Issued | 2013011 | 03/09/2001 | 05/24/2013 | 2013011 | 06/16/2015 |
| GW Pharma Limited | PHARMACEUTICAL COMPOSITIONS COMPRISING CABBINOCHREME TYPE COMPOUNDS | Hong Kong | Issued | 06106628.1 | 06/09/2006 | 06/09/2006 | HK1084670 | 09/19/2014 |
| GW Pharma Limited | PHARMACEUTICAL COMPOSITIONS COMPRISING CABBINOCHREME TYPE COMPOUNDS | United Kingdom | Issued | 04743065.7 | 06/24/2004 | 01/16/2006 | EP1644349 | 04/09/2014 |
| GW Pharma Limited | PHARMACEUTICAL COMPOSITIONS COMPRISING CABBINOCHREME TYPE COMPOUNDS | Spain | Issued | 04743065.7 | 06/24/2004 | 01/16/2006 | 1644349 | 04/09/2014 |
| GW Pharma Limited | PHARMACEUTICAL COMPOSITIONS COMPRISING CABBINOCHREME TYPE COMPOUNDS | Italy | Issued | 04743065.7 | 06/24/2004 | 01/16/2006 | 502014902271127 | 04/09/2014 |
| GW Pharma Limited | PHARMACEUTICAL COMPOSITIONS COMPRISING CABBINOCHREME TYPE COMPOUNDS | Germany | Issued | 04743065.7 | 06/24/2004 | 01/16/2006 | 602004044789 | 04/09/2014 |
| GW Pharma Limited | PHARMACEUTICAL COMPOSITIONS COMPRISING CABBINOCHREME TYPE COMPOUNDS | France | Issued | 04743065.7 | 06/24/2004 | 01/16/2006 | 1644349 | 04/09/2014 |
| GW Pharma Limited | Pharmaceutical compositions comprising cannabigerol | Japan | Issued | 2009-514901 | 06/14/2007 | 12/15/2008 | 5286255 | 06/07/2013 |
| GW Pharma Limited | Pharmaceutical compositions comprising cannabigerol | Germany | Issued | 07733222.9 | 01/14/2009 | 01/14/2009 | 602007034652 | 01/08/2014 |

| | | | | | | | | |
|-------------------|--|----------------|---------|------------------|------------|------------|------------------|------------|
| GW Pharma Limited | Pharmaceutical compositions comprising cannabigerol | Canada | Issued | 2655094 | 06/14/2007 | 12/11/2008 | 2655094 | 09/30/2014 |
| GW Pharma Limited | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASE AND/OR SYMPTOMS IN ARTHRITIS. | Mexico | Pending | PA/A/2006/014057 | 06/07/2005 | 12/08/2006 | | |
| GW Pharma Limited | Pharmaceutical formulations (Sativex product) | Switzerland | Issued | 1542657 | 08/14/2003 | 02/14/2014 | CO1542657/01 | 03/31/2016 |
| GW Pharma Limited | Pharmaceutical formulations (Sativex product) | Spain | Issued | C201200015 | 08/14/2003 | 04/27/2012 | C201200015 | 07/26/2013 |
| GW Pharma Limited | Pharmaceutical formulations (Sativex product) | Denmark | Issued | CA 2012 00016 | 08/14/2003 | 05/01/2012 | EP1542657 | 07/30/2012 |
| GW Pharma Limited | Pharmaceutical formulations (Sativex product) | Austria | Issued | SZ 25/2012 | 08/14/2003 | 05/31/2012 | SZ 25/2012 | 04/08/2013 |
| GW Pharma Limited | Pharmaceutical formulations (Sativex product) | Germany | Issued | 122012000032.2 | 08/14/2003 | 05/15/2012 | DE122012000032.2 | 07/24/2017 |
| GW Pharma Limited | Pharmaceutical formulations (Sativex product) | Sweden | Issued | 1290014-8 | 08/14/2003 | 04/26/2012 | 1542657 | 11/27/2012 |
| GW Pharma Limited | Pharmaceutical formulations (Sativex product) | Ireland | Issued | 1542657 | 08/14/2003 | 09/10/2014 | 2014/049 | 10/17/2016 |
| GW Pharma Limited | Pharmaceutical formulations (Sativex product) | Slovakia | Issued | 5023-2012 | 08/14/2003 | 12/10/2012 | DO144 | 05/26/2014 |
| GW Pharma Limited | Pharmaceutical formulations (Sativex product) | Netherlands | Issued | EP1542657 | 08/14/2003 | 01/18/2013 | 300572 | 08/15/2013 |
| GW Pharma Limited | Pharmaceutical formulations (Sativex product) | Czechia | Issued | SPC/CZ 2012-219 | 08/14/2003 | 04/24/2012 | 1542657/219 | 04/16/2011 |
| GW Pharma Limited | Pharmaceutical formulations (Sativex product) | Belgium | Issued | 2013C/010 | 08/14/2003 | 02/13/2013 | 2013C/010 | 07/22/2015 |
| GW Pharma Limited | Pharmaceutical formulations (Sativex product) | Luxembourg | Issued | 92233 | 08/14/2003 | 06/26/2013 | 92233 | 08/26/2013 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | United Kingdom | Issued | 1218732.4 | 10/18/2012 | 10/18/2012 | GB2495841 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Sweden | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Portugal | Pending | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Poland | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Netherlands | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Japan | Issued | 2014-536325 | 10/17/2012 | 04/16/2014 | 6316193 | 04/06/2018 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Italy | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Iceland | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Ireland | Issued | 12780523.2 | 10/17/2012 | | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Hungary | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | United Kingdom | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |

| | | | | | | | | |
|-------------------|--|----------------|--------|--------------|------------|------------|--------------|------------|
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | France | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Finland | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Spain | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Germany | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Switzerland | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Belgium | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | Austria | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES | United Kingdom | Issued | 1120067.2 | 11/21/2011 | 11/21/2011 | GB2496688 | 06/29/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES | Spain | Issued | 12794753.9 | 11/21/2012 | 11/21/2012 | EP2782563 | 04/25/2018 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES | Italy | Issued | 12794753.9 | 11/21/2012 | 11/21/2012 | EP2782563 | 04/25/2018 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES | Germany | Issued | 12794753.9 | 11/21/2012 | 11/21/2012 | 602012045683 | 04/25/2018 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES | France | Issued | 12794753.9 | 11/21/2012 | 11/21/2012 | EP2782563 | 04/25/2018 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | New Zealand | Issued | 629136 | 03/11/2011 | 08/27/2014 | 629136 | 07/01/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | New Zealand | Issued | 602953 | 03/11/2011 | 10/11/2012 | 602953 | 01/06/2015 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Malta | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Japan | Issued | 2012-556592 | 03/11/2011 | 09/10/2012 | 5785569 | 07/31/2015 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Israel | Issued | 221871 | 03/11/2011 | 09/10/2012 | 221871 | 07/01/2017 |
| GW Pharma Limited | Phytocannabinoids in the treatment of cancer | United Kingdom | Issued | 1718726.1 | 03/12/2010 | 11/13/2017 | GB2554592 | 07/11/2018 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | United Kingdom | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Switzerland | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Sweden | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Spain | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Norway | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |

| | | | | | | | | |
|-------------------|---|-------------|-----------|------------------|------------|------------|-----------------|------------|
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Netherlands | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Luxembourg | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Italy | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | 502016000047511 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Ireland | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Iceland | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Germany | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | 602011023212 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | France | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Finland | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Denmark | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Belgium | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Austria | Issued | EP11709175.1 | 03/11/2011 | 03/11/2011 | 774321 | 02/10/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | Australia | Issued | 2018217273 | 03/11/2011 | 08/16/2018 | 2018217273 | 06/25/2020 |
| GW Pharma Limited | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | New Zealand | Pending | 805429 | 05/11/2022 | 11/10/2023 | | |
| GW Pharma Limited | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Mexico | Pending | MX/A/2023/013250 | 05/11/2022 | 11/09/2023 | | |
| GW Pharma Limited | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Japan | Pending | 2023-569987 | 05/11/2022 | 11/10/2023 | | |
| GW Pharma Limited | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | China | Published | 202280034615.9 | 05/11/2022 | 11/10/2023 | | |
| GW Pharma Limited | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Canada | Pending | 3218211 | 05/11/2022 | 11/07/2023 | | |
| GW Pharma Limited | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Taiwan | Published | 111117727 | 05/11/2022 | | | |
| GW Pharma Limited | SPC - Pharmaceutical formulations (Sativex product) | Portugal | Issued | 509 | 08/14/2003 | 12/12/2012 | 509 | 03/20/2013 |
| GW Pharma Limited | Supplementary Protection Certificate | Italy | Issued | UB2013001319 | 08/14/2003 | 07/26/2013 | 0000001319 | 10/28/2013 |

| | | | | | | | | |
|-------------------|--|-------------|--------|------------------|------------|------------|------------------|------------|
| GW Pharma Limited | Supplementary Protection Certificate | France | Issued | 1542657 | 08/14/2003 | 03/21/2014 | FR14C0025 | 08/08/2014 |
| GW Pharma Limited | Supplementary Protection Certificate based on P-375224 | Poland | Issued | 0245/0215220 | 08/14/2003 | 09/10/2013 | EP215220 | 01/10/2017 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Mexico | Issued | MX/A/2014/014839 | 06/10/2013 | 12/04/2014 | 356052 | 05/11/2018 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Turkey | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | TR 2016 09966 T4 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Switzerland | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Sweden | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Spain | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Slovenia | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | San Marino | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Romania | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Portugal | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Poland | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Norway | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Netherlands | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Monaco | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Malta | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Luxembourg | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Lithuania | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Latvia | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Italy | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | 502016000081741 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Iceland | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Hungary | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Greece | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Germany | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | 602013009393 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | France | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Finland | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |

| | | | | | | | | |
|-------------------|---|-----------------|--------|------------------|------------|------------|-----------|------------|
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Estonia | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Denmark | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Czechia | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Cyprus | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Croatia | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Bulgaria | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Belgium | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Austria | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | 811710 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Albania | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES OF CANNABIDIOL WITH HYPOTHERMIA FOR NEUROPROTECTION | Serbia | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES OF CANNABIDIOL WITH HYPOTHERMIA FOR NEUROPROTECTION | North Macedonia | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES OF CANNABIDIOL WITH HYPOTHERMIA FOR NEUROPROTECTION | Slovakia | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | SYNERGISTIC THERAPIES OF CANNABIDIOL WITH HYPOTHERMIA FOR NEUROPROTECTION | Ireland | Issued | 13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Turkey | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Poland | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Mexico | Issued | MX/A/2014/006057 | 11/20/2012 | 05/20/2014 | 348564 | 06/20/2017 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Japan | Issued | 2014-541761 | 11/20/2012 | 05/20/2014 | 6338531 | 05/18/2018 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Italy | Issued | 15185536.8 | 09/16/2015 | 09/16/2015 | EP3028697 | 12/26/2018 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | United Kingdom | Issued | 15185536.8 | 09/16/2015 | 09/16/2015 | EP3028697 | 12/26/2018 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | France | Issued | 15185536.8 | 11/20/2012 | 09/16/2015 | EP3028697 | 12/26/2018 |

| | | | | | | | |
|-------------------|--|--------|------------|------------|------------|-----------------|------------|
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Spain USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 15185536.8 | 09/16/2015 | 09/16/2015 | EP3028697 | 12/26/2018 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR United Kingdom USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | EP2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Sweden USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Spain USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Portugal USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Norway USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Netherlands USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Malta USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Luxembourg USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Italy USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 502016000007799 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Ireland USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Iceland USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Germany USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 602012012034 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR France USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Finland USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Denmark USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR Czechia USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |

| | | | | | | | | |
|-------------------|--|-------------------|--------|--------------------|------------|------------|--------------------|------------|
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Germany | Issued | 15185536.8 | 09/16/2015 | 09/16/2015 | EP3028697 | 12/26/2018 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Switzerland | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Belgium | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Australia | Issued | 2013201809 | 11/20/2012 | 03/22/2013 | 2013201809 | 08/06/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | Austria | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 757545 | 10/28/2015 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES | United Kingdom | Issued | 12794753.9 | 11/21/2012 | 11/21/2012 | EP2782563 | 04/25/2018 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING | United Kingdom | Issued | 1307047.9 | 04/18/2013 | | GB2513167 | 03/02/2016 |
| GW Pharma Limited | THCV in treatment of appetite disorders | United Kingdom | Issued | 05803521.3 | 05/18/2007 | 05/18/2007 | EP1811983 | 10/07/2020 |
| GW Pharma Limited | THCV in treatment of appetite disorders | Spain | Issued | 05803521.3 | 05/18/2007 | 05/18/2007 | EP1811983 | 10/07/2020 |
| GW Pharma Limited | THCV in treatment of appetite disorders | Italy | Issued | 05803521.3 | 05/18/2007 | 05/18/2007 | EP1811983 | 10/07/2020 |
| GW Pharma Limited | THCV in treatment of appetite disorders | Germany | Issued | 05803521.3 | 05/18/2007 | 05/18/2007 | EP1811983 | 10/07/2020 |
| GW Pharma Limited | THCV in treatment of appetite disorders | France | Issued | 05803521.3 | 05/18/2007 | 05/18/2007 | EP1811983 | 10/07/2020 |
| GW Pharma Limited | THCV in treatment of appetite disorders | China | Issued | 200580039064.10001 | 11/15/2005 | 05/15/2007 | 200580039064.10001 | 08/17/2016 |
| GW Pharma Limited | THCV in treatment of appetite disorders | Republic of Korea | Issued | 10-2012-7003649 | 11/15/2005 | 02/10/2012 | 10-1221505 | 01/07/2013 |
| GW Pharma Limited | THCV in treatment of appetite disorders | New Zealand | Issued | 554868 | 11/15/2005 | 05/01/2007 | 554868 | 08/12/2010 |
| GW Pharma Limited | THCV in treatment of appetite disorders | Mexico | Issued | MX/A/2007/005626 | 11/15/2005 | 05/16/2007 | 296744 | 03/06/2012 |
| GW Pharma Limited | THCV in treatment of appetite disorders | Japan | Issued | 2007-540721 | 11/15/2005 | 05/15/2007 | 4934048 | 02/24/2012 |
| GW Pharma Limited | THCV in treatment of appetite disorders | Israel | Issued | 183101 | 11/15/2005 | 05/10/2007 | IL 183101 | 07/31/2015 |
| GW Pharma Limited | THCV in treatment of appetite disorders | Canada | Issued | 2586358 | 11/15/2005 | 05/03/2007 | 2586358 | 11/24/2015 |
| GW Pharma Limited | THCV in treatment of appetite disorders | Australia | Issued | 2005305675 | 11/15/2005 | 05/02/2007 | 2005305675 | 03/25/2013 |
| GW Pharma Limited | Treatment of Rheumatoid Arthritis (Sativex) | Poland | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Pharma Limited | Treatment of Rheumatoid Arthritis (Sativex) | Hungary | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Pharma Limited | USE OF A COMBINATION OF DELTA-9-TETRAHYDROCANNBINOL AND CANNABIDIOL IN THE TREATMENT OF BRAIN CANCER | Canada | Issued | 2726258 | 06/04/2009 | 11/29/2010 | 2726258 | 09/12/2017 |
| GW Pharma Limited | USE OF CANNABIDIOL FOR THE INHIBITION OF BRAIN TUMOUR CELL MIGRATION | United Kingdom | Issued | EP05788521.2 | 09/30/2005 | | EP1802274 | 09/17/2008 |
| GW Pharma Limited | USE OF CANNABIDIOL FOR THE INHIBITION OF BRAIN TUMOUR CELL MIGRATION | Switzerland | Issued | EP05788521.2 | 09/30/2005 | | EP1802274 | 09/17/2008 |

| | | | | | | | | |
|-------------------|---|----------------|---------|------------------|------------|------------|--------------|------------|
| GW Pharma Limited | USE OF CANNABIDIOL FOR THE INHIBITION OF BRAIN TUMOUR CELL MIGRATION | Sweden | Issued | EP05788521.2 | 09/30/2005 | | EP1802274 | 09/17/2008 |
| GW Pharma Limited | USE OF CANNABIDIOL FOR THE INHIBITION OF BRAIN TUMOUR CELL MIGRATION | Spain | Issued | EP05788521.2 | 09/30/2005 | | EP1802274 | 09/17/2008 |
| GW Pharma Limited | USE OF CANNABIDIOL FOR THE INHIBITION OF BRAIN TUMOUR CELL MIGRATION | Netherlands | Issued | EP05788521.2 | 09/30/2005 | | EP1802274 | 09/17/2008 |
| GW Pharma Limited | USE OF CANNABIDIOL FOR THE INHIBITION OF BRAIN TUMOUR CELL MIGRATION | Ireland | Issued | EP05788521.2 | 09/30/2005 | | EP1802274 | 09/17/2008 |
| GW Pharma Limited | USE OF CANNABIDIOL FOR THE INHIBITION OF BRAIN TUMOUR CELL MIGRATION | Germany | Issued | 05788521.2 | 09/30/2005 | | 602005009852 | 09/17/2008 |
| GW Pharma Limited | USE OF CANNABIDIOL FOR THE INHIBITION OF BRAIN TUMOUR CELL MIGRATION | France | Issued | EP05788521.2 | 09/30/2005 | | EP1802274 | 09/17/2008 |
| GW Pharma Limited | USE OF CANNABIDIOL FOR THE INHIBITION OF BRAIN TUMOUR CELL MIGRATION | Denmark | Issued | 05788521.2 | 09/30/2005 | | EP1802274 | 09/17/2008 |
| GW Pharma Limited | USE OF CANNABIDIOL IN COMBINATION WITH ARIPIRAZOLE | Poland | Issued | 16167562.4 | 12/17/2008 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABIDIOL IN COMBINATION WITH ARIPIRAZOLE | Netherlands | Issued | 16167562.4 | 12/17/2008 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABIDIOL IN COMBINATION WITH ARIPIRAZOLE | Iceland | Issued | 16167562.4 | 12/17/2008 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABIDIOL IN COMBINATION WITH ARIPIRAZOLE | Ireland | Issued | 16167562.4 | 12/17/2008 | | EP3095452 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABIDIOL IN COMBINATION WITH ARIPIRAZOLE | Hungary | Issued | 16167562.4 | 12/17/2008 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABIDIOL IN COMBINATION WITH ARIPIRAZOLE | United Kingdom | Issued | 16167562.4 | 12/17/2008 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABIDIOL IN COMBINATION WITH ARIPIRAZOLE | Germany | Issued | 16167562.4 | 12/17/2008 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABIDIOL IN COMBINATION WITH ARIPIRAZOLE | Switzerland | Issued | 16167562.4 | 12/17/2008 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABIDIOL IN COMBINATION WITH ARIPIRAZOLE | Belgium | Issued | 16167562.4 | 12/17/2008 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABIDIOL IN COMBINATION WITH ARIPIRAZOLE | Austria | Issued | 16167562.4 | 12/17/2008 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Mexico | Pending | MX/A/2022/008278 | 06/17/2015 | 07/01/2022 | | |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | New Zealand | Allowed | 765223 | 06/17/2015 | 06/15/2020 | | |

| | | | | | | | | |
|-------------------|---|----------------|---------|------------------|------------|------------|--------------|------------|
| GW Pharma Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | United Kingdom | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | 3157511 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Switzerland | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | 3157511 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Sweden | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | 3157511 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Spain | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | 3157511 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Poland | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | 3157511 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Netherlands | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | 3157511 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Germany | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | 602015010464 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | France | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | 3157511 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Belgium | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | 3157511 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Austria | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | E992121 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Mexico | Pending | MX/A/2022/004851 | 06/17/2015 | 04/21/2022 | | |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | New Zealand | Allowed | 765231 | 06/17/2015 | 06/15/2020 | | |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | New Zealand | Allowed | 727511 | 06/17/2015 | 12/15/2016 | | |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Switzerland | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | EP3157512 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Sweden | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | EP3157512 | 04/25/2018 |

| | | | | | | | | |
|-------------------|--|--------------------|-----------|------------------|------------|------------|---------------|------------|
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Spain | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | EP3157512 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Poland | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | EP3157512 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Netherlands | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | EP3157512 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Italy | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | EP3157512 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Ireland | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | EP3157512 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | France | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | EP3157512 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Belgium | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | EP3157512 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | New Zealand | Pending | 768000 | 10/14/2015 | 09/24/2020 | | |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | New Zealand | Published | 730980 | 10/14/2015 | 04/12/2017 | | |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Japan | Issued | 2017-520526 | 10/14/2015 | 04/13/2017 | 6692805 | 04/17/2020 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Israel | Issued | 251526 | 10/14/2015 | 04/03/2017 | 251526 | 10/01/2021 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY. | Mexico | Issued | MX/A/2016/016460 | 06/17/2015 | 12/13/2016 | 373797 | 03/24/2020 |
| GW Pharma Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX. | Mexico | Issued | MX/A/2017/004763 | 10/14/2015 | 04/11/2017 | 374007 | 07/23/2020 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Indonesia | Issued | W00201002655 | 12/17/2008 | 08/03/2010 | IDP000080694 | 01/06/2022 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | South Africa | Issued | 2010/05443 | 12/17/2008 | 07/29/2010 | 2010/05443 | 04/28/2011 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Taiwan | Issued | 97151656 | 12/31/2008 | | I519299 | 02/01/2016 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Singapore | Issued | 201004196-0 | 12/17/2008 | 06/15/2010 | 162310 | 01/31/2013 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Sweden | Issued | 16167562.4 | 04/28/2016 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Sweden | Issued | 13152600.6 | 01/24/2013 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Russian Federation | Issued | 2010132649 | 12/17/2008 | 08/03/2010 | 2503448 | 01/10/2014 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Portugal | Issued | 16167562.4 | 04/28/2016 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Portugal | Issued | 13152600.6 | 12/17/2008 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Philippines | Issued | 1-2010-501375 | 12/17/2008 | 06/16/2010 | 1-2010-501375 | 04/11/2016 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | New Zealand | Issued | 586648 | 12/17/2008 | 07/06/2010 | 586648 | 03/22/2013 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Mexico | Issued | MX/A/2010/007073 | 12/17/2008 | 06/24/2010 | 334359 | 10/27/2015 |

| | | | | | | | | |
|-------------------|--|-------------------|---------|-----------------|------------|------------|-----------------|------------|
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Republic of Korea | Issued | 10-2010-7017111 | 12/17/2008 | 07/30/2010 | 10-1631518 | 06/13/2016 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Japan | Issued | 2010-541094 | 12/17/2008 | 07/01/2010 | 5409650 | 11/15/2013 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Italy | Issued | 16167562.4 | 04/28/2016 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Italy | Issued | 8869534.1 | 08/03/2010 | 08/03/2010 | 502016000062126 | 05/18/2016 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Israel | Issued | 206784 | 12/17/2008 | 07/04/2010 | 206784 | 01/31/2015 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Hong Kong | Issued | 13114250.1 | 12/24/2013 | 12/24/2013 | HK1186416B | 09/04/2020 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Hong Kong | Issued | 11102763.8 | 03/21/2011 | 03/21/2011 | 1148672B | 11/10/2017 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | United Kingdom | Issued | 13152600.6 | 12/17/2008 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | United Kingdom | Issued | 08869534.1 | 08/03/2010 | 08/03/2010 | EP2249848 | 05/18/2016 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | United Kingdom | Issued | 1012953.4 | 12/17/2008 | 08/02/2010 | GB2468828 | 11/07/2012 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | France | Issued | 16167562.4 | 12/17/2008 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Finland | Issued | 16167562.4 | 04/28/2016 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Finland | Issued | 13152600.6 | 01/24/2013 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Spain | Issued | 16167562.4 | 04/28/2016 | 04/28/2016 | EP3095452 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Spain | Issued | 13152600.6 | 01/24/2013 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Chile | Allowed | 2008003902 | 12/24/2008 | 12/24/2008 | 2008003902 | |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Canada | Issued | 2708921 | 12/17/2008 | 06/10/2010 | 2708921 | 03/20/2018 |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | Australia | Issued | 2008346285 | 12/17/2008 | 07/15/2010 | 2008346285 | 07/16/2015 |
| GW Pharma Limited | USE OF CANNABINOIDS IN COMBINATION WITH ARIPIPRAZOLE | Sweden | Issued | 08869534.1 | 08/03/2010 | | 2249848 | 05/18/2016 |
| GW Pharma Limited | Use of cannabinoids in combination with Aripiprazole | Poland | Issued | 13152600.6 | 12/17/2008 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with Aripiprazole | Netherlands | Issued | 13152600.6 | 12/17/2008 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABINOIDS IN COMBINATION WITH ARIPIPRAZOLE | Netherlands | Issued | 08869534.1 | 12/17/2008 | 08/03/2010 | 2249848 | 05/18/2016 |
| GW Pharma Limited | Use of cannabinoids in combination with Aripiprazole | Italy | Issued | 13152600.6 | 12/17/2008 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with Aripiprazole | Iceland | Issued | 13152600.6 | 12/17/2008 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with Aripiprazole | Ireland | Issued | 13152600.6 | 12/17/2008 | | EP2609928 | 07/17/2019 |

| | | | | | | | | |
|-------------------|--|--------------------------|-----------|------------------|------------|------------|--------------|------------|
| GW Pharma Limited | Use of cannabinoids in combination with Aripiprazole | Hungary | Issued | 13152600.6 | 12/17/2008 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with Aripiprazole | France | Issued | 13152600.6 | 12/17/2008 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABINOIDS IN COMBINATION WITH ARIPIPRAZOLE | France | Issued | 08869534.1 | 08/03/2010 | 08/03/2010 | 2249848 | 05/18/2016 |
| GW Pharma Limited | Use of cannabinoids in combination with Aripiprazole | Germany | Issued | 13152600.6 | 12/17/2008 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABINOIDS IN COMBINATION WITH ARIPIPRAZOLE | Germany | Issued | 08869534.1 | 12/17/2008 | 08/03/2010 | 602008044365 | 05/18/2016 |
| GW Pharma Limited | USE OF CANNABINOIDS IN COMBINATION WITH ARIPIPRAZOLE | Czechia | Issued | 08869534.1 | 12/17/2008 | 08/03/2010 | 2249848 | 05/18/2016 |
| GW Pharma Limited | Use of cannabinoids in combination with Aripiprazole | Switzerland | Issued | 13152600.6 | 12/17/2008 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABINOIDS IN COMBINATION WITH ARIPIPRAZOLE | Switzerland | Issued | 08869534.1 | 08/03/2010 | 08/03/2010 | 2249848 | 05/18/2016 |
| GW Pharma Limited | Use of cannabinoids in combination with Aripiprazole | Belgium | Issued | 13152600.6 | 12/17/2008 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | Use of cannabinoids in combination with Aripiprazole | Austria | Issued | 13152600.6 | 12/17/2008 | 01/24/2013 | EP2609928 | 07/17/2019 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF COMORBIDITIES ASSOCIATED WITH EPILEPSY | Hong Kong | Published | 62022053511.1 | 01/16/2020 | 05/13/2022 | | |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | Israel | Issued | 251530 | 10/14/2015 | 04/03/2017 | 251530 | 02/01/2020 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | New Zealand | Allowed | 730985 | 10/14/2015 | 04/12/2017 | | |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | Mexico | Issued | MX/A/2017/004761 | 10/14/2015 | 04/11/2017 | 364633 | 05/03/2019 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Japan | Pending | 2023-199214 | 10/14/2015 | 11/24/2023 | | |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Japan | Issued | 2021-153168 | 07/29/2016 | 09/21/2021 | 7303267 | 06/26/2023 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Gulf Cooperation Council | Pending | GC2015-30192 | 10/13/2015 | | | |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Japan | Published | 2022-31730 | 10/14/2015 | 03/02/2022 | | |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Gulf Cooperation Council | Pending | GC2015-30191 | 10/13/2015 | | | |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | New Zealand | Pending | 768001 | 10/14/2015 | 09/24/2020 | | |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | New Zealand | Published | 730982 | 10/14/2015 | 04/12/2017 | | |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Israel | Issued | 281793 | 10/14/2015 | 03/24/2021 | 281793 | 02/02/2023 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Israel | Issued | 251529 | 10/14/2015 | 04/03/2017 | 251529 | 07/30/2021 |

| | | | | | | | | |
|-------------------|--|----------------|-----------|------------------|------------|------------|------------|------------|
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Mexico | Issued | MX/A/2017/004762 | 10/14/2015 | 04/11/2017 | 374009 | 07/23/2020 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | New Zealand | Allowed | 727509 | 06/17/2015 | 12/15/2016 | | |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Italy | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | 3157511 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Ireland | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | 3157511 | 04/25/2018 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY. | Mexico | Issued | MX/A/2016/016459 | 06/17/2015 | 12/13/2016 | 367338 | 08/15/2019 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATORY SKIN DISEASES | United Kingdom | Issued | 16777760.6 | 09/29/2016 | 09/29/2016 | EP3355873 | 10/21/2020 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATORY SKIN DISEASES | Spain | Issued | 16777760.6 | 09/29/2016 | 09/29/2016 | EP3355873 | 10/21/2020 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATORY SKIN DISEASES | Italy | Issued | 16777760.6 | 09/29/2016 | 09/29/2016 | EP3355873 | 10/21/2020 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATORY SKIN DISEASES | France | Issued | 16777760.6 | 09/29/2016 | 09/29/2016 | EP3355873 | 10/21/2020 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS | New Zealand | Published | 778912 | 09/08/2016 | 08/18/2021 | | |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS | New Zealand | Published | 739933 | 09/08/2016 | 02/15/2018 | | |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | United Kingdom | Issued | 1010897.5 | 06/29/2010 | 06/29/2010 | GB2471565 | 07/04/2012 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | South Africa | Issued | 2012/00373 | 06/29/2010 | 01/17/2012 | 2012/00373 | 09/26/2012 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Taiwan | Issued | 99121811 | 07/02/2010 | | 1461191 | 11/21/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Slovakia | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Malta | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Lithuania | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Singapore | Issued | 201109404-2 | 06/29/2010 | 12/16/2011 | 176914 | 09/17/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Sweden | Issued | 10734541.5 | 06/29/2010 | | 2448637 | 03/12/2014 |

| | | | | | | | | |
|-------------------|--|-------------------|-----------|------------------|------------|------------|------------|------------|
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Portugal | Issued | 10734541.5 | 06/29/2010 | | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Poland | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | New Zealand | Issued | 620838 | 06/29/2010 | 02/10/2014 | 620838 | 12/01/2015 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | New Zealand | Issued | 597704 | 06/29/2010 | 01/19/2012 | 597704 | 09/02/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Norway | Issued | 10734541.5 | 06/29/2010 | | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Netherlands | Issued | 10734541.5 | 06/29/2010 | | EP2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Mexico | Issued | MX/A/2012/000257 | 06/29/2010 | | 318952 | 04/02/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Latvia | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Luxembourg | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | EP2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Republic of Korea | Issued | 10-2012-7003123 | 06/29/2010 | 02/03/2012 | 10-1727000 | 04/10/2017 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Japan | Issued | 2012-516867 | 06/29/2010 | 12/27/2011 | 5904938 | 03/25/2016 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Italy | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | EP2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Iceland | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Israel | Issued | 217280 | 06/29/2010 | 12/29/2011 | 217280 | 09/01/2018 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Ireland | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Croatia | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | Hong Kong | Published | 62021028470.4 | 06/29/2010 | 03/30/2021 | | |

| | | | | | | | | |
|-------------------|---|----------------|--------|------------|------------|------------|--------------|------------|
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | Hong Kong | Issued | 12105434.9 | 06/05/2012 | 06/05/2012 | HK1164766B | 01/30/2015 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | Greece | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | United Kingdom | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | EP2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | France | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | Finland | Issued | 10734541.5 | 06/29/2010 | | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | Estonia | Issued | 10734541.5 | 06/29/2010 | | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | Germany | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 602010014230 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | Czechia | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | Switzerland | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | Canada | Issued | 2766082 | 06/29/2010 | 12/20/2011 | 2766082 | 06/11/2019 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | Bulgaria | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | Belgium | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | EP2448637 | 03/12/2014 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | Australia | Issued | 2010267775 | 06/29/2010 | 01/27/2012 | 2010267775 | 01/19/2017 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | Austria | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 655834 | 03/12/2014 |
| GW Pharma Limited | Use of one phytocannabinoid or combination of phytocannabinoids for the treatment of epilepsy | Denmark | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited | USE OF PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIGEROL FOR THE TREATMENT OF DEPRESSION | United Kingdom | Issued | 07733222.9 | 06/14/2007 | 01/14/2009 | EP2037501 | 01/08/2014 |

| | | | | | | | | |
|-------------------|--|----------------|--------|-------------|------------|------------|------------|------------|
| GW Pharma Limited | USE OF PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIGEROL FOR THE TREATMENT OF DEPRESSION | France | Issued | 07733222.9 | 06/14/2007 | 01/14/2009 | 2037901 | 01/08/2014 |
| GW Pharma Limited | Use of phytocannabinoid cannabidiol (CBD) | Hong Kong | Issued | 14100698.9 | 01/22/2014 | 01/22/2014 | HK1187543B | 08/06/2021 |
| GW Pharma Limited | USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER | United Kingdom | Issued | GB1310909.5 | 06/19/2013 | 06/19/2013 | GB2516814 | 08/31/2016 |
| GW Pharma Limited | USE OF TETRAHYDROCANNABIVARIN IN THE TREATMENT OF GENERALISED SEIZURES | Canada | Issued | 3,040,410 | 06/29/2010 | 04/15/2019 | 3040410 | 03/28/2023 |
| GW Pharma Limited | Use of the cannabidiol in the treatment of an epilepsy | Japan | Issued | 2020-014572 | 06/17/2015 | 01/31/2020 | 6919000 | 07/27/2021 |
| GW Pharma Limited | Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy | New Zealand | Issued | 709911 | 01/03/2012 | 07/10/2015 | 709911 | 03/24/2017 |
| GW Pharma Limited | Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy | New Zealand | Issued | 613307 | 01/03/2012 | 07/17/2013 | 613307 | 03/01/2016 |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | Sweden | Issued | 12700294.7 | 01/03/2012 | | EP2661263 | 04/14/2021 |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | Netherlands | Issued | 12700294.7 | 01/03/2012 | 01/03/2012 | EP2661263 | 04/14/2021 |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | Luxembourg | Issued | 12700294.7 | 01/03/2012 | 01/03/2012 | EP2661263 | 04/14/2021 |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | Italy | Issued | 12700294.7 | 01/03/2012 | 01/03/2012 | EP2661263 | 04/14/2021 |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | Ireland | Issued | 12700294.7 | 01/03/2012 | | EP2661263 | 04/14/2021 |

| | | | | | | | | |
|-------------------|---|----------------|-----------|----------------|------------|------------|--------------|------------|
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | United Kingdom | Issued | 12700294.7 | 01/03/2012 | 01/03/2012 | EP2661263 | 04/14/2021 |
| GW Pharma Limited | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy | United Kingdom | Issued | 1100043.7 | 01/04/2011 | | GB2487712 | 10/28/2015 |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | France | Issued | 12700294.7 | 01/03/2012 | 01/03/2012 | EP2661263 | 04/14/2021 |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | Finland | Issued | 12700294.7 | 01/03/2012 | | EP2661263 | 04/14/2021 |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | Switzerland | Issued | 12700294.7 | 01/03/2012 | 01/03/2012 | 2661263 | 04/14/2021 |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | Canada | Issued | 2822907 | 01/03/2012 | 06/25/2013 | 2822907 | 08/18/2020 |
| GW Pharma Limited | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy | Australia | Issued | 2012204800 | 01/03/2012 | 07/16/2013 | 2012204800 | 09/07/2017 |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY. | Mexico | Issued | 2013/007609 | 01/03/2012 | 06/28/2013 | 349027 | 07/07/2017 |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY | Singapore | Issued | 10201502480X | 03/30/2011 | 03/29/2015 | 10201502480X | 11/21/2019 |
| GW Pharma Limited | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy | United Kingdom | Issued | 1100042.9 | 01/04/2011 | | GB2487183 | 10/03/2018 |
| GW Pharma Limited | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy | Australia | Issued | 2011234225 | 03/30/2011 | 10/15/2012 | 2011234225 | 02/16/2017 |
| GW Pharma Limited | Zero cannabinoid plant CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS | Germany | Issued | 602008063905.3 | 05/30/2008 | 05/30/2008 | EP2162144 | 04/28/2021 |
| GW Pharma Limited | | US | Published | 17/102,109 | 11/23/2020 | | | |

| | | | | | | | | |
|-------------------|---|------------------------|-----------|------------|------------|------------|-----------|------------|
| GW Pharma Limited | (+)-CIS TETRAHYDROCANNABINOL ((+)-CIS-THC) FOR USE AS A MEDICAMENT | US | Published | 17/771,190 | 10/23/2020 | 04/22/2022 | | |
| GW Pharma Limited | USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY | US | Published | 17/012,448 | 09/04/2020 | | | |
| GW Pharma Limited | USE OF TETRAHYDROCANNABINOL AND/OR CANNABIDIOL FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF A BRAIN TUMOUR | US | Issued | 15/969,422 | 05/02/2018 | | 10758514 | 09/01/2020 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 16/090,039 | 03/28/2017 | 09/28/2018 | 10583096 | 03/10/2020 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATORY SKIN DISEASES | European Patent Office | Issued | 16777760.6 | 09/29/2016 | 09/29/2016 | EP3355873 | 10/21/2020 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATORY SKIN DISEASES | US | Issued | 15/763,186 | 09/29/2016 | 03/26/2018 | 11413266 | 08/16/2022 |
| GW Pharma Limited | USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS | US | Issued | 15/757,899 | 09/08/2016 | 03/06/2018 | 10653641 | 05/19/2020 |
| GW Pharma Limited | Use for cannabinoid | US | Issued | 14/851,378 | 09/11/2015 | 09/11/2015 | US9669002 | 06/06/2017 |
| GW Pharma Limited | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy | US | Issued | 14/685,753 | 04/14/2015 | | 10799467 | 10/13/2020 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | US | Issued | 14/579,061 | 12/22/2014 | 12/22/2014 | 9522123 | 12/20/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | US | Issued | 14/260,876 | 04/24/2014 | 04/24/2014 | 9675654 | 06/13/2017 |
| GW Pharma Limited | SYNERGISTIC THERAPIES OF CANNABIDIOL WITH HYPOTHERMIA FOR NEUROPROTECTION | European Patent Office | Issued | 13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES | US | Issued | 14/359,192 | 11/21/2012 | 05/19/2014 | US9421187 | 08/23/2016 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES | European Patent Office | Issued | 12794753.9 | 11/21/2012 | 11/21/2012 | EP2782563 | 04/25/2018 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | European Patent Office | Issued | 15185536.8 | 11/20/2012 | 09/16/2015 | EP3028697 | 12/26/2018 |
| GW Pharma Limited | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS | European Patent Office | Issued | 12795839.5 | 11/20/2012 | 11/20/2012 | 2782568 | 10/28/2015 |
| GW Pharma Limited | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER | European Patent Office | Issued | 12780523.2 | 10/17/2012 | 10/17/2012 | EP2768493 | 07/31/2019 |
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | US | Issued | 16/709,401 | 09/14/2012 | | 11318109 | 05/03/2022 |

| | | | | | | | | |
|-------------------|---|------------------------|-----------|------------|------------|------------|------------|------------|
| GW Pharma Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | US | Issued | 14/345,968 | 09/14/2012 | 03/20/2014 | 10729665 | 08/04/2020 |
| GW Pharma Limited | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders | US | Issued | 14/128,208 | 06/29/2012 | 03/25/2014 | US10258580 | 04/16/2019 |
| GW Pharma Limited | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders | European Patent Office | Issued | 12731151.2 | 06/29/2012 | 06/29/2012 | EP2726069 | 05/01/2019 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | US | Issued | 14/118,563 | 05/18/2012 | 11/19/2013 | 9895342 | 02/20/2018 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | European Patent Office | Issued | 12722495.4 | 05/18/2012 | 05/18/2012 | EP2709604 | 02/01/2017 |
| GW Pharma Limited | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy | US | Issued | 13/075,873 | 03/30/2011 | | 9125859 | 09/08/2015 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | US | Issued | 13/634,343 | 03/11/2011 | 11/19/2012 | 8790719 | 07/29/2014 |
| GW Pharma Limited | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | European Patent Office | Issued | 11709175.1 | 03/11/2011 | 03/11/2011 | EP2544682 | 02/10/2016 |
| GW Pharma Limited | Use of one or a combination of phytocannabinoids in the treatment of epilepsy | US | Issued | 13/380,305 | 06/29/2010 | 03/19/2012 | 9066920 | 06/30/2015 |
| GW Pharma Limited | Methods of preparing cannabinoids from plant material | US | Issued | 12/714,907 | 03/01/2010 | 03/01/2010 | 8846409 | 09/30/2014 |
| GW Pharma Limited | Anti-tumoural effects of cannabinoid combinations | US | Issued | 12/996,124 | 06/04/2009 | 01/28/2011 | 8632825 | 01/21/2014 |
| GW Pharma Limited | Anti-tumoural effects of cannabinoid combinations | European Patent Office | Published | 20201377.7 | 06/04/2009 | 10/12/2020 | | |
| GW Pharma Limited | Use of cannabinoids in combination with an anti-psychotic medicament | US | Issued | 12/811,393 | 12/17/2008 | 11/02/2010 | 9017737 | 04/28/2015 |
| GW Pharma Limited | USE OF TETRAHYDROCANNABINOL AND/OR CANNABIDIOL FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | European Patent Office | Issued | 08762489.6 | 06/25/2008 | 02/05/2010 | 2182940 | 03/12/2014 |
| GW Pharma Limited | A NOVEL REFERENCE PLANT, A METHOD FOR ITS PRODUCTION, EXTRACTS OBTAINED THEREFROM AND THEIR USE | European Patent Office | Issued | 08750728.1 | 05/30/2008 | 12/28/2009 | EP2162144 | 04/28/2021 |
| GW Pharma Limited | Reference plant, a method for its production, extracts obtained therefrom and their use | US | Issued | 12/156,460 | 05/30/2008 | | 9035130 | 05/19/2015 |
| GW Pharma Limited | CANNABINOID-CONTAINING PLANT EXTRACTS FOR THE TREATMENT OF PROSTATE CANCER | European Patent Office | Issued | 08737019.3 | 04/17/2008 | 11/17/2009 | EP2146731 | 01/16/2019 |
| GW Pharma Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | European Patent Office | Issued | 07733311.0 | 06/21/2007 | 01/20/2009 | 2037902 | 07/03/2013 |

| | | | | | | | | |
|--|--|--------------------------|---------|--------------|------------|------------|-----------|------------|
| GW Pharma Limited | USE OF PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIGEROL FOR THE TREATMENT OF DEPRESSION | European Patent Office | Issued | 07733222.9 | 06/14/2007 | 01/14/2009 | 2037901 | 01/08/2014 |
| GW Pharma Limited | Pharmaceutical compositions comprising cannabigerol | US | Issued | 11/760,364 | 06/08/2007 | | 8481085 | 07/09/2013 |
| GW Pharma Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | European Patent Office | Issued | 10189019.2 | 01/17/2007 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Pharma Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | European Patent Office | Issued | 07704916.1 | 01/17/2007 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Pharma Limited | NEW USE FOR CANNABINOID | European Patent Office | Issued | 05803521.3 | 11/15/2005 | 05/18/2007 | EP1811983 | 10/07/2020 |
| GW Pharma Limited | Use for cannabinoind | US | Issued | 11/667,890 | 11/15/2005 | 11/15/2007 | 9168278 | 10/27/2015 |
| GW Pharma Limited | Treatment of Rheumatoid Arthritis (Sativex) | European Patent Office | Issued | 05749393.4 | 06/07/2005 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Pharma Limited | Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions | US | Issued | 10/502,822 | 03/02/2005 | 03/02/2005 | 8034843 | 10/11/2011 |
| GW Pharma Limited | Pharmaceutical compositions comprising cannabichromene type compounds | US | Issued | 10/561,756 | 06/24/2004 | 12/21/2005 | 8470874 | 06/25/2013 |
| GW Pharma Limited | Gabrielle | European Union | Issued | 20040022 | 01/14/2004 | | | 10/10/2005 |
| GW Pharma Limited | Galina | European Union | Issued | 20040020 | 01/14/2004 | | | 10/10/2005 |
| GW Pharma Limited | Gayle | European Union | Issued | 20040023 | 01/14/2004 | | | 10/10/2005 |
| GW Pharma Limited | Georgia | European Union | Issued | 20040024 | 01/14/2004 | | | 10/10/2005 |
| GW Pharma Limited | Gill | European Union | Issued | 20040026 | 01/14/2004 | | | 10/10/2005 |
| GW Pharma Limited | Gina | European Union | Issued | 20040021 | 01/14/2004 | | | 10/10/2005 |
| GW Pharma Limited | Grace | European Union | Issued | 20040025 | 01/14/2004 | | | 02/07/2005 |
| GW Pharma Limited | Guinevere | European Union | Issued | 20040019 | 01/14/2004 | | | 10/10/2005 |
| GW Pharma Limited | Gwen | European Union | Issued | 20040018 | 01/14/2004 | | | 10/10/2005 |
| GW Pharma Limited | Methods of purifying cannabinoids from plant material | US | Issued | 10/528,951 | 09/23/2003 | 03/22/2005 | 7700368 | 04/20/2010 |
| GW Pharma Limited | DOSE DISPENSING SYSTEM AND APPARATUS | European Patent Office | Issued | 03708317.7 | 02/24/2003 | 09/18/2004 | 1478420 | 09/09/2009 |
| GW Pharma Limited | Dose dispensing system and apparatus | European Patent Office | Issued | 09169652.6 | 02/24/2003 | 09/07/2009 | EP2123318 | 01/13/2016 |
| GW Pharma Limited | Extraction of pharmaceutically active components from plant materials | US | Issued | 10/218,972 | 08/14/2002 | | 7344736 | 03/18/2008 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Venezuela | Pending | 01245-2012 | 09/28/2012 | | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Gulf Cooperation Council | Pending | GC2012-22307 | 09/24/2012 | | | |

| | | | | | | | | |
|--|--|--------------------|-----------|-----------------|------------|------------|------------------|------------|
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Anti-tumoural effects of cannabinoid combinations | Indonesia | Issued | W00201100018 | 06/04/2009 | 01/04/2011 | IDP000046588 | 06/20/2017 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Anti-tumoural effects of cannabinoid combinations cannabinoids in combination with non-cannabinoid | Venezuela | Published | 00984-2009 | 06/03/2009 | | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G SERM OR ALKYLATING AGENTS) | Malaysia | Issued | PI 2010005535 | 06/04/2009 | 11/24/2010 | MY-156264-A | 01/29/2016 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G.SERM OF ALKYLATING AGENTS) | India | Issued | 8136/DELNP/2010 | 06/04/2009 | 11/18/2010 | 292146 | 01/25/2018 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | CBD / SAED'S combination | Venezuela | Published | 00008-2012 | 01/04/2012 | | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | CBDV EPILEPSY | Venezuela | Published | 00418-2011 | 03/30/2011 | | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | CBDV EPILEPSY | China | Issued | 201180026947.4 | 03/30/2011 | 11/30/2012 | ZL201180026947.4 | 03/16/2016 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Chemotherapeutic Agents | Venezuela | Pending | 00986-2009 | 06/03/2009 | | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Chemotherapeutic Agents | Israel | Issued | 209739 | 06/04/2009 | 12/02/2010 | 209739 | 05/01/2016 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Include the pharmaceutical composition of plant cannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) | China | Published | 201810149043.4 | 09/14/2012 | 02/13/2018 | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | ONE OR A COMBINATION OF FITO-CANABINOIDES IN THE TREATMENT OF EPILEPSY | Argentina | Pending | 20100102377 | 07/02/2010 | 07/02/2010 | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | Russian Federation | Issued | 201490711 | 09/14/2012 | 04/28/2014 | 029697 | 05/31/2018 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Phytocannabinoids in the treatment of cancer | Venezuela | Published | 00294-2011 | 03/11/2011 | | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | The purposes of cannabinoid compound compositions in preparation treatment brain tumor medicine | China | Issued | 200980120759.0 | 06/04/2009 | 12/03/2010 | ZL200980120759.0 | 10/07/2015 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Use of cannabinoids in combination with an anti-psychotic medicament | China | Issued | 200880125822.5 | 12/17/2008 | 07/29/2010 | ZL200880125822.5 | 08/17/2016 |

| | | | | | | | | |
|--|---|--------------------------|---------|---------------|------------|------------|------------------|------------|
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | USE OF CANNABINOIDS IN COMBINATION WITH ARIPIRAZOLE | Turkey | Issued | 08869534.1 | 12/17/2008 | 08/03/2010 | 2249848 | 05/18/2016 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | USE OF CANNABINOIDS IN COMBINATION WITH ARIPIRAZOLE | Spain | Issued | 08869534.1 | 12/17/2008 | 08/03/2010 | 2249848 | 05/18/2016 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Use of one or a combination of phyto- cannabinoids in the treatment of epilepsy | Venezuela | Pending | 0001086-2010 | 07/02/2010 | | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Use of one or a combination of phyto- cannabinoids in the treatment of epilepsy | Cyprus | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Use of one or a combination of phyto- cannabinoids in the treatment of epilepsy | Turkey | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | TR 2014 05518 T4 | 03/12/2014 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Use of one or a combination of phyto- cannabinoids in the treatment of epilepsy | Slovenia | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Use of one or a combination of phyto- cannabinoids in the treatment of epilepsy | Romania | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Use of one or a combination of phyto- cannabinoids in the treatment of epilepsy | Monaco | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Use of one or a combination of phyto- cannabinoids in the treatment of epilepsy | Hungary | Issued | 10734541.5 | 06/29/2010 | | 2448637 | 03/12/2014 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Use of one or a combination of phyto- cannabinoids in the treatment of epilepsy | Spain | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | 2448637 | 03/12/2014 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Use of One or More Cannabinoids in the Treatment of Epilepsy | Gulf Cooperation Council | Issued | GC 2010-16200 | 06/30/2010 | 06/30/2010 | GC0005382 | 04/13/2017 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | Turkey | Issued | 12700294.7 | 01/03/2012 | 01/03/2012 | EP2661263 | 04/14/2021 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | Norway | Issued | 12700294.7 | 01/03/2012 | | EP2661263 | 04/14/2021 |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | Spain | Issued | 12700294.7 | 01/03/2012 | 01/03/2012 | EP2661263 | 04/14/2021 |

| | | | | | | | | |
|--|---|------------------------|-----------|----------------|------------|------------|-----------|------------|
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | China | Published | 201710873483.X | 01/03/2012 | 09/25/2017 | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) | European Patent Office | Published | 20192084.0 | 09/14/2012 | 09/14/2012 | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | European Patent Office | Published | 20193228.2 | 01/03/2012 | 08/27/2020 | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | CANNABIDIVARIN (CBDV) FOR USE IN THE TREATMENT OF EPILEPSY | European Patent Office | Published | 20194696.9 | 03/30/2011 | 09/04/2020 | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Use of one or a combination of phyto- cannabinoids in the treatment of epilepsy | European Patent Office | Published | 20175934.7 | 06/29/2010 | 05/21/2020 | | |
| GW Pharma Limited Otsuka Pharmaceutical Co., Limited | Use of one or a combination of phyto- cannabinoids in the treatment of epilepsy | European Patent Office | Issued | 10734541.5 | 06/29/2010 | 06/29/2010 | EP2448637 | 03/12/2014 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING | US | Pending | 18/545,754 | 12/19/2023 | | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Pending | 18/526,795 | 12/01/2023 | | | |
| GW Research Limited | CANNABINOID FORMULATIONS | US | Pending | 18/479,671 | 10/02/2023 | | | |
| GW Research Limited | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | US | Pending | 18/477,467 | 09/28/2023 | 09/28/2023 | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | US | Pending | 18/446,405 | 08/08/2023 | | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Published | 18/320,906 | 05/19/2023 | | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME | US | Published | 18/311,221 | 05/02/2023 | 05/02/2023 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Published | 18/186,792 | 03/20/2023 | | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Pending | 18/170,235 | 02/16/2023 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | US | Published | 18/161,603 | 01/30/2023 | 01/30/2023 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 17/819,046 | 08/11/2022 | | 11633369 | 04/25/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Published | 17/817,753 | 08/05/2022 | | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 17/816,349 | 07/29/2022 | | 11766411 | 09/26/2023 |

| | | | | | | | |
|---------------------|--|------------------------|-----------|------------|------------|------------|---------------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | US | Published | 17/853,367 | 06/29/2022 | | |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | US | Published | 17/841,167 | 06/15/2022 | 06/15/2022 | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | US | Issued | 17/743,653 | 05/13/2022 | 05/13/2022 | 11590087 02/28/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Published | 17/744,224 | 05/13/2022 | | |
| GW Research Limited | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | US | Pending | 18/560,341 | 05/12/2022 | 11/10/2023 | |
| GW Research Limited | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | European Patent Office | Pending | 22724861.4 | 05/12/2022 | 11/28/2023 | |
| GW Research Limited | 6-HYDROXY-CANNABIDIOL-C4 | US | Pending | 18/560,316 | 05/11/2022 | 11/10/2023 | |
| GW Research Limited | DERIVATIVES OF CANNABIDIOL-C4 FOR THE TREATMENT OF EPILEPSY | US | Pending | 18/560,337 | 05/11/2022 | 11/10/2023 | |
| GW Research Limited | NOVEL COMPOUND | European Patent Office | Pending | 22724856.4 | 05/11/2022 | 11/28/2023 | |
| GW Research Limited | NOVEL COMPOUNDS | European Patent Office | Pending | 22724857.2 | 05/11/2022 | 11/28/2023 | |
| GW Research Limited | RESCORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | European Patent Office | Pending | 22724858.0 | 05/11/2022 | 11/28/2023 | |
| GW Research Limited | USE OF CANNABIDIOL PREPARATIONS IN THE TREATMENT OF ABSENCE EPILEPSY | US | Published | 17/771,183 | 04/04/2022 | 04/22/2022 | |
| GW Research Limited | CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Published | 17/689,607 | 03/08/2022 | | |
| GW Research Limited | Oral Cannabinoid Formulations | US | Published | 17/689,245 | 03/08/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL AND CLOBAZAM IN THE TREATMENT OF CHILDHOOD-ONSET EPILEPSY SYNDROMES | US | Pending | 18/548,003 | 02/22/2022 | 08/25/2023 | |
| GW Research Limited | USE OF CANNABIDIOL AND CLOBAZAM IN THE TREATMENT OF CHILDHOOD-ONSET EPILEPSY SYNDROMES | European Patent Office | Published | 22707819.3 | 02/22/2022 | 08/23/2023 | |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CANINE EPILEPSY | US | Pending | 18/546,254 | 01/27/2022 | 08/11/2023 | |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CANINE EPILEPSY | European Patent Office | Published | 22703438.6 | 01/27/2022 | 08/30/2023 | |
| GW Research Limited | IDENTIFICATION AND TREATMENT OF PATIENTS WITH EPILEPSY | US | Pending | 18/258,485 | 12/17/2021 | 06/20/2023 | |
| GW Research Limited | IDENTIFICATION AND TREATMENT OF PATIENTS WITH EPILEPSY | European Patent Office | Published | 21840606.4 | 12/17/2021 | 06/14/2023 | |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | US | Pending | 18/257,537 | 12/15/2021 | 06/14/2023 | |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|------------|------------|------------|----------|------------|
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | European Patent Office | Published | 21830743.7 | 12/15/2021 | 07/10/2023 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | US | Pending | 18/257,373 | 12/15/2021 | 06/14/2023 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | European Patent Office | Published | 21831332.8 | 12/15/2021 | 07/10/2023 | | |
| GW Research Limited | PARENTERAL FORMULATIONS | US | Published | 17/548,232 | 12/10/2021 | 12/10/2021 | | |
| GW Research Limited | A METHOD FOR EVALUATING THE PRO- OR ANTI CONVULSIVE PROPERTIES OF TEST COMPOUNDS | European Patent Office | Published | 21827632.7 | 12/08/2021 | 07/10/2023 | | |
| GW Research Limited | A METHOD FOR EVALUATING THE PRO- OR ANTI CONVULSIVE PROPERTIES OF TEST COMPOUNDS | US | Pending | 18/257,479 | 12/08/2021 | 06/14/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH EPILEPSY SYNDROMES IN PATIENTS TAKING BRIVARACETAM | US | Pending | 18/256,307 | 12/08/2021 | 06/07/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH EPILEPSY SYNDROMES IN PATIENTS TAKING BRIVARACETAM | European Patent Office | Published | 21827631.9 | 12/08/2021 | 06/14/2023 | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | US | Issued | 17/529,005 | 11/17/2021 | | 11865102 | 01/09/2024 |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | US | Issued | 17/509,939 | 10/25/2021 | | 11406623 | 08/09/2022 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 17/477,172 | 09/16/2021 | | 11446258 | 09/20/2022 |
| GW Research Limited | CANNABINOIDS FOR USE IN THE TREATMENT OF EPILEPSY | US | Pending | 18/245,856 | 09/15/2021 | 03/17/2023 | | |
| GW Research Limited | 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) FOR USE IN THE TREATMENT OF EPILEPSY | US | Issued | 17/472,000 | 09/10/2021 | | 11793770 | 10/24/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 17/472,016 | 09/10/2021 | | 11701330 | 07/18/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 17/470,382 | 09/09/2021 | | 11684598 | 06/27/2023 |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21769152.6 | 09/08/2021 | 03/17/2023 | | |

| | | | | | | |
|---------------------|---|------------------------|-----------|------------|------------|------------|
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/044,941 | 09/08/2021 | 03/10/2023 |
| GW Research Limited | METHOD OF PREPARING CANNABINOIDS | US | Pending | 18/043,810 | 08/27/2021 | 03/02/2023 |
| GW Research Limited | METHOD OF PREPARING CANNABINOIDS | European Patent Office | Published | 21772706.4 | 08/27/2021 | 03/17/2023 |
| GW Research Limited | CANNABINOID FORMULATIONS | US | Published | 17/406,401 | 08/19/2021 | 08/19/2021 |
| GW Research Limited | CANNABIDIOL FOR USE IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/005,851 | 07/15/2021 | 01/18/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CHRNA4 MUTATION | US | Published | 18/005,868 | 07/15/2021 | 01/18/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CHRNA4 MUTATION | European Patent Office | Published | 21751517.0 | 07/15/2021 | 02/16/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS | US | Pending | 18/005,838 | 07/15/2021 | 01/17/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS | European Patent Office | Published | 21751754.9 | 07/15/2021 | 02/16/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH MUTATIONS IN THE SYNGAP1 GENE | European Patent Office | Published | 21751515.4 | 07/15/2021 | 02/16/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH MUTATIONS IN THE SYNGAP1 GENE | US | Published | 18/005,848 | 07/15/2021 | 01/17/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO BRAIN INIURY | US | Published | 18/006,131 | 07/15/2021 | 01/19/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO BRAIN INIURY | European Patent Office | Published | 21746671.3 | 07/15/2021 | 02/16/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/005,847 | 07/15/2021 | 01/17/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21745342.2 | 07/15/2021 | 02/16/2023 |

| | | | | | | | | |
|---------------------|--|--------------------------|-----------|-----------------|------------|------------|-------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21751514.7 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/006,133 | 07/15/2021 | 01/19/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21749784.1 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/005,961 | 07/15/2021 | 08/30/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21749785.8 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/005,959 | 07/15/2021 | 01/18/2023 | | |
| GW Research Limited | (-)-CIS-TETRAHYDROCANNABINOL ((-)-CIS-THC) FOR USE AS A MEDICAMENT | Republic of Korea | Published | 10-2022-7017473 | 10/23/2020 | 05/24/2022 | | |
| GW Research Limited | (-)-CIS-TETRAHYDROCANNABINOL ((-)-CIS-THC) FOR USE AS A MEDICAMENT | Japan | Pending | 2022-523987 | 10/23/2020 | 04/22/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21751748.1 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | (-)-CIS-TETRAHYDROCANNABINOL ((-)-CIS-THC) FOR USE AS MEDICAMENT | China | Published | 202080074337.0 | 10/23/2020 | 04/22/2022 | | |
| GW Research Limited | (-)-cis-THC First Medical Use | Venezuela | Pending | 2020-000180 | 10/23/2020 | 10/23/2020 | | |
| GW Research Limited | (-)-cis-THC First Medical Use | Gulf Cooperation Council | Pending | 2020/40720 | 10/22/2020 | 10/22/2020 | | |
| GW Research Limited | (+)-CIS-TETRAHYDROCANNABINOL ((+)-CIS-THC) FOR USE AS A MEDICAMENT | Republic of Korea | Pending | 10-2022-7017481 | 10/23/2020 | 05/24/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/005,960 | 07/15/2021 | 08/28/2023 | | |
| GW Research Limited | (+)-CIS-TETRAHYDROCANNABINOL ((+)-CIS-THC) FOR USE AS MEDICAMENT | China | Published | 202080074392.X | 10/23/2020 | 04/22/2022 | | |
| GW Research Limited | (+)-cis-THC First Medical Use | Japan | Published | 2022-523991 | 10/23/2020 | 04/22/2022 | | |
| GW Research Limited | (+)-cis-THC First Medical Use | Lebanon | Issued | 12033 | 10/20/2020 | | 12033 | 10/28/2020 |
| GW Research Limited | (+)-cis-THC First Medical Use | Venezuela | Pending | 2020-000182 | 10/23/2020 | 10/23/2020 | | |
| GW Research Limited | (+)-cis-THC First Medical Use | Lebanon | Issued | 12032 | 10/20/2020 | | 12032 | 10/28/2020 |
| GW Research Limited | (+)-cis-THC First Medical Use | Gulf Cooperation Council | Pending | 2020/40719 | 10/22/2020 | 10/22/2020 | | |
| GW Research Limited | (+)-cis-THC First Medical Use | Lebanon | Issued | 12034 | 10/20/2020 | | 12034 | 10/28/2020 |

| | | | | | | | | |
|---------------------|--|--------------------------|-----------|-------------------|------------|------------|-----------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21749786.6 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | (+)-TRANS-TETRAHYDROCANNABINOL ((+)-TRANS-THC) FOR USE AS A MEDICAMENT | Republic of Korea | Pending | 10-2022-7017485 | 10/23/2020 | 05/24/2022 | | |
| GW Research Limited | (+)-TRANS-TETRAHYDROCANNABINOL ((+)-TRANS-THC) FOR USE AS A MEDICAMENT | Japan | Pending | 2022-523985 | 10/23/2020 | 04/22/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/005,853 | 07/15/2021 | 01/18/2023 | | |
| GW Research Limited | (+)-TRANS-TETRAHYDROCANNABINOL ((+)-TRANS-THC) FOR USE AS MEDICAMENT | China | Published | 202080074391.5 | 10/23/2020 | 04/22/2022 | | |
| GW Research Limited | (+)-trans-THC First Medical Use | Venezuela | Pending | 2020-000181 | 10/23/2020 | 10/23/2020 | | |
| GW Research Limited | (+)-trans-THC First Medical Use | Gulf Cooperation Council | Pending | 2020/40718 | 10/22/2020 | 10/22/2020 | | |
| GW Research Limited | (+)-trans-THC First Medical Use | PCT | Published | PCT/G92020/052680 | 10/23/2020 | 10/23/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21751750.7 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | 6-HYDROXY-CANNABIDIOL-C4 | Republic of Korea | Pending | 10-2023-7041283 | 05/11/2022 | 11/29/2023 | | |
| GW Research Limited | 6-HYDROXY-CANNABIDIOL-C4 | New Zealand | Pending | 804804 | 05/11/2022 | 10/20/2023 | | |
| GW Research Limited | 6-HYDROXY-CANNABIDIOL-C4 | Mexico | Pending | MX/A/2023/013328 | 05/11/2022 | 11/09/2023 | | |
| GW Research Limited | 6-HYDROXY-CANNABIDIOL-C4 | Japan | Pending | 2023-569984 | 05/11/2022 | 11/10/2023 | | |
| GW Research Limited | 6-HYDROXY-CANNABIDIOL-C4 | China | Published | 202280032455.4 | 05/11/2022 | 11/01/2023 | | |
| GW Research Limited | 6-HYDROXY-CANNABIDIOL-C4 | Canada | Pending | 3216180 | 05/11/2022 | 10/20/2023 | | |
| GW Research Limited | 6-HYDROXY-CANNABIDIOL-C4 | Australia | Pending | 2022274249 | 05/11/2022 | 10/20/2023 | | |
| GW Research Limited | 7-HYDROXY CANNABIDIOL (7-OH-CBD) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) | United Kingdom | Issued | 15733513.4 | 06/29/2015 | 06/29/2015 | EP3160456 | 09/25/2019 |
| GW Research Limited | 7-HYDROXY-CANNABIDIVARIN (7-OH-CBDV) FOR USE IN THE TREATMENT OF EPILEPSY | Spain | Issued | 15733514.2 | 06/29/2015 | 06/29/2015 | EP3160457 | 11/20/2019 |
| GW Research Limited | 7-HYDROXY-CANNABIDIVARIN (7-OH-CBDV) FOR USE IN THE TREATMENT OF EPILEPSY | Italy | Issued | 15733514.2 | 06/29/2015 | 06/29/2015 | EP3160457 | 11/20/2019 |
| GW Research Limited | 7-HYDROXY-CANNABIDIVARIN (7-OH-CBDV) FOR USE IN THE TREATMENT OF EPILEPSY | Germany | Issued | 15733514.2 | 06/29/2015 | 06/29/2015 | EP3160457 | 11/20/2019 |
| GW Research Limited | 7-HYDROXY-CANNABIDIVARIN (7-OH-CBDV) FOR USE IN THE TREATMENT OF EPILEPSY | France | Issued | 15733514.2 | 06/29/2015 | 06/29/2015 | EP3160457 | 11/20/2019 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/005,852 | 07/15/2021 | 01/18/2023 | | |

| | | | | | | | | |
|---------------------|--|------------------------|-----------|-------------------|------------|------------|-----------|------------|
| GW Research Limited | 7-HYDROXY-CANNABIDIVARIN (7-OH-CBDV) FOR USE IN THE TREATMENT OF EPILEPSY | United Kingdom | Issued | 15733514.2 | 06/29/2015 | 06/29/2015 | EP3160457 | 11/20/2019 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21751757.2 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/005,845 | 07/15/2021 | 01/17/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21751758.0 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | 7-OH-CBD DIABETES | Italy | Issued | 15733513.4 | 06/29/2015 | 06/29/2015 | EP3160456 | 09/25/2019 |
| GW Research Limited | 7-OH-CBD DIABETES | France | Issued | 15733513.4 | 06/29/2015 | 06/29/2015 | EP3160456 | 09/25/2019 |
| GW Research Limited | 7-OH-CBD DIABETES | Spain | Issued | 15733513.4 | 06/29/2015 | 06/29/2015 | EP3160456 | 09/25/2019 |
| GW Research Limited | 7-OH-CBD DIABETES | Germany | Issued | 15733513.4 | 06/29/2015 | 06/29/2015 | EP3160456 | 09/25/2019 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/005,843 | 07/15/2021 | 01/17/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21751759.8 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | A METHOD FOR EVALUATING THE PRO-OR ANTI CONVULSIVE PROPERTIES OF TEST COMPOUNDS | PCT | Published | PCT/G82021/053204 | 12/08/2021 | | | |
| GW Research Limited | A METHOD FOR EVALUATING THE PRO-OR ANTI CONVULSIVE PROPERTIES OF TEST COMPOUNDS | United Kingdom | Published | 2019787.7 | 12/15/2020 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/005,841 | 07/15/2021 | 01/17/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21751761.4 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | US | Published | 18/006,121 | 07/15/2021 | 01/19/2023 | | |
| GW Research Limited | ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER | United Kingdom | Issued | 15733502.7 | 06/26/2015 | 06/26/2015 | EP3160455 | 05/12/2021 |
| GW Research Limited | ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER | Spain | Issued | 15733502.7 | 06/26/2015 | 06/26/2015 | EP3160455 | 05/12/2021 |

| | | | | | | | | |
|---------------------|--|------------------------|-----------|-------------------|------------|------------|-----------|------------|
| GW Research Limited | ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER | Netherlands | Issued | 15733502.7 | 06/26/2015 | 06/26/2015 | EP3160455 | 05/12/2021 |
| GW Research Limited | ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER | Italy | Issued | 15733502.7 | 06/26/2015 | 06/26/2015 | EP3160455 | 05/12/2021 |
| GW Research Limited | ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER | Germany | Issued | 60 2015 069 220.9 | 06/26/2015 | 06/26/2015 | EP3160455 | 05/12/2021 |
| GW Research Limited | ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER | France | Issued | 15733502.7 | 06/26/2015 | 06/26/2015 | EP3160455 | 05/12/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21752643.3 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | European Patent Office | Published | 21746419.7 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | CANNABIDIOL COMPOSITIONS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND NEUROLOGICAL DISORDERS | PCT | Pending | PCT/EP2023/072328 | 08/11/2023 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | US | Published | 18/006,125 | 07/15/2021 | 01/19/2023 | | |
| GW Research Limited | CANNABIDIOL FOR USE IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | PCT | Published | PCT/EP2021/069875 | 07/15/2021 | | | |
| GW Research Limited | cannabidiol for use, method for treating atonic seizures, and, composition. | Brazil | Published | BR 112017007779 | 10/14/2015 | 04/13/2017 | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | Japan | Pending | 2023-219428 | 04/26/2019 | 12/26/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | European Patent Office | Published | 21745341.4 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | US | Published | 18/006,129 | 07/15/2021 | 01/19/2023 | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | South Africa | Pending | 2020/06655 | 04/26/2019 | 10/26/2020 | | |

| | | | | | | | | |
|---------------------|--|------------------------|-----------|-------------------|------------|------------|-----------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | European Patent Office | Published | 21749549.8 | 07/15/2021 | 02/16/2023 | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | Mexico | Issued | MX/A/2020/011163 | 04/26/2019 | 10/21/2020 | 401314 | 03/29/2023 |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | Japan | Published | 2020-560164 | 04/26/2019 | 10/26/2020 | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | Hong Kong | Published | 62021034570.3 | 04/26/2019 | 07/06/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RETT SYNDROME | US | Published | 18/006,127 | 07/15/2021 | 01/19/2023 | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | Canada | Pending | 3097665 | 04/26/2019 | 10/19/2020 | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | Brazil | Pending | BR 112020021884 7 | 04/26/2019 | 10/26/2020 | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | Australia | Pending | 2019259230 | 04/26/2019 | 11/09/2020 | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | ARIPO | Allowed | AP/P/2020/012751 | 04/26/2019 | 10/26/2020 | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | United Arab Emirates | Pending | P6001496/2020 | 04/26/2019 | 10/26/2020 | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND THEIR APPLICATION | Turkmenistan | Issued | 202092582 | 04/26/2019 | | 044243 | 08/03/2023 |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND THEIR APPLICATION | Tajikistan | Issued | 202092582 | 04/26/2019 | | 044243 | 08/03/2023 |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND THEIR APPLICATION | Kyrgyzstan | Issued | 202092582 | 04/26/2019 | | 044243 | 08/03/2023 |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND THEIR APPLICATION | Kazakhstan | Issued | 202092582 | 04/26/2019 | | 044243 | 08/03/2023 |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND THEIR APPLICATION | Belarus | Issued | 202092582 | 04/26/2019 | | 044243 | 08/03/2023 |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND THEIR APPLICATION | Azerbaijan | Issued | 202092582 | 04/26/2019 | | 044243 | 08/03/2023 |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND THEIR APPLICATION | Armenia | Issued | 202092582 | 04/26/2019 | | 044243 | 08/03/2023 |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND THEIR APPLICATION | Eurasian Patent Office | Issued | 202092582 | 04/26/2019 | 11/26/2020 | 044243 | 08/03/2023 |
| GW Research Limited | Cannabidiol preparations and uses thereof | Republic of Korea | Pending | 10-2020-7033611 | 04/26/2019 | 11/20/2020 | | |
| GW Research Limited | Cannabidiol product and application thereof | China | Published | 201980043260.8 | 04/26/2019 | 12/25/2020 | | |
| GW Research Limited | Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy | United Kingdom | Issued | 2018129.3 | 11/18/2020 | | GB2590793 | 10/26/2022 |
| GW Research Limited | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder | United Kingdom | Issued | GB1606097.2 | 04/11/2016 | 04/11/2016 | GB2549277 | 02/17/2021 |

| | | | | | | | | |
|---------------------|---|--------------------------|-----------|------------------|------------|------------|----------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | US | Published | 18/002,437 | 06/16/2021 | 12/19/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | European Patent Office | Published | 21736654.1 | 06/16/2021 | 01/11/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | US | Issued | 17/340,885 | 06/07/2021 | | 11400055 | 08/02/2022 |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Republic of Korea | Pending | 10-2022-7020505 | 11/18/2020 | 06/16/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Republic of Korea | Published | 10-2022-7020695 | 11/18/2020 | 06/17/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Republic of Korea | Published | 10-2022-7020511 | 11/18/2020 | 06/16/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Republic of Korea | Published | 10-2022-7020682 | 11/18/2020 | 06/17/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | South Africa | Pending | 2022/06321 | 11/18/2020 | 06/07/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | South Africa | Issued | 2022/06386 | 11/18/2020 | 06/08/2022 | | 12/20/2023 |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Singapore | Pending | 112022050005 | 11/18/2020 | 05/12/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Singapore | Pending | 11202205026P | 11/18/2020 | 05/13/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Mexico | Pending | MX/A/2022/005933 | 11/18/2020 | 05/16/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Mexico | Pending | MX/A/2022/005931 | 11/18/2020 | 05/16/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Japan | Published | 2022-529065 | 11/18/2020 | 05/18/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | China | Published | 202080080992.7 | 11/18/2020 | 05/19/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | China | Published | 202080080989.5 | 11/18/2020 | 05/19/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | China | Published | 202080079589.2 | 11/18/2020 | 05/16/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Brazil | Published | 112022009539.2 | 11/18/2020 | 05/17/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Australia | Pending | 2020389360 | 11/18/2020 | 05/31/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Australia | Pending | 2020388278 | 11/18/2020 | 05/30/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Venezuela | Pending | 2020-000200 | 11/20/2020 | 11/20/2020 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Taiwan | Published | 109140702 | 11/20/2020 | | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Lebanon | Issued | 12054 | 11/16/2020 | 11/17/2020 | 12054 | 11/17/2020 |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Gulf Cooperation Council | Pending | 2020/40928 | 11/19/2020 | 11/19/2020 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | United Kingdom | Published | 2018139.2 | 11/18/2020 | | | |

| | | | | | | | | |
|---------------------|--|--------------------------|-----------|-----------------|------------|------------|-----------|------------|
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | United Kingdom | Issued | 2018135.0 | 11/18/2020 | | GB2591567 | 11/16/2022 |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Venezuela | Pending | 2020-000203 | 11/20/2020 | 11/20/2020 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Taiwan | Published | 109140701 | 11/20/2020 | | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Lebanon | Issued | 12055 | 11/16/2020 | 11/17/2020 | 12055 | 11/17/2020 |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Gulf Cooperation Council | Pending | 2020/40927 | 11/19/2020 | 11/19/2020 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Venezuela | Pending | 2020-000202 | 11/19/2020 | 11/19/2020 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Lebanon | Issued | 12053 | 11/16/2020 | 11/17/2020 | 12053 | 11/17/2020 |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Gulf Cooperation Council | Pending | 2020/40918 | 11/18/2020 | 11/18/2020 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Venezuela | Pending | 2020-000201 | 11/19/2020 | 11/19/2020 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Lebanon | Issued | 12056 | 11/16/2020 | 11/16/2020 | 12056 | 11/17/2020 |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Gulf Cooperation Council | Pending | 2020/40917 | 11/17/2020 | 11/17/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 17/242,075 | 04/27/2021 | | 11154517 | 10/26/2021 |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | New Zealand | Pending | 776300 | 11/20/2019 | 05/19/2021 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Republic of Korea | Published | 10-2021-7019012 | 11/20/2019 | 06/18/2021 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Japan | Published | 2021-528420 | 11/20/2019 | 05/20/2021 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | Canada | Published | 3119907 | 11/20/2019 | 05/13/2021 | | |
| GW Research Limited | Cannabidiol-type cannabinoid compound | Australia | Published | 2019382961 | 11/20/2019 | 05/18/2021 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | United Arab Emirates | Pending | P6000829/2021 | 11/20/2019 | 05/23/2021 | | |
| GW Research Limited | cannabidiol-type cannabinoid compounds | China | Published | 201980077018.2 | 11/20/2019 | 05/21/2021 | | |
| GW Research Limited | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis | United Kingdom | Issued | 0412753.6 | 06/08/2004 | 06/08/2004 | GB2414933 | 07/15/2009 |
| GW Research Limited | CANNABINOID COMPOUND | United Kingdom | Issued | 1915515.9 | 10/25/2019 | | GB2588457 | 12/21/2022 |
| GW Research Limited | Cannabinoid compound | United Kingdom | Issued | 1915514.2 | 10/25/2019 | | GB2588456 | 02/01/2023 |
| GW Research Limited | CANNABINOID COMPOUND | United Kingdom | Issued | 1915513.4 | 10/25/2019 | | GB2588455 | 12/21/2022 |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Hong Kong | Pending | 62023082939.7. | 11/21/2023 | | | |

| | | | | | | |
|---------------------|--|----------------------|-----------|------------------|------------|------------|
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | United Arab Emirates | Pending | P6001442/2023 | 12/15/2021 | 06/12/2023 |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | South Africa | Pending | 2023/06451 | 12/15/2021 | 06/21/2023 |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Singapore | Pending | 11202304454X | 12/15/2021 | 06/08/2023 |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Saudi Arabia | Pending | 523441188 | 12/15/2021 | 06/14/2023 |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Republic of Korea | Pending | 10-2023-7023619 | 12/15/2021 | 07/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | New Zealand | Pending | 801079 | 12/15/2021 | 06/23/2023 |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Mexico | Pending | MX/A/2023/007027 | 12/15/2021 | 06/13/2023 |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Japan | Pending | 2023-536528 | 12/15/2021 | 06/15/2023 |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Israel | Pending | 303599 | 12/15/2021 | 06/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | India | Published | 202337041275 | 12/15/2021 | 06/17/2023 |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | China | Published | 202180084912.X | 12/15/2021 | 06/15/2023 |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Canada | Pending | 3,202,250 | 12/15/2021 | 06/14/2023 |

| | | | | | | | | |
|---------------------|--|-------------------|-----------|-------------------|------------|------------|-------|------------|
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Brazil | Pending | BR112023011624 4. | 12/15/2021 | 06/13/2023 | | |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Australia | Pending | 2021404158 | 12/15/2021 | 06/23/2023 | | |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Venezuela | Pending | 2021-000292 | 12/15/2021 | | | |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Taiwan | Published | 110146767 | 12/14/2021 | | | |
| GW Research Limited | CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Lebanon | Issued | 12419 | 12/03/2021 | 12/03/2021 | 12419 | 12/29/2021 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | Australia | Pending | 2021404159 | 12/15/2021 | 06/23/2023 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | New Zealand | Pending | 801084 | 12/15/2021 | 06/23/2023 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | Mexico | Pending | MX/A/2023/007026 | 12/15/2021 | 06/13/2023 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | Republic of Korea | Pending | 10-2023-7024015 | 12/15/2021 | 07/13/2023 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | Canada | Pending | 3,202,111 | 12/15/2021 | 06/13/2023 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | Japan | Pending | 2023-536532. | 12/15/2021 | 06/15/2023 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | Israel | Pending | 303602 | 12/15/2021 | 06/11/2023 | | |

| | | | | | | | |
|---------------------|---|----------------|-----------|----------------|------------|------------|--------------------|
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | China | Published | 202180084920.4 | 12/15/2021 | 06/15/2023 | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | France | Issued | 20751200.5 | 07/17/2020 | | 3999042 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | United Kingdom | Issued | 20751200.5 | 07/17/2020 | | 3999042 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Switzerland | Issued | 20751200.5 | 07/17/2020 | | 3999042 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Sweden | Issued | 20751200.5 | 07/17/2020 | | 3999042 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Spain | Issued | 20751200.5 | 07/17/2020 | | 3999042 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Norway | Issued | 20751200.5 | 07/17/2020 | | 3999042 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Netherlands | Issued | 20751200.5 | 07/17/2020 | | 3999042 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Luxembourg | Issued | 20751200.5 | 07/17/2020 | | 3999042 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Italy | Issued | 20751200.5 | 07/17/2020 | | 3999042 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Ireland | Issued | 20751200.5 | 07/17/2020 | | 3999042 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Germany | Issued | 20751200.5 | 07/17/2020 | | 3999042 10/11/2023 |

| | | | | | | | | |
|---------------------|---|-------------------|-----------|------------------|------------|------------|-------------------|------------|
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Finland | Issued | 20751200.5 | 07/17/2020 | | 3999042 | 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Denmark | Issued | 20751200.5 | 07/17/2020 | | 3999042 | 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Belgium | Issued | 20751200.5 | 07/17/2020 | | 3999042 | 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Austria | Issued | 20751200.5 | 07/17/2020 | | 3999042 | 10/11/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Hong Kong | Allowed | 62022062815.5 | 07/17/2020 | 10/27/2022 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | New Zealand | Published | 784332 | 07/17/2020 | 01/17/2022 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Mexico | Pending | MX/A/2022/000733 | 07/17/2020 | 01/17/2022 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Republic of Korea | Pending | 10-2022-7005472 | 07/17/2020 | 02/17/2022 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Japan | Pending | 2022-503536 | 07/17/2020 | 01/18/2022 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Israel | Pending | 289786 | 07/17/2020 | 01/12/2022 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | China | Issued | 202080052158.7 | 07/17/2020 | 01/18/2022 | ZL 202080052158.7 | 12/08/2023 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Canada | Pending | 3143580 | 07/17/2020 | 01/11/2022 | | |

| | | | | | | | | |
|---------------------|---|----------------|---------|-------------|------------|------------|-----------------|------------|
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Venezuela | Pending | 2020-000111 | 07/20/2020 | 07/20/2020 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Lebanon | Issued | 2069 | 07/17/2020 | 07/17/2020 | 11964 | 07/20/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 17/198,965 | 03/11/2021 | | US11096905 | 08/24/2021 |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | Australia | Pending | 2020318928 | 07/17/2020 | 01/17/2022 | | |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Canada | Issued | 2636634 | 01/17/2007 | 07/09/2008 | 2636634 | 07/11/2017 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Turkey | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2018/17443 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Turkey | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | 2019/14473 | 06/26/2019 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Portugal | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Italy | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | 502019000078080 | 06/26/2019 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Ireland | Issued | 07704916.1 | 08/05/2008 | | EP1976506 | 06/26/2019 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Greece | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | United Kingdom | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | EP2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | France | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Spain | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Cyprus | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Bulgaria | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Austria | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 1031658 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Switzerland | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Sweden | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Slovenia | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Slovakia | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Netherlands | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |

| | | | | | | | | |
|---------------------|--|------------------------|-----------|---------------------|------------|------------|-----------------|------------|
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Luxembourg | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Lithuania | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Latvia | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Italy | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 502018000035823 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Ireland | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Iceland | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Germany | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 602007055900 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Finland | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Estonia | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Denmark | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | Cannabinoid extracts as neuroprotectants | Belgium | Issued | 10189019.2 | 10/27/2010 | 10/27/2010 | 2332533 | 08/22/2018 |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | European Patent Office | Published | 21709791.4 | 03/01/2021 | 09/26/2022 | | |
| GW Research Limited | CANNABINOID FORMULATIONS | Hong Kong | Published | 62022059291.4 | 05/28/2020 | 08/31/2022 | | |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | US | Issued | 17/188,766 | 03/01/2021 | | US11160795 | 11/02/2021 |
| GW Research Limited | CANNABINOID FORMULATIONS | Japan | Pending | 2021-570995 | 05/28/2020 | 11/29/2021 | | |
| GW Research Limited | CANNABINOID FORMULATIONS | Israel | Pending | 288423 | 05/28/2020 | 11/25/2021 | | |
| GW Research Limited | CANNABINOID FORMULATIONS | Canada | Published | 3,141,987 | 05/28/2020 | 11/25/2021 | | |
| GW Research Limited | CANNABINOID FORMULATIONS | Brazil | Pending | BR 11 2021 022692 3 | 05/28/2020 | 11/23/2021 | | |
| GW Research Limited | CANNABINOID FORMULATIONS | Republic of Korea | Published | 10-2021-7042619 | 05/28/2020 | 12/27/2021 | | |
| GW Research Limited | Cannabinoid formulations | United Kingdom | Issued | G81907786.6 | 05/31/2019 | | G82584341 | 03/01/2023 |
| GW Research Limited | CANNABINOID FORMULATIONS | New Zealand | Issued | 749142 | 06/30/2017 | 12/10/2018 | 749142 | 07/04/2023 |
| GW Research Limited | CANNABINOID FORMULATIONS | Mexico | Issued | MX/A/2018/015699 | 06/30/2017 | 12/14/2018 | 392436 | 05/18/2022 |
| GW Research Limited | CANNABINOID FORMULATIONS | Australia | Issued | 2017287868 | 06/30/2017 | 12/10/2018 | 2017287868 | 07/27/2023 |
| GW Research Limited | Cannabinoid liquid formulations for mucosal administration | Australia | Issued | 2009202434 | 08/14/2003 | 06/18/2009 | 2009202434 | 12/13/2012 |
| GW Research Limited | Cannabinoid liquid formulations for mucosal administration | Australia | Issued | 2003253005 | 08/14/2003 | 02/08/2005 | 2003253005 | 07/03/2009 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Slovakia | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Slovenia | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Sweden | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |

| | | | | | | | | |
|---------------------|---|----------------|--------|------------|------------|------------|-----------|------------|
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Portugal | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Netherlands | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Latvia | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Luxembourg | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Lithuania | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Iceland | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Hong Kong | Issued | 11113495.0 | 12/14/2011 | 12/14/2011 | 1158956B | 10/04/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Greece | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | United Kingdom | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | Cannabinoid-containing plant extracts as neuroprotective agents | United Kingdom | Issued | 0601013.6 | 01/18/2006 | 01/18/2006 | G92434312 | 06/29/2011 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | France | Issued | 07704916.1 | 01/17/2007 | 08/05/2008 | 1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Finland | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Spain | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Estonia | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Germany | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Cyprus | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Switzerland | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |

| | | | | | | | | |
|---------------------|---|--------------------------|-----------|---------------------|------------|------------|------------------|------------|
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Bulgaria | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS | Belgium | Issued | 07704916.1 | 08/05/2008 | 08/05/2008 | EP1976506 | 06/26/2019 |
| GW Research Limited | CBD COMORBIDITIES | PCT | Published | PCT/G82020/050090 | 01/16/2020 | 01/16/2020 | | |
| GW Research Limited | CBD COMORBIDITIES | Mexico | Pending | MX/A/2021/008702 | 01/16/2020 | 07/19/2021 | | |
| GW Research Limited | CBD COMORBIDITIES | China | Published | 2020800090054 | 01/16/2020 | 07/13/2021 | | |
| GW Research Limited | CBD COMORBIDITIES | Australia | Published | 2020211035 | 01/16/2020 | 07/14/2021 | | |
| GW Research Limited | CBD EIFMS | Mexico | Pending | MX/A/2021/009646 | 02/18/2020 | 08/11/2021 | | |
| GW Research Limited | CBD EIFMS | PCT | Published | PCT/G82020/050383 | 02/18/2020 | 02/18/2020 | | |
| GW Research Limited | CBD EIFMS | China | Published | 2020800133844 | 02/18/2020 | 08/09/2021 | | |
| GW Research Limited | CBD EIFMS | Australia | Published | 2020224371 | 02/18/2020 | 08/04/2021 | | |
| GW Research Limited | CBD for use in TSC tumours | Mexico | Pending | MX/A/2021/006270 | 06/21/2018 | 05/28/2021 | | |
| GW Research Limited | CBD for use in TSC tumours | Mexico | Issued | MX/A/2019/014715 | 06/21/2018 | 12/06/2019 | MX/A/2019/014715 | 06/23/2021 |
| GW Research Limited | CBD for use in TSC tumours | United Kingdom | Issued | GB1710042.1 | 06/23/2017 | 06/23/2017 | | |
| GW Research Limited | CBD in epileptic spasms | Mexico | Pending | MX/A/2021/014158 | 05/15/2020 | 11/18/2021 | | |
| GW Research Limited | CBD in epileptic spasms | Republic of Korea | Pending | 10-2021-7040679 | 05/15/2020 | 12/10/2021 | | |
| GW Research Limited | CBD in epileptic spasms | China | Published | 2020800379416 | 05/15/2020 | 11/22/2021 | | |
| GW Research Limited | CBD in epileptic spasms | Canada | Published | 3138980 | 05/15/2020 | 11/02/2021 | | |
| GW Research Limited | CBD in epileptic spasms | Australia | Pending | 2020279889 | 05/15/2020 | 10/29/2021 | | |
| GW Research Limited | CBD in epileptic spasms | PCT | Published | PCT/G82020/051185 | 05/15/2020 | 05/15/2020 | | |
| GW Research Limited | CBD in epileptic spasms | Lebanon | Issued | 1291 | 04/28/2020 | 04/28/2020 | 11923 | 05/22/2020 |
| GW Research Limited | CBD in epileptic spasms | Gulf Cooperation Council | Pending | 2020/39811 | 05/21/2020 | 05/21/2020 | | |
| GW Research Limited | CBD STP epilepsy | South Africa | Pending | 2020/04733 | 01/22/2019 | 07/30/2020 | | |
| GW Research Limited | CBD STP epilepsy | New Zealand | Pending | 766517 | 01/22/2019 | 07/24/2020 | | |
| GW Research Limited | CBD STP epilepsy | Brazil | Pending | BR 11 2020 015018 5 | 01/22/2019 | 07/23/2020 | | |
| GW Research Limited | CBDA for use in epilepsy | Mexico | Issued | MX/A/2018/001472 | 07/29/2016 | 02/02/2018 | 379255 | 01/22/2021 |
| GW Research Limited | CBDA for use in epilepsy | Japan | Issued | 2018-507504 | 07/29/2016 | 02/13/2018 | 6949822 | 09/27/2021 |
| GW Research Limited | CBDA for use in epilepsy | Brazil | Published | BR 1120180026026 | 07/29/2016 | 02/07/2018 | | |
| GW Research Limited | CBDA for use in epilepsy | Australia | Issued | 2016305545 | 07/29/2016 | 01/17/2018 | 2016305545 | 03/24/2022 |
| GW Research Limited | CBD-C4 first medical use | South Africa | Pending | 2021/03219 | 11/20/2019 | 05/12/2021 | | |
| GW Research Limited | CBD-C4 first medical use | Mexico | Pending | MX/A/2021/005919 | 11/20/2019 | 05/19/2021 | | |
| GW Research Limited | CBD-C4 first medical use | Hong Kong | Pending | 62022049149.7 | 11/20/2019 | 03/01/2022 | | |
| GW Research Limited | COMBINATION OF CANNABINOIDS IN THE TREATMENT OF LEUKAEMIA | United Kingdom | Issued | 18706846.5 | 02/16/2018 | | 3585368 | 02/08/2023 |
| GW Research Limited | COMBINATION OF CANNABINOIDS IN THE TREATMENT OF LEUKAEMIA | Switzerland | Issued | 18706846.5 | 02/16/2018 | | 3585368 | 02/08/2023 |
| GW Research Limited | COMBINATION OF CANNABINOIDS IN THE TREATMENT OF LEUKAEMIA | Netherlands | Issued | 18706846.5 | 02/16/2018 | | 3585368 | 02/08/2023 |
| GW Research Limited | COMBINATION OF CANNABINOIDS IN THE TREATMENT OF LEUKAEMIA | Germany | Issued | 18706846.5 | 02/16/2018 | 02/16/2018 | 602018046005. | 02/08/2023 |
| GW Research Limited | COMBINATION OF CANNABINOIDS IN THE TREATMENT OF LEUKAEMIA | France | Issued | 18706846.5 | 02/16/2018 | | 3585368 | 02/08/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | US | Issued | 17/147,005 | 01/12/2021 | | 11065209 | 07/20/2021 |

| | | | | | | | | |
|---------------------|--|------------------------|-----------|---------------------|------------|------------|-----------|------------|
| GW Research Limited | COMBINATION OF TETRAHYDROCANNABINOL WITH OLESOXIME FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | United Kingdom | Issued | 18742590.5 | 07/10/2018 | | 3651760 | 12/20/2023 |
| GW Research Limited | COMBINATION OF TETRAHYDROCANNABINOL WITH OLESOXIME FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Switzerland | Issued | 18742590.5 | 07/10/2018 | | 3651760 | 12/20/2023 |
| GW Research Limited | COMBINATION OF TETRAHYDROCANNABINOL WITH OLESOXIME FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Netherlands | Issued | 18742590.5 | 07/10/2018 | | 3651760 | 12/20/2023 |
| GW Research Limited | COMBINATION OF TETRAHYDROCANNABINOL WITH OLESOXIME FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Germany | Issued | 18742590.5 | 07/10/2018 | | 3651760 | 12/20/2023 |
| GW Research Limited | COMBINATION OF TETRAHYDROCANNABINOL WITH OLESOXIME FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | France | Issued | 18742590.5 | 07/10/2018 | | 3651760 | 12/20/2023 |
| GW Research Limited | CRYSTALLINE FORMS OF A CANNABIDIOL- LIKE CANNABINOID | PCT | Published | PCT/G82023/051181 | 05/04/2023 | | | |
| GW Research Limited | CRYSTALLINE FORMS OF A SYNTHETIC CANNABINOID | PCT | Published | PCT/G82023/051563 | 06/15/2023 | | | |
| GW Research Limited | Dravet trilogy | New Zealand | Pending | 775265 | 06/16/2016 | 04/22/2021 | | |
| GW Research Limited | Dravet trilogy | New Zealand | Published | 738403 | 06/16/2016 | 12/19/2017 | | |
| GW Research Limited | Dravet trilogy | Brazil | Published | BR112017027166.4 | 06/16/2016 | 12/15/2017 | | |
| GW Research Limited | Gel Formulation | Japan | Issued | 2018-567205 | 06/30/2017 | 12/21/2018 | 7136703 | 09/05/2022 |
| GW Research Limited | Gel Formulation | Israel | Issued | 263901 | 06/30/2017 | 12/23/2019 | 263901 | 05/02/2022 |
| GW Research Limited | Gel Formulation | Hong Kong | Published | 19131875.7 | 11/05/2019 | 11/05/2019 | | |
| GW Research Limited | Gel Formulation | Canada | Pending | 3028580 | 06/30/2017 | 12/19/2018 | | |
| GW Research Limited | Gel Formulation Packaging | New Zealand | Pending | 765835 | 01/02/2019 | 06/30/2020 | | |
| GW Research Limited | Gel Formulation Packaging | Hong Kong | Published | 62021029619.5 | 04/20/2021 | 04/20/2021 | | |
| GW Research Limited | Gel Formulation Packaging | United Kingdom | Issued | GB1800072.9 | 01/03/2018 | 01/03/2018 | GB2569961 | 12/22/2021 |
| GW Research Limited | Gel Formulation Packaging | Brazil | Pending | BR 11 2020 013433 3 | 01/02/2019 | 06/30/2020 | | |
| GW Research Limited | GRIN2A epilepsy | Mexico | Pending | MX/A/2021/006094 | 11/28/2019 | 05/24/2021 | | |
| GW Research Limited | GRIN2A epilepsy | Israel | Pending | 283372 | 11/28/2019 | 05/23/2021 | | |
| GW Research Limited | GRIN2A epilepsy | China | Published | 2019800789117 | 11/28/2019 | 05/28/2021 | | |
| GW Research Limited | GRIN2A epilepsy | Australia | Published | 2019387553 | 11/28/2019 | 05/27/2021 | | |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | US | Published | 17/128,458 | 12/21/2020 | | | |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | European Patent Office | Published | 20838209.3 | 12/18/2020 | 07/05/2022 | | |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | US | Published | 17/786,949 | 12/18/2020 | 06/17/2022 | | |
| GW Research Limited | Use of cannabinoids in the treatment of epilepsy | US | Issued | 17/119,873 | 12/11/2020 | | 11154516 | 10/26/2021 |
| GW Research Limited | MANAGEMENT OF MULTIPLE SCLEROSIS SPASTICITY IN PATIENTS WITH RENAL IMPAIRMENT | PCT | Pending | PCT/EP2023/061030 | 04/26/2023 | | | |
| GW Research Limited | Method for preparing cannabinoids | China | Published | 202180054371.6 | 08/27/2021 | 03/02/2023 | | |

| | | | | | | | | |
|---------------------|--|-------------------|-----------|------------------|------------|------------|-------|------------|
| GW Research Limited | METHOD OF PREPARING CANNABINOIDS | New Zealand | Pending | 797481 | 08/27/2021 | 02/22/2023 | | |
| GW Research Limited | METHOD OF PREPARING CANNABINOIDS | Mexico | Pending | MX/A/2023/002535 | 08/27/2021 | 02/28/2023 | | |
| GW Research Limited | METHOD OF PREPARING CANNABINOIDS | Japan | Pending | 2023-514802 | 08/27/2021 | 03/02/2023 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | US | Published | 17/777,734 | 11/18/2020 | 05/18/2022 | | |
| GW Research Limited | METHOD OF PREPARING CANNABINOIDS | Canada | Pending | 3,190,849 | 08/27/2021 | 02/24/2023 | | |
| GW Research Limited | METHOD OF PREPARING CANNABINOIDS | Australia | Pending | 2021338469 | 08/27/2021 | 02/22/2023 | | |
| GW Research Limited | METHOD OF PREPARING CANNABINOIDS | Venezuela | Published | 2021-000198 | 09/02/2021 | | | |
| GW Research Limited | METHOD OF PREPARING CANNABINOIDS | Taiwan | Published | 110132437 | 09/01/2021 | | | |
| GW Research Limited | METHOD OF PREPARING CANNABINOIDS | Paraguay | Pending | 2175980 | 09/02/2021 | | | |
| GW Research Limited | METHOD OF PREPARING CANNABINOIDS | Lebanon | Issued | 12306 | 08/17/2021 | 08/17/2021 | 12306 | 09/13/2021 |
| GW Research Limited | METHOD OF PREPARING CANNABINOIDS | United Kingdom | Published | 2112397.1 | 08/31/2021 | | | |
| GW Research Limited | Methods of making cannabinoids | Republic of Korea | Pending | 10-2023-7011264 | 08/27/2021 | 03/31/2023 | | |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | Australia | Pending | 2021227591 | 03/01/2021 | 08/05/2022 | | |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | Japan | Pending | 2022-552217 | 03/01/2021 | 08/29/2022 | | |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | Mexico | Pending | MX/a/2022/010483 | 03/01/2021 | 08/24/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | US | Published | 17/777,677 | 11/18/2020 | 05/18/2022 | | |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | China | Published | 202180017611.5 | 03/01/2021 | 08/29/2022 | | |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | New Zealand | Pending | 791111 | 03/01/2021 | 08/05/2022 | | |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | Israel | Pending | 295459 | 03/01/2021 | 08/08/2022 | | |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | Republic of Korea | Pending | 10-2022-7033308 | 03/01/2021 | 09/23/2022 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | US | Published | 17/777,681 | 11/18/2020 | 05/18/2022 | | |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | Canada | Published | 3169026 | 03/01/2021 | 08/22/2022 | | |

| | | | | | | | | |
|---------------------|--|--------------------------|-----------|---------------------|------------|------------|------------------|------------|
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | PCT | Published | PCT/G82021/050509 | 03/01/2021 | | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | European Patent Office | Published | 20815899.8 | 11/18/2020 | 05/16/2022 | | |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | Taiwan | Published | 110106939 | 02/26/2021 | 02/26/2021 | | |
| GW Research Limited | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS | Lebanon | Issued | 485/IP | 02/26/2021 | 02/26/2021 | 12142 | 03/16/2021 |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | European Patent Office | Published | 20812408.1 | 11/18/2020 | 05/16/2022 | | |
| GW Research Limited | Microparticulate formulations | New Zealand | Published | 782692 | 05/28/2020 | 11/24/2021 | | |
| GW Research Limited | Microparticulate formulations | Mexico | Pending | MX/A/2021/014428 | 05/28/2020 | 11/24/2021 | | |
| GW Research Limited | Microparticulate formulations | China | Published | 202080040182.9 | 05/28/2020 | 11/29/2021 | | |
| GW Research Limited | Microparticulate formulations | Australia | Pending | 2020282638 | 05/28/2020 | 11/24/2021 | | |
| GW Research Limited | Microparticulate formulations | Gulf Cooperation Council | Pending | 2020/39850 | 05/30/2020 | 05/30/2020 | | |
| GW Research Limited | Microparticulate formulations | Venezuela | Published | 2020-000085 | 05/29/2020 | 05/29/2020 | | |
| GW Research Limited | Microparticulate formulations | Lebanon | Issued | 11928 | 05/27/2020 | 05/27/2020 | 11928 | 12/14/2020 |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | European Patent Office | Allowed | 20815902.0 | 11/18/2020 | 06/17/2022 | | |
| GW Research Limited | MODIFIED RELEASE COMPOSITION COMPRISING A CANNABINOID | Mexico | Issued | MX/A/2020/006957 | 01/02/2019 | 07/13/2020 | 403835 | 06/28/2023 |
| GW Research Limited | MODIFIED RELEASE COMPOSITION COMPRISING A CANNABINOID | Japan | Allowed | 2020-536959 | 01/02/2019 | 07/02/2020 | | |
| GW Research Limited | MODIFIED RELEASE COMPOSITION COMPRISING A CANNABINOID | Israel | Allowed | 275703 | 01/02/2019 | 06/28/2020 | | |
| GW Research Limited | MODIFIED RELEASE COMPOSITION COMPRISING A CANNABINOID | Hong Kong | Published | 62021029618.7 | 04/20/2021 | 04/20/2021 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | European Patent Office | Published | 20815903.8 | 11/18/2020 | 06/17/2022 | | |
| GW Research Limited | MODIFIED RELEASE COMPOSITION COMPRISING A CANNABINOID | Canada | Published | 3,087,125 | 01/02/2019 | 06/26/2020 | | |
| GW Research Limited | MODIFIED RELEASE COMPOSITION COMPRISING A CANNABINOID | Australia | Pending | 2019205118 | 01/02/2019 | 06/30/2020 | | |
| GW Research Limited | Modified release composition containing cannabinoids | Republic of Korea | Published | 10-2020-7021894 | 01/02/2019 | 07/27/2020 | | |
| GW Research Limited | Modified release compositions comprising cannabinoids | China | Issued | 201980015013.7 | 01/02/2019 | 08/24/2020 | ZL 2019800150137 | 08/08/2023 |
| GW Research Limited | Modified Release Formulation | South Africa | Pending | 2020/04050 | 01/02/2019 | 07/02/2020 | | |
| GW Research Limited | Modified Release Formulation | New Zealand | Published | 765844 | 01/02/2019 | 06/30/2020 | | |
| GW Research Limited | Modified Release Formulation | United Kingdom | Issued | G81800073.7 | 01/03/2018 | 01/03/2018 | G82572125 | 01/13/2021 |
| GW Research Limited | Modified Release Formulation | Brazil | Pending | BR 11 2020 013446 5 | 01/02/2019 | 06/30/2020 | | |
| GW Research Limited | NOVEL COMPOUNDS | Republic of Korea | Pending | 10-2023-7041272 | 05/11/2022 | 11/29/2023 | | |
| GW Research Limited | NOVEL COMPOUNDS | New Zealand | Pending | 804805 | 05/11/2022 | 10/20/2023 | | |
| GW Research Limited | NOVEL COMPOUNDS | Mexico | Pending | MX/A/2023/013338 | 05/11/2022 | 11/09/2023 | | |
| GW Research Limited | NOVEL COMPOUNDS | Japan | Pending | 2023-569986 | 05/11/2022 | 11/10/2023 | | |
| GW Research Limited | NOVEL COMPOUNDS | China | Published | 202280033614.2 | 05/11/2022 | 11/07/2023 | | |
| GW Research Limited | NOVEL COMPOUNDS | Canada | Pending | 3216179 | 05/11/2022 | 10/20/2023 | | |
| GW Research Limited | NOVEL COMPOUNDS | Australia | Pending | 2022273928 | 05/11/2022 | 10/20/2023 | | |

| | | | | | | | | |
|---------------------|--|------------------------|-----------|-------------------|------------|------------|----------------|------------|
| GW Research Limited | NOVEL COMPOUNDS | PCT | Published | PCT/G82022/051199 | 05/11/2022 | | | |
| GW Research Limited | NOVEL COMPOUNDS AND USES THEREOF | United Kingdom | Pending | 2315506.2 | 10/10/2023 | | | |
| GW Research Limited | NOVEL COMPOUNDS AND USES THEREOF | United Kingdom | Pending | 2307065.9 | 05/12/2023 | | | |
| GW Research Limited | NOVEL COMPOUNDS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | Venezuela | Pending | 2021-000293 | 12/15/2021 | | | |
| GW Research Limited | NOVEL COMPOUNDS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | Taiwan | Published | 110146775 | 12/14/2021 | | | |
| GW Research Limited | NOVEL COMPOUNDS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | Paraguay | Published | 21109835 | 12/15/2021 | | | |
| GW Research Limited | NOVEL COMPOUNDS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | Lebanon | Issued | 12418 | 12/07/2021 | 12/07/2021 | 12418 | 12/29/2021 |
| GW Research Limited | Novel formulation | United Kingdom | Issued | GB1611544.6 | 07/01/2016 | 07/01/2016 | GB2551985 | 01/30/2019 |
| GW Research Limited | NOVEL RESORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | Taiwan | Published | 111117928 | 05/12/2022 | | | |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | United Kingdom | Issued | 18706562.8 | 02/15/2018 | | 3582750 | 07/26/2023 |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Switzerland | Issued | 18706562.8 | 02/15/2018 | | 3582750 | 07/26/2023 |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Netherlands | Issued | 18706562.8 | 02/15/2018 | | 3582750 | 07/26/2023 |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Germany | Issued | 18706562.8 | 02/15/2018 | | 602018053995.6 | 07/26/2023 |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | France | Issued | 18706562.8 | 02/15/2018 | | 3582750 | 07/26/2023 |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | United Kingdom | Issued | 17737351.1 | 06/29/2017 | | EP3478267 | 03/29/2023 |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Switzerland | Issued | 17737351.1 | 06/29/2017 | | EP3478267 | 03/29/2023 |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Netherlands | Issued | 17737351.1 | 06/29/2017 | | EP3478267 | 03/29/2023 |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Germany | Issued | 17737351.1 | 06/29/2017 | | EP3478267 | 03/29/2023 |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | France | Issued | 17737351.1 | 06/29/2017 | | EP3478267 | 03/29/2023 |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | New Zealand | Pending | 789835 | 12/18/2020 | 06/27/2022 | | |
| GW Research Limited | (-) - CIS TETRAHYDROCANNABINOL ((-) - CIS-THC) FOR USE AS A MEDICAMENT | US | Published | 17/771,184 | 10/23/2020 | 04/22/2022 | | |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Australia | Pending | 2020408010 | 12/18/2020 | 06/27/2022 | | |
| GW Research Limited | (-)-CIS TETRAHYDROCANNABINOL ((-)-CIS-THC) FOR USE AS A MEDICAMENT | European Patent Office | Published | 20800267.5 | 10/23/2020 | 05/16/2022 | | |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Mexico | Pending | MX/a/2022/007557 | 12/18/2020 | 06/16/2022 | | |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Japan | Pending | 2022-537763 | 12/18/2020 | 06/17/2022 | | |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | China | Published | 202080095465.3 | 12/18/2020 | 08/02/2022 | | |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Canada | Pending | 3,162,353 | 12/18/2020 | 06/17/2022 | | |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Republic of Korea | Pending | 10-2022-7024566 | 12/18/2020 | 07/15/2022 | | |
| GW Research Limited | (+)-CIS TETRAHYDROCANNABINOL ((+)-CIS-THC) FOR USE AS A MEDICAMENT | European Patent Office | Published | 20800268.3 | 10/23/2020 | 05/16/2022 | | |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Lebanon | Issued | 12090 | 12/18/2020 | | 12090 | 12/24/2020 |
| GW Research Limited | (+)-TRANS TETRAHYDROCANNABINOL ((+)-TRANS-THC) FOR USE AS A MEDICAMENT | US | Published | 17/771,195 | 10/23/2020 | 04/22/2022 | | |
| GW Research Limited | Oral cannabinoid formulations | United Kingdom | Issued | GB1702613.9 | 02/17/2017 | 02/17/2017 | GB2559774 | 09/29/2021 |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|-------------------|------------|------------|------------------|------------|
| GW Research Limited | (+)-TRANS TETRAHYDROCANNABINOL ((+)-TRANS-THC) FOR USE AS A MEDICAMENT | European Patent Office | Published | 20800269.1 | 10/23/2020 | 05/16/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL PREPARATIONS IN THE TREATMENT OF ABSENCE EPILEPSY | European Patent Office | Published | 20800276.6 | 10/23/2020 | 05/25/2022 | | |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | Hong Kong | Issued | 19131879.9 | 06/29/2017 | 11/05/2019 | HK40008398 | 06/09/2023 |
| GW Research Limited | USE OF CANNABIDIOL PREPARATIONS IN THE TREATMENT OF FRAGILE X SYNDROME | US | Published | 17/770,435 | 10/23/2020 | 04/20/2022 | | |
| GW Research Limited | Oral pharmaceutical formulation comprising cannabinoid and poloxamer | China | Issued | 201980014990.5 | 01/02/2019 | 08/24/2020 | ZL 2019800149905 | 08/11/2023 |
| GW Research Limited | ORAL PHARMACEUTICAL FORMULATION COMPRISING CANNABINOIDS AND POLOXAMER | South Africa | Pending | 2020/04051 | 01/02/2019 | 07/02/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL PREPARATIONS IN THE TREATMENT OF TEMPORAL LOBE EPILEPSY | US | Pending | 17/768,048 | 10/23/2020 | 04/11/2022 | | |
| GW Research Limited | ORAL PHARMACEUTICAL FORMULATION COMPRISING CANNABINOIDS AND POLOXAMER | Mexico | Allowed | MX/A/2020/006965 | 01/02/2019 | 07/13/2020 | | |
| GW Research Limited | ORAL PHARMACEUTICAL FORMULATION COMPRISING CANNABINOIDS AND POLOXAMER | Israel | Allowed | 275704 | 01/02/2019 | 06/28/2020 | | |
| GW Research Limited | ORAL PHARMACEUTICAL FORMULATION COMPRISING CANNABINOIDS AND POLOXAMER | Hong Kong | Published | 62021029617.9 | 04/20/2021 | 04/20/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL PREPARATIONS IN THE TREATMENT OF TEMPORAL LOBE EPILEPSY | European Patent Office | Published | 20795810.5 | 10/23/2020 | 05/25/2022 | | |
| GW Research Limited | ORAL PHARMACEUTICAL FORMULATION COMPRISING CANNABINOIDS AND POLOXAMER | Canada | Published | 3,087,802 | 01/02/2019 | 06/26/2020 | | |
| GW Research Limited | ORAL PHARMACEUTICAL FORMULATION COMPRISING CANNABINOIDS AND POLOXAMER | Australia | Published | 2019205119 | 01/02/2019 | 06/30/2020 | | |
| GW Research Limited | Oral pharmaceutical formulation containing cannabinoids and poloxamers | Republic of Korea | Published | 10-2020-7021895 | 01/02/2019 | 07/27/2020 | | |
| GW Research Limited | oral pharmaceutical formulation, methods for treating a patient, and use of a formulation | Brazil | Pending | BR1120180766011 | 06/30/2017 | 12/19/2018 | | |
| GW Research Limited | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | Taiwan | Pending | 112130364 | 08/11/2023 | | | |
| GW Research Limited | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | PCT | Pending | PCT/EP2023/072292 | 08/11/2023 | | | |
| GW Research Limited | Oral solution cannabinoid formulations | United Kingdom | Issued | 2020117.4 | 12/18/2020 | | G82592117 | 07/06/2022 |
| GW Research Limited | CANNABINOID FORMULATIONS | US | Issued | 17/068,326 | 10/12/2020 | | 11160757 | 11/02/2021 |
| GW Research Limited | Parenteral Formulations | Hong Kong | Published | 19131877.3 | 11/05/2019 | 11/05/2019 | | |
| GW Research Limited | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | South Africa | Pending | 2020/04049 | 01/02/2019 | 07/02/2020 | | |

| | | | | | | | | |
|---------------------|---|--------------------|-----------|-------------------|------------|------------|------------------|------------|
| GW Research Limited | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | Mexico | Allowed | MX/A/2020/006964 | 01/02/2019 | 07/13/2020 | | |
| GW Research Limited | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | Republic of Korea | Allowed | 10-2020-7021893 | 01/02/2019 | 07/27/2020 | | |
| GW Research Limited | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | Japan | Published | 2020-536981 | 01/02/2019 | 07/02/2020 | | |
| GW Research Limited | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | Israel | Allowed | 275702 | 01/02/2019 | 06/28/2020 | | |
| GW Research Limited | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | Canada | Published | 3,087,122 | 01/02/2019 | 06/26/2020 | | |
| GW Research Limited | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | Australia | Published | 2019205117 | 01/02/2019 | 06/30/2020 | | |
| GW Research Limited | Pharmaceutical compositions comprising cannabinoids | China | Issued | 201980015028.3 | 01/02/2019 | 08/24/2020 | ZL 2019800150283 | 08/08/2023 |
| GW Research Limited | Pharmaceutical compositions containing cannabinoids - PTE | Australia | Issued | 2002231970 | 02/14/2002 | 02/14/2002 | 2002231970 | 11/29/2007 |
| GW Research Limited | Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis | Australia | Issued | 2005251505 | 06/07/2005 | 11/30/2006 | 2005251505 | 07/14/2011 |
| GW Research Limited | PHARMACEUTICAL DRUG | Russian Federation | Issued | 2020125315 | 01/02/2019 | 08/03/2020 | 2795027 | 04/27/2023 |
| GW Research Limited | Pharmaceutical formulations (Sativex product) | United Kingdom | Issued | SPC/G810/049 | 08/14/2003 | 12/13/2010 | SPC/G810/049 | 12/12/2018 |
| GW Research Limited | PLANT EXTRACT OR SYNTHETIC CBD-C6 FOR USE IN THERAPY | United Kingdom | Issued | 2018130.1 | 11/18/2020 | | G82590794 | 07/27/2022 |
| GW Research Limited | Project Nano CBD | Israel | Allowed | 278224 | 04/26/2019 | 10/21/2020 | | |
| GW Research Limited | Project Nano CBD | New Zealand | Pending | 769785 | 04/26/2019 | 11/09/2020 | | |
| GW Research Limited | Release-regulating composition containing cannabinoids | Japan | Issued | 2020-536983 | 01/02/2019 | 07/02/2020 | 7378402 | 11/02/2023 |
| GW Research Limited | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | Republic of Korea | Pending | 10-2023-7042317 | 05/12/2022 | 12/07/2023 | | |
| GW Research Limited | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | New Zealand | Pending | 805558 | 05/12/2022 | 11/14/2023 | | |
| GW Research Limited | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | Mexico | Pending | MX/A/2023/013245 | 05/12/2022 | 11/08/2023 | | |
| GW Research Limited | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | Japan | Pending | 2023-569988 | 05/12/2022 | 11/10/2023 | | |
| GW Research Limited | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | China | Pending | 202280034811.6 | 05/12/2022 | 11/13/2023 | | |
| GW Research Limited | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | Canada | Pending | 3218225 | 05/12/2022 | 11/07/2023 | | |
| GW Research Limited | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | Australia | Pending | 2022275207 | 05/12/2022 | 11/14/2023 | | |
| GW Research Limited | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | PCT | Published | PCT/G82022/051207 | 05/12/2022 | | | |
| GW Research Limited | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Republic of Korea | Pending | 10-2023-7042624 | 05/11/2022 | 12/08/2023 | | |

| | | | | | | | | |
|---------------------|---|----------------|-----------|---------------------|------------|------------|--------------|------------|
| GW Research Limited | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | Australia | Pending | 2022272860 | 05/11/2022 | 11/10/2023 | | |
| GW Research Limited | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | PCT | Published | PCT/GB2022/051200 | 05/11/2022 | | | |
| GW Research Limited | Cannabidiol preparations and its uses | US | Issued | 17/011,715 | 09/03/2020 | 09/03/2020 | 11207292 | 12/28/2021 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DYSKINESIA ASSOCIATED WITH PARKINSON'S DISEASE | US | Published | 17/638,629 | 08/25/2020 | 02/25/2022 | | |
| GW Research Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Japan | Issued | 2015-515588 | 06/10/2013 | 12/05/2014 | 6284525 | 02/08/2018 |
| GW Research Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | Canada | Issued | 2874968 | 06/10/2013 | 11/27/2014 | 2874968 | 02/18/2020 |
| GW Research Limited | SYNERGISTIC THERAPIES OF CANNABIDIOL WITH HYPOTHERMIA FOR NEUROPROTECTION | United Kingdom | Issued | EP13729798.2 | 06/10/2013 | 06/10/2013 | EP2858633 | 07/13/2016 |
| GW Research Limited | TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING | Italy | Issued | 14717843.8 | 04/14/2014 | 04/14/2014 | EP2986289 | 10/31/2018 |
| GW Research Limited | TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING | United Kingdom | Issued | 14717843.8 | 04/14/2014 | 04/14/2014 | EP2986289 | 10/31/2018 |
| GW Research Limited | TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING | France | Issued | 14717843.8 | 04/14/2014 | 04/14/2014 | EP2986289 | 10/31/2018 |
| GW Research Limited | TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING | Spain | Issued | 14717843.8 | 04/14/2014 | 04/14/2014 | EP2986289 | 10/31/2018 |
| GW Research Limited | TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING | Germany | Issued | 14717843.8 | 04/14/2014 | 04/14/2014 | 602014035073 | 10/31/2018 |
| GW Research Limited | THC/CBD Gel Formulation | New Zealand | Published | 765839 | 01/02/2019 | 06/30/2020 | | |
| GW Research Limited | THC/CBD Gel Formulation | United Kingdom | Issued | G91800074.5 | 01/03/2018 | 01/03/2018 | G92572126 | 01/13/2021 |
| GW Research Limited | THC/CBD Gel Formulation | Brazil | Pending | BR 11 2020 013450 3 | 01/02/2019 | 06/30/2020 | | |
| GW Research Limited | THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA | United Kingdom | Issued | 14732614.4 | 06/19/2014 | 06/19/2014 | EP3010498 | 03/04/2020 |
| GW Research Limited | THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA | United Kingdom | Issued | 1406473.7 | 04/10/2014 | 04/10/2014 | G92516335 | 02/08/2017 |
| GW Research Limited | THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA | Spain | Issued | 14732614.4 | 06/19/2014 | 06/19/2014 | EP3010498 | 03/04/2020 |
| GW Research Limited | THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA | Italy | Issued | 14732614.4 | 06/19/2014 | 06/19/2014 | EP3010498 | 03/04/2020 |

| | | | | | | | | |
|---------------------|--|------------------------|-----------|-------------------|------------|------------|-------------------|------------|
| GW Research Limited | THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA | Germany | Issued | 14732614.4 | 06/19/2014 | 06/19/2014 | EP3010498 | 03/04/2020 |
| GW Research Limited | THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA | France | Issued | 14732614.4 | 06/19/2014 | 06/19/2014 | EP3010498 | 03/04/2020 |
| GW Research Limited | TREATING TREMORS IN PATIENTS | PCT | Pending | PCT/EP2023/084007 | 12/01/2023 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF DRAVET SYNDROME | US | Published | 17/631,069 | 07/27/2020 | 01/28/2022 | | |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Sweden | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Netherlands | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Italy | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | 502019000054816 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Iceland | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Ireland | Issued | 05749393.4 | 06/07/2005 | | EP1765314 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Finland | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Germany | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | DE602005055714.8 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Switzerland | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Portugal | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | United Kingdom | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | France | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Spain | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Belgium | Issued | 05749393.4 | 12/05/2006 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Austria | Issued | 05749393.4 | 06/07/2005 | 12/05/2006 | EP1765314 | 05/01/2019 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | South Africa | Issued | 2006/10242 | 06/07/2005 | | 2006/10242 | 05/28/2008 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Japan | Issued | 2007-526537 | 06/07/2005 | 12/07/2006 | 4920588 | 02/10/2012 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | China | Issued | 200580018647.6 | 06/07/2005 | 12/07/2006 | ZL 200580018647.6 | 05/25/2011 |
| GW Research Limited | Treatment of Rheumatoid Arthritis (Sativex) | Canada | Issued | 2568997 | 06/07/2005 | 12/01/2006 | 2568997 | 12/04/2012 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF DRAVET SYNDROME | European Patent Office | Published | 20751249.2 | 07/27/2020 | 02/28/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL AND CLOBAZAM IN THE TREATMENT OF CHILDHOOD-ONSET EPILEPSY SYNDROMES | New Zealand | Pending | 802888 | 02/22/2022 | 08/17/2023 | | |

| | | | | | | | |
|---------------------|---|--------------|-----------|-------------------|------------|------------|----------------------------|
| GW Research Limited | USE OF CANNABIDIOL AND CLOBAZAM IN THE TREATMENT OF CHILDHOOD-ONSET EPILEPSY SYNDROMES | Mexico | Pending | MX/A/2023/009898 | 02/22/2022 | 08/23/2023 | |
| GW Research Limited | USE OF CANNABIDIOL AND CLOBAZAM IN THE TREATMENT OF CHILDHOOD-ONSET EPILEPSY SYNDROMES | Japan | Pending | 2023-551776 | 02/22/2022 | 08/24/2023 | |
| GW Research Limited | USE OF CANNABIDIOL AND CLOBAZAM IN THE TREATMENT OF CHILDHOOD-ONSET EPILEPSY SYNDROMES | Israel | Pending | 305289 | 02/22/2022 | 08/16/2023 | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | US | Published | 16/935,005 | 07/21/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL AND CLOBAZAM IN THE TREATMENT OF CHILDHOOD-ONSET EPILEPSY SYNDROMES | China | Published | 202280017030.6 | 02/22/2022 | 08/24/2023 | |
| GW Research Limited | USE OF CANNABIDIOL AND CLOBAZAM IN THE TREATMENT OF CHILDHOOD-ONSET EPILEPSY SYNDROMES | Canada | Published | 3,209,208 | 02/22/2022 | 08/21/2023 | |
| GW Research Limited | USE OF CANNABIDIOL AND CLOBAZAM IN THE TREATMENT OF CHILDHOOD-ONSET EPILEPSY SYNDROMES | Australia | Pending | 2022227223 | 02/22/2022 | 08/17/2023 | |
| GW Research Limited | USE OF CANNABIDIOL AND CLOBAZAM IN THE TREATMENT OF CHILDHOOD-ONSET EPILEPSY SYNDROMES | PCT | Published | PCT/G82022/050476 | 02/22/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL FOR THE INHIBITION OF BRAIN TUMOUR CELL MIGRATION | Italy | Issued | EP05788521.2 | 09/30/2005 | | 502008901684809 09/17/2008 |
| GW Research Limited | USE OF CANNABIDIOL FOR THE TREATMENT OF FOCAL SEIZURES IN DRAVET SYNDROME | Hong Kong | Published | 42022061853.2 | 06/16/2016 | 10/10/2022 | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | US | Published | 17/627,946 | 07/17/2020 | 01/18/2022 | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINE IN THE TREATMENT OF EPILEPSY | Mexico | Pending | MX/A/2020/003934 | 10/01/2018 | 07/13/2020 | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINS IN THE TREATMENT OF EPILEPSY | South Africa | Pending | 2020/02365 | 10/01/2018 | 05/04/2020 | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINS IN THE TREATMENT OF EPILEPSY | Canada | Pending | 3,076,995 | 10/01/2018 | 03/25/2020 | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINS IN THE TREATMENT OF EPILEPSY | New Zealand | Pending | 763135 | 10/01/2018 | 03/31/2020 | |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|------------------|------------|------------|------------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINS IN THE TREATMENT OF EPILEPSY | Republic of Korea | Pending | 10-2020-7011141 | 10/01/2018 | 04/17/2020 | | |
| GW Research Limited | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | European Patent Office | Issued | 20751200.5 | 07/17/2020 | 01/26/2022 | 3999042 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINS IN THE TREATMENT OF EPILEPSY | Brazil | Pending | BR112020006105 | 10/01/2018 | 09/15/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINS IN THE TREATMENT OF EPILEPSY | Australia | Published | 2018341091 | 10/01/2018 | 03/31/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH ANTIBIOTICS | United Kingdom | Allowed | 20709307.1 | 03/03/2020 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH ANTIBIOTICS | Switzerland | Allowed | 20709307.1 | 03/03/2020 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH ANTIBIOTICS | Netherlands | Allowed | 20709307.1 | 03/03/2020 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH ANTIBIOTICS | Germany | Allowed | 20709307.1 | 03/03/2020 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH ANTIBIOTICS | France | Allowed | 20709307.1 | 03/03/2020 | | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 16/911,914 | 06/25/2020 | | 10966939 | 04/06/2021 |
| GW Research Limited | Use of cannabinoids in the treatment of epilepsy | US | Issued | 16/893,018 | 06/04/2020 | | 11357741 | 06/14/2022 |
| GW Research Limited | Use of cannabidiol in combination with antibiotics | United Kingdom | Issued | 1903002.2 | 03/06/2019 | 03/06/2019 | G82581987 | 11/17/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN EPILEPSY TREATMENT | Japan | Published | 2023-010188 | 06/17/2015 | 01/26/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Japan | Pending | 2023-179226 | 06/17/2015 | 10/18/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Japan | Allowed | 2022-002833 | 06/17/2015 | 01/12/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Australia | Issued | 2020220135 | 06/17/2015 | 08/20/2020 | 2020220135 | 07/07/2022 |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Mexico | Issued | MX/A/2019/008337 | 06/17/2015 | 07/11/2019 | 393712 | 07/04/2022 |
| GW Research Limited | CANNABINOID FORMULATIONS | European Patent Office | Published | 20731538.3 | 05/28/2020 | 12/02/2021 | | |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|-----------------|------------|------------|-----------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPTIC SPASMS | US | Published | 17/611,824 | 05/15/2020 | 11/16/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPTIC SPASMS | European Patent Office | Published | 20728156.9 | 05/15/2020 | 12/23/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | US | Pending | 17/606,370 | 05/01/2020 | 10/25/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Canada | Issued | 2,952,994 | 06/17/2015 | 12/19/2016 | 2952994 | 03/14/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | Japan | Issued | 2016-573558 | 06/17/2015 | 12/15/2016 | 6654282 | 02/03/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | European Patent Office | Published | 20724924.4 | 05/01/2020 | 12/03/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | United Kingdom | Issued | GB1410771.8 | 06/17/2014 | 06/17/2014 | GB2530001 | 01/16/2019 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF AICARDI SYNDROME | United Kingdom | Issued | 15784112.3 | 10/14/2015 | | EP3206679 | 11/30/2022 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF AICARDI SYNDROME | Switzerland | Issued | 15784112.3 | 10/14/2015 | | EP3206679 | 11/30/2022 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF AICARDI SYNDROME | Netherlands | Issued | 15784112.3 | 10/14/2015 | | EP3206679 | 11/30/2022 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF AICARDI SYNDROME | Germany | Issued | 15784112.3 | 10/14/2015 | | EP3206679 | 11/30/2022 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF AICARDI SYNDROME | France | Issued | 15784112.3 | 10/14/2015 | | EP3206679 | 11/30/2022 |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH ANTIBIOTICS | US | Published | 17/435,892 | 03/03/2020 | 09/02/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF ANGELMAN SYNDROME | Hong Kong | Published | 62020004785.5 | 03/24/2020 | 03/24/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH ANTIBIOTICS | European Patent Office | Allowed | 20709307.1 | 03/03/2020 | 03/03/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF ANGELMAN SYNDROME | Canada | Pending | 3046442 | 12/13/2017 | 06/07/2019 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF DRAVET SYNDROME | Hong Kong | Published | 62022063974.9 | 07/27/2020 | 11/17/2022 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Published | 17/426,442 | 02/18/2020 | 07/28/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF DRAVET SYNDROME | New Zealand | Published | 784686 | 07/27/2020 | 01/27/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF DRAVET SYNDROME | Republic of Korea | Published | 10-2022-7006462 | 07/27/2020 | 02/24/2022 | | |

| | | | | | | | | |
|---------------------|--|--------------------------|-----------|---------------------|------------|------------|-------|------------|
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | European Patent Office | Published | 20708559.8 | 02/18/2020 | 02/18/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF DRAVET SYNDROME | China | Pending | 202080055259.X | 07/27/2020 | 01/28/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF DRAVET SYNDROME | Brazil | Published | BR 11 2022 001413 9 | 07/27/2020 | 02/08/2022 | | |
| GW Research Limited | Use Of Cannabidiol In The Treatment Of Dravet Syndrome | Australia | Pending | 2020321667 | 07/27/2020 | 01/27/2022 | | |
| GW Research Limited | Use Of Cannabidiol In The Treatment Of Dravet Syndrome | PCT | Published | PCT/GB2020/051803 | 07/27/2020 | 07/27/2020 | | |
| GW Research Limited | Use Of Cannabidiol In The Treatment Of Dravet Syndrome | Mexico | Pending | MX/A/2022/001337 | 07/27/2020 | 01/28/2022 | | |
| GW Research Limited | Use Of Cannabidiol In The Treatment Of Dravet Syndrome | Lebanon | Issued | 11977 | 07/28/2020 | 07/28/2020 | 11977 | 12/14/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF DRAVET SYNDROME | Japan | Pending | 2022-506241 | 07/27/2020 | 01/28/2022 | | |
| GW Research Limited | Use Of Cannabidiol In The Treatment Of Dravet Syndrome | Israel | Pending | 289975 | 07/27/2020 | 01/19/2022 | | |
| GW Research Limited | Use Of Cannabidiol In The Treatment Of Dravet Syndrome | Gulf Cooperation Council | Pending | 2020/40191 | 07/28/2020 | 07/28/2020 | | |
| GW Research Limited | Use Of Cannabidiol In The Treatment Of Dravet Syndrome | Canada | Pending | 3145369 | 07/27/2020 | 01/24/2022 | | |
| GW Research Limited | Use Of Cannabidiol In The Treatment Of Dravet Syndrome | Venezuela | Pending | 2020-000114 | 07/29/2020 | 07/29/2020 | | |
| GW Research Limited | Use Of Cannabidiol In The Treatment Of Dravet Syndrome | Taiwan | Published | 109125384 | 07/28/2020 | | | |
| GW Research Limited | Use Of Cannabidiol In The Treatment Of Dravet Syndrome | Paraguay | Pending | 2040196 | 07/29/2020 | 07/29/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Canada | Pending | 3,181,694 | 06/16/2021 | 12/06/2022 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF COMORBIDITIES ASSOCIATED WITH EPILEPSY | US | Published | 17/424,682 | 01/16/2020 | 07/21/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Republic of Korea | Pending | 10-2022-7044124 | 06/16/2021 | 12/15/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | New Zealand | Pending | 793816 | 06/16/2021 | 10/26/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Mexico | Pending | MX/A/2022/016038 | 06/16/2021 | 12/13/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Japan | Published | 2022-578719 | 06/16/2021 | 06/15/2023 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF COMORBIDITIES ASSOCIATED WITH EPILEPSY | European Patent Office | Published | 20701845.8 | 01/16/2020 | 01/16/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | China | Published | 202180042463.2 | 06/16/2021 | 12/13/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Australia | Pending | 2021291128 | 06/16/2021 | 10/26/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | PCT | Published | PCT/GB2022/051961 | 07/27/2022 | | | |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|-------------------|------------|------------|------------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | PCT | Published | PCT/G82021/051520 | 06/16/2021 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Mexico | Issued | MX/A/2020/003182 | 06/17/2015 | 03/20/2020 | 391834 | 04/25/2022 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Japan | Issued | 2021-120246 | 06/17/2015 | 07/21/2021 | 7238037 | 03/03/2023 |
| GW Research Limited | Use of cannabidiol in the treatment of epilepsy | Japan | Issued | 2016-573518 | 06/17/2015 | 12/15/2016 | 6655850 | 02/06/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | United Kingdom | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | EP3157512 | 04/25/2018 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Canada | Issued | 2,952,858 | 06/17/2015 | 12/16/2016 | 2952858 | 10/11/2022 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | European Patent Office | Published | 19816424.6 | 11/28/2019 | 11/28/2019 | | |
| GW Research Limited | USE OF CANNABINOLIDS IN THE TREATMENT OF EPILEPSY | US | Pending | 17/296,076 | 11/28/2019 | 05/21/2021 | | |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | US | Published | 17/296,066 | 11/20/2019 | 05/21/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Japan | Issued | 2020-72217 | 10/14/2015 | 04/14/2020 | 6985449 | 11/29/2021 |
| GW Research Limited | CANNABIDIOL-TYPE CANNABINOID COMPOUND | European Patent Office | Published | 19809598.6 | 11/20/2019 | 11/20/2019 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Turkey | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Ireland | Issued | 15784107.3 | 10/14/2015 | | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Croatia | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | P20201325T | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Hong Kong | Issued | 18101164.8 | 01/25/2018 | 01/25/2018 | HK1241723 | 04/23/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Finland | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Brazil | Published | BR 112017007767 1 | 10/14/2015 | 04/13/2017 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Australia | Issued | 2015332208 | 10/14/2015 | 03/31/2017 | 2015332208 | 06/03/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPTIC SPASMS | New Zealand | Pending | 781837 | 05/15/2020 | 10/29/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPTIC SPASMS | Japan | Pending | 2021-569522 | 05/15/2020 | 11/22/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPTIC SPASMS | Israel | Pending | 288195 | 05/15/2020 | 11/17/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF MENTAL DISORDERS | United Kingdom | Issued | 16766051.3 | 09/08/2016 | 09/08/2016 | EP3346999 | 06/19/2019 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 16/678,961 | 11/08/2019 | | 10709674 | 07/14/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF MENTAL DISORDERS | Italy | Issued | 16766051.3 | 09/08/2016 | 09/08/2016 | EP3346999 | 06/19/2019 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF MENTAL DISORDERS | France | Issued | 16766051.3 | 09/08/2016 | 09/08/2016 | EP3346999 | 06/19/2019 |

| | | | | | | | | |
|---------------------|--|------------------------|-----------|-------------------|------------|------------|-----------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF MENTAL DISORDERS | Spain | Issued | 16766051.3 | 09/08/2016 | 09/08/2016 | EP3346999 | 06/19/2019 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF MENTAL DISORDERS | Germany | Issued | 602016015672.5 | 09/08/2016 | 09/08/2016 | EP3346999 | 06/19/2019 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING | Hong Kong | Pending | 42022050010.2 | 10/14/2015 | 03/15/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING | Turkey | Issued | 15784113.1 | 10/14/2015 | 10/14/2015 | EP3206680 | 04/21/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING | Spain | Issued | 15784113.1 | 10/14/2015 | 10/14/2015 | EP3206680 | 04/21/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING | Netherlands | Issued | 15784113.1 | 10/14/2015 | 10/14/2015 | EP3206680 | 04/21/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING | Italy | Issued | 15784113.1 | 10/14/2015 | 10/14/2015 | EP3206680 | 04/21/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING | Germany | Issued | 60 2015 068 406.0 | 10/14/2015 | 10/14/2015 | EP3206680 | 04/21/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING | France | Issued | 15784113.1 | 10/14/2015 | 10/14/2015 | EP3206680 | 04/21/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING | United Kingdom | Issued | 15784113.1 | 10/14/2015 | 10/14/2015 | EP3206680 | 04/21/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING IN DOOSE SYNDROME | Switzerland | Issued | 15784113.1 | 10/14/2015 | | EP3206680 | 04/21/2021 |
| GW Research Limited | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy | US | Issued | 16/591,702 | 10/03/2019 | 10/03/2019 | 11147776 | 10/19/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CHRNA4 MUTATION | PCT | Published | PCT/EP2021/069884 | 07/15/2021 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH EPILEPSY SYNDROMES | United Kingdom | Published | 2019301.7 | 12/08/2020 | | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 16/570,220 | 09/13/2019 | | 10709673 | 07/14/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH EPILEPSY SYNDROMES IN PATIENTS TAKING BRIVARACETAM | PCT | Published | PCT/G92021/053203 | 12/08/2021 | | | |
| GW Research Limited | CANNABIDIOL PREPARATIONS AND ITS USES | European Patent Office | Published | 19721363.0 | 04/26/2019 | 11/04/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS | United Kingdom | Published | 2011148 | 07/20/2020 | 07/20/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS | PCT | Published | PCT/EP2021/069896 | 07/15/2021 | | | |
| GW Research Limited | HIGH CANNABIDIOL CONTAINING CANNABIS CHEMOTYPES | US | Published | 17/050,956 | 04/26/2019 | 10/27/2020 | | |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|-------------------|------------|------------|------------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH MUTATIONS IN THE SYNGAP1 GENE | PCT | Published | PCT/EP2021/069877 | 07/15/2021 | | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | European Patent Office | Issued | 19702670.1 | 01/22/2019 | 08/06/2020 | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO BRAIN INJURY | PCT | Published | PCT/EP2021/069794 | 07/15/2021 | | | |
| GW Research Limited | MODIFIED RELEASE COMPOSITION COMPRISING A CANNABINOID | US | Published | 16/959,354 | 01/02/2019 | 06/30/2020 | | |
| GW Research Limited | MODIFIED RELEASE COMPOSITION COMPRISING A CANNABINOID | European Patent Office | Published | 19700427.8 | 01/02/2019 | 08/03/2020 | | |
| GW Research Limited | ORAL PHARMACEUTICAL FORMULATION COMPRISING CANNABINOIDS AND POLOXAMER | US | Published | 16/959,357 | 01/02/2019 | 06/30/2020 | | |
| GW Research Limited | ORAL PHARMACEUTICAL FORMULATION COMPRISING CANNABINOIDS AND POLOXAMER | European Patent Office | Published | 19700428.6 | 01/02/2019 | 07/23/2020 | | |
| GW Research Limited | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | US | Issued | 16/959,350 | 01/02/2019 | 06/30/2020 | 11806319 | 11/07/2023 |
| GW Research Limited | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | European Patent Office | Published | 19700426.0 | 01/02/2019 | 08/03/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Published | 16/768,241 | 11/30/2018 | 05/29/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | European Patent Office | Published | 18815319.1 | 11/30/2018 | 05/15/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 16/198,141 | 11/21/2018 | | US10849860 | 12/01/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME | European Patent Office | Published | 18808075.8 | 11/15/2018 | 05/15/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINS IN THE TREATMENT OF EPILEPSY | European Patent Office | Published | 18782178.0 | 10/01/2018 | 04/29/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINS IN THE TREATMENT OF EPILEPSY | US | Issued | 16/651,751 | 10/01/2018 | 03/27/2020 | 11419829 | 08/23/2022 |
| GW Research Limited | COMBINATION OF TETRAHYDROCANNABINOL WITH OLESOXIME FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | European Patent Office | Issued | 18742590.5 | 07/10/2018 | 02/12/2020 | 3651760 | 12/20/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | US | Allowed | 16/629,722 | 07/10/2018 | 01/09/2020 | | |

| | | | | | | | | |
|---------------------|--|------------------------|-----------|-------------------|------------|------------|-----------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | European Patent Office | Issued | 18737374.1 | 06/21/2018 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | PCT | Published | PCT/EP2021/069872 | 07/15/2021 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | PCT | Published | PCT/EP2021/069889 | 07/15/2021 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | PCT | Published | PCT/EP2021/069900 | 07/15/2021 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | PCT | Published | PCT/EP2021/069902 | 07/15/2021 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | PCT | Published | PCT/EP2021/069904 | 07/15/2021 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | PCT | Published | PCT/EP2021/069906 | 07/15/2021 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | PCT | Published | PCT/EP2021/069834 | 07/15/2021 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | United Kingdom | Published | 2011141.5 | 07/20/2020 | 07/20/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | PCT | Published | PCT/EP2021/069867 | 07/15/2021 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RETT SYNDROME | PCT | Published | PCT/EP2021/069870 | 07/15/2021 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF STURGE WEBER SYNDROME | United Kingdom | Issued | G81605448.8 | 03/31/2016 | 03/31/2016 | G82548873 | 12/02/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF THE TUBEROUS SCLEROSIS COMPLEX | Argentina | Published | 20200101225 | 04/30/2020 | 04/30/2020 | | |

| | | | | | | | |
|---------------------|---|----------------|--------|------------|------------|----------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | United Kingdom | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Norway | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Netherlands | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Switzerland | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Sweden | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Spain | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Luxembourg | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Italy | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Ireland | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Germany | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | France | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Finland | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Denmark | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Belgium | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Austria | Issued | 18737374.1 | 06/21/2018 | 3641819 | 10/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | US | Issued | 15/948,412 | 04/09/2018 | 10603288 | 03/31/2020 |

| | | | | | | | | |
|---------------------|---|--------------------------|-----------|-------------------|------------|------------|-----------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Serbia | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | North Macedonia | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | New Zealand | Published | 781375 | 05/01/2020 | 10/18/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Mexico | Pending | MX/A/2021/013285 | 05/01/2020 | 10/28/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Republic of Korea | Published | 10-2021-7039505 | 05/01/2020 | 12/01/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Japan | Pending | 2021-565086 | 05/01/2020 | 11/02/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Israel | Pending | 287704 | 05/01/2020 | 10/31/2021 | | |
| GW Research Limited | COMBINATION OF CANNABINOIDS IN THE TREATMENT OF LEUKAEMIA | US | Issued | 16/488,821 | 02/16/2018 | 08/26/2019 | 11000486 | 05/11/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | China | Published | 2020800330147 | 05/01/2020 | 11/02/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Canada | Pending | 3136274 | 05/01/2020 | 10/06/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Australia | Pending | 2020267908 | 05/01/2020 | 10/18/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | PCT | Published | PCT/GB2020/051080 | 05/01/2020 | 05/01/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Paraguay | Published | 2018655 | 05/06/2020 | | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Lebanon | Issued | 1132 | 04/28/2020 | 04/28/2020 | 11906 | 04/30/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Gulf Cooperation Council | Pending | 2020/39667 | 05/01/2020 | 05/01/2020 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Japan | Issued | 2019-571439 | 06/21/2018 | 12/20/2019 | 7383488 | 11/10/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Israel | Pending | 271492 | 06/21/2018 | 12/17/2019 | | |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|---------------------|------------|------------|------------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | New Zealand | Pending | 759615 | 06/21/2018 | 11/27/2019 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Hong Kong | Published | 62020018338.7 | 10/19/2020 | 10/19/2020 | | |
| GW Research Limited | COMBINATION OF CANNABINOID IN THE TREATMENT OF LEUKAEMIA | European Patent Office | Issued | 18706846.5 | 02/16/2018 | 08/15/2019 | 3585368 | 02/08/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Canada | Published | 3065449 | 06/21/2018 | 11/28/2019 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Brazil | Pending | BR 11 2019 027454 5 | 06/21/2018 | 12/31/2019 | | |
| GW Research Limited | Use of cannabidiol in the treatment of Tuberous Sclerosis complex | Australia | Issued | 2018288021 | 06/21/2018 | 11/27/2019 | 2018288021 | 01/04/2024 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Mexico | Issued | MX/A/2020/006954 | 10/14/2015 | 06/30/2020 | 395380 | 09/06/2022 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | San Marino | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Slovakia | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Slovenia | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Sweden | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Romania | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Portugal | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Poland | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Norway | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Netherlands | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Malta | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |

| | | | | | | | | |
|---------------------|---|----------------|--------|------------|------------|------------|-----------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Monaco | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Latvia | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Luxembourg | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Lithuania | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Italy | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Iceland | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Israel | Issued | 283086 | 10/14/2015 | 05/10/2021 | 283086 | 10/02/2022 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Hungary | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Greece | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | United Kingdom | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | France | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Spain | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Estonia | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Denmark | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Germany | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Czechia | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Cyprus | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|-------------------|------------|------------|----------------|------------|
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Switzerland | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Canada | Issued | 2,963,202 | 10/14/2015 | 03/30/2017 | 2963202 | 04/11/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Bulgaria | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Belgium | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Austria | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Albania | Issued | 15784107.3 | 10/14/2015 | 10/14/2015 | EP3206715 | 05/27/2020 |
| GW Research Limited | LEUKAEMIA | US | Published | 17/231,625 | 02/16/2018 | 04/15/2021 | | |
| GW Research Limited | USE OF CANNABIDIOL PREPARATIONS IN THE TREATMENT OF FRAGILE X SYNDROME | PCT | Published | PCT/G92020/052696 | 10/23/2020 | 10/23/2020 | | |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | US | Issued | 16/486,750 | 02/15/2018 | 08/16/2019 | 11426362 | 08/30/2022 |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | European Patent Office | Issued | 18706562.8 | 02/15/2018 | 06/26/2019 | 3582750 | 07/26/2023 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Netherlands | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Ireland | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Spain | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Denmark | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Germany | Issued | 60 2017 043 797.2 | 04/11/2017 | 04/11/2017 | 602017043797.2 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Czechia | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|------------|------------|------------|-----------|------------|
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Switzerland | Issued | 17718582.4 | 04/11/2017 | | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Belgium | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Austria | Issued | 17718582.4 | 04/11/2017 | | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF ANGELMAN SYNDROME | European Patent Office | Published | 17817833.1 | 12/13/2017 | 07/16/2019 | | |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | New Zealand | Issued | 748016 | 04/11/2017 | 11/05/2018 | 748016 | 08/01/2023 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | United Kingdom | Issued | 17718582.4 | 04/11/2017 | 10/26/2021 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Turkey | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Sweden | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Norway | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Luxembourg | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Italy | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | France | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Finland | Issued | 17718582.4 | 04/11/2017 | 04/11/2017 | EP3442513 | 08/11/2021 |

| | | | | | | | | |
|---------------------|---|-----------------|-----------|------------|------------|------------|----------------|------------|
| GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome | US | Issued | 16/467,639 | 12/13/2017 | 06/07/2019 | 11679087 | 06/20/2023 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Canada | Published | 3,020,528 | 04/11/2017 | 10/10/2018 | | |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | Australia | Issued | 2017251607 | 04/11/2017 | 11/08/2018 | 2017251607 | 06/08/2023 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | United Kingdom | Issued | 20182674.0 | 07/29/2016 | | 3769755 | 05/24/2023 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Switzerland | Issued | 20182674.0 | 07/29/2016 | | 3769755 | 05/24/2023 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Netherlands | Issued | 20182674.0 | 07/29/2016 | | 3769755 | 05/24/2023 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Germany | Issued | 20182674.0 | 07/29/2016 | | 602016079664.3 | 05/24/2023 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | France | Issued | 20182674.0 | 07/29/2016 | | 3769755 | 05/24/2023 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Serbia | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | North Macedonia | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Ireland | Issued | 16747593.8 | 07/29/2016 | | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | United Kingdom | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Turkey | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Switzerland | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Sweden | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Spain | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Slovenia | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Slovakia | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | San Marino | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Romania | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Portugal | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Poland | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Norway | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |

| | | | | | | | | |
|---------------------|---|----------------|---------|-------------|------------|------------|-----------|------------|
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Netherlands | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Monaco | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Malta | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Luxembourg | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Lithuania | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Latvia | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Italy | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Iceland | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Hungary | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Greece | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Germany | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | France | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Finland | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Estonia | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Denmark | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Czechia | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Cyprus | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Croatia | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Bulgaria | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Belgium | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Austria | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | Albania | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABIDIOLS IN THE TREATMENT OF EPILEPSY | Australia | Pending | 2022209295 | 06/17/2015 | 07/28/2022 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF MULTIPLE MYELOMA | US | Issued | 16/328,209 | 07/31/2017 | 02/25/2019 | 11065227 | 07/20/2021 |
| GW Research Limited | Use of cannabidiol in the treatment of autism spectrum disorder | United Kingdom | Issued | GB1606098.0 | 04/11/2016 | 04/11/2016 | GB2549278 | 02/17/2021 |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|-------------------|------------|------------|------------|------------|
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA | Netherlands | Issued | 17718580.8 | 04/11/2017 | 04/11/2017 | EP3442581 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA | Italy | Issued | 17718580.8 | 04/11/2017 | 04/11/2017 | EP3442581 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA | United Kingdom | Issued | 17718580.8 | 04/11/2017 | 04/11/2017 | EP3442581 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA | France | Issued | 17718580.8 | 04/11/2017 | | EP3442581 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA | Spain | Issued | 17718580.8 | 04/11/2017 | 04/11/2017 | EP3442581 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA | Germany | Issued | 60 2017043796.4 | 04/11/2017 | 04/11/2017 | EP3442581 | 08/11/2021 |
| GW Research Limited | CANNABINOID FORMULATIONS | European Patent Office | Published | 17737028.5 | 06/30/2017 | 06/30/2017 | | |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA | New Zealand | Issued | 748021 | 04/11/2017 | 11/05/2018 | 748021 | 08/01/2023 |
| GW Research Limited | CANNABINOID FORMULATIONS | US | Published | 15/640,033 | 06/30/2017 | | | |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA | Canada | Published | 3,020,500 | 04/11/2017 | 10/10/2018 | | |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA | Australia | Issued | 2017251604 | 04/11/2017 | 11/08/2018 | 2017251604 | 05/18/2023 |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SCHIZOPHRENIA | Hong Kong | Published | 42022060718.8 | 04/11/2017 | 09/20/2022 | | |
| GW Research Limited | Oral Cannabinoid Formulations | US | Issued | 16/314,569 | 06/29/2017 | 12/31/2018 | 11291631 | 04/05/2022 |
| GW Research Limited | ORAL CANNABINOID FORMULATIONS | European Patent Office | Issued | 17737351.1 | 06/29/2017 | 02/01/2019 | 3478267 | 03/29/2023 |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CANINE EPILEPSY | PCT | Published | PCT/G92022/050221 | 01/27/2022 | | | |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | Republic of Korea | Pending | 10-2023-7012089 | 09/08/2021 | 04/07/2023 | | |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|-------------------|------------|------------|-----------|------------|
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | New Zealand | Pending | 797525 | 09/08/2021 | 02/23/2023 | | |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | Mexico | Pending | MX/A/2023/002837 | 09/08/2021 | 03/08/2023 | | |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | Japan | Pending | 2023-515815 | 09/08/2021 | 03/09/2023 | | |
| GW Research Limited | Parenteral Formulations | US | Issued | 16/314,583 | 06/29/2017 | 12/31/2018 | 11229612 | 01/25/2022 |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | China | Published | 2021800623049 | 09/08/2021 | 03/10/2023 | | |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | Canada | Pending | 3,191,266 | 09/08/2021 | 02/28/2023 | | |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | Australia | Pending | 2021341452 | 09/08/2021 | 02/23/2023 | | |
| GW Research Limited | Parenteral Formulations | European Patent Office | Published | 17736733.1 | 06/29/2017 | 06/29/2017 | | |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | PCT | Published | PCT/EP2021/074661 | 09/08/2021 | 09/08/2021 | | |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | US | Issued | 16/092,560 | 04/11/2017 | 10/10/2018 | 10898462 | 01/26/2021 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | United Kingdom | Issued | 1711190.7 | 07/12/2017 | 07/12/2017 | GB2564459 | 03/09/2022 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME | Australia | Published | 2023251394 | 12/13/2017 | 10/16/2023 | | |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS | European Patent Office | Issued | 17718582.4 | 04/11/2017 | 11/12/2018 | EP3442513 | 08/11/2021 |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF SCHIZOPHRENIA | European Patent Office | Published | 21190540.1 | 04/11/2017 | 08/10/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME | New Zealand | Pending | 754352 | 12/13/2017 | 06/07/2019 | | |

| | | | | | | | | |
|---------------------|--|-----------------|--------|--------------|------------|------------|------------|------------|
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME | Australia | Issued | 2017374777 | 12/13/2017 | 06/07/2019 | 2017374777 | 11/09/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Serbia | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | North Macedonia | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Ireland | Issued | EP15784111.5 | 10/14/2015 | | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | United Kingdom | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Turkey | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Switzerland | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Sweden | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Spain | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Slovenia | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Slovakia | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | San Marino | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Romania | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Portugal | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Poland | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Norway | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Netherlands | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |

| | | | | | | | | |
|---------------------|--|------------|--------|--------------|------------|------------|-----------|------------|
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Monaco | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Malta | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Luxembourg | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Lithuania | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Latvia | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Italy | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Iceland | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Hungary | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Greece | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Germany | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | France | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Finland | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA | US | Issued | 16/092,374 | 04/11/2017 | 10/09/2018 | 11752111 | 09/12/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Estonia | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Denmark | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Czechia | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |

| | | | | | | | | |
|---------------------|--|------------------------|-----------|-----------------|------------|------------|------------|------------|
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Cyprus | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Croatia | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | P20201230T | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Bulgaria | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Belgium | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Austria | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | Albania | Issued | EP15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF COMORBIDITIES ASSOCIATED WITH EPILEPSY | Canada | Published | 3125711 | 01/16/2020 | 07/05/2021 | | |
| GW Research Limited | USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA | European Patent Office | Issued | 17718580.8 | 04/11/2017 | 11/12/2018 | EP3442581 | 08/11/2021 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF COMORBIDITIES ASSOCIATED WITH EPILEPSY | New Zealand | Published | 777770 | 01/16/2020 | 07/14/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF COMORBIDITIES ASSOCIATED WITH EPILEPSY | Republic of Korea | Pending | 10-2021-7025106 | 01/16/2020 | 08/06/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF COMORBIDITIES ASSOCIATED WITH EPILEPSY | Japan | Pending | 2021-542170 | 01/16/2020 | 07/20/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF COMORBIDITIES ASSOCIATED WITH EPILEPSY | Israel | Pending | 284758 | 01/16/2020 | 07/11/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF COMORBIDITIES ASSOCIATED WITH EPILEPSY | Brazil | Pending | BR1120210134654 | 01/16/2020 | 07/20/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF STURGE WEBER SYNDROME | European Patent Office | Published | 17715974.6 | 03/28/2017 | 03/28/2017 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | Japan | Issued | 2017-520535 | 10/14/2015 | 04/13/2017 | 6655076 | 02/04/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | Italy | Issued | 15784121.4 | 10/14/2015 | 10/14/2015 | EP3206681 | 04/10/2019 |

| | | | | | | | | |
|---------------------|---|----------------|---------|------------|------------|------------|------------|------------|
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | United Kingdom | Issued | 15784121.4 | 10/14/2015 | 10/14/2015 | EP3206681 | 04/10/2019 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | France | Issued | 15784121.4 | 10/14/2015 | 10/14/2015 | EP3206681 | 04/10/2019 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | Spain | Issued | 15784121.4 | 10/14/2015 | 10/14/2015 | EP3206681 | 04/10/2019 |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | US | Issued | 15/449,185 | 03/03/2017 | | 9949937 | 04/24/2018 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | Germany | Issued | 15784121.4 | 10/14/2015 | 10/14/2015 | EP3206681 | 04/10/2019 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | Canada | Issued | 2963211 | 10/14/2015 | 03/30/2017 | 2963211 | 09/05/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | Australia | Issued | 2015332220 | 10/14/2015 | 03/31/2017 | 2015332220 | 01/14/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | US | Issued | 15/449,124 | 03/03/2017 | | 9956184 | 05/01/2018 |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | US | Issued | 15/449,084 | 03/03/2017 | | 9956183 | 05/01/2018 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Australia | Pending | 2023258400 | 10/14/2015 | 11/02/2023 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | United Kingdom | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Switzerland | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Sweden | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Spain | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Norway | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Netherlands | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Luxembourg | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Italy | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Ireland | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |

| | | | | | | | | |
|---------------------|---|-------------------|-----------|------------------|------------|------------|-----------|------------|
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Germany | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | France | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Finland | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Denmark | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Belgium | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Austria | Issued | 19702670.1 | 01/22/2019 | | EP3743053 | 11/29/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Mexico | Pending | MX/A/2023/012352 | 11/15/2018 | 10/18/2023 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | US | Issued | 15/449,177 | 03/03/2017 | | 9956185 | 05/01/2018 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Mexico | Pending | MX/A/2023/003337 | 10/14/2015 | 03/22/2023 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 15/449,535 | 03/03/2017 | | 10137095 | 11/27/2018 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 15/449,402 | 03/03/2017 | | 10092525 | 10/09/2018 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Mexico | Pending | MX/A/2022/015027 | 06/16/2016 | 11/28/2022 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Israel | Pending | 296865 | 10/14/2015 | 09/28/2022 | | |
| GW Research Limited | Use of cannabinoids in the treatment of epilepsy | US | Issued | 15/449,204 | 03/03/2017 | | 9956186 | 05/01/2018 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Canada | Pending | 3,157,008 | 06/17/2015 | 04/29/2022 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Hong Kong | Published | 62022053982.4 | 02/18/2020 | 05/24/2022 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Taiwan | Published | 110134745 | 09/17/2021 | | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Paraguay | Pending | 2181479 | 09/17/2021 | 09/17/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Lebanon | Issued | 1944 | 09/02/2021 | 09/02/2021 | 12342 | 10/13/2021 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Taiwan | Published | 110122055 | 06/17/2021 | | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | New Zealand | Published | 778788 | 02/18/2020 | 08/04/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Republic of Korea | Pending | 10-2021-7029033 | 02/18/2020 | 09/09/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Japan | Pending | 2021-549379 | 02/18/2020 | 08/20/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Israel | Pending | 285662 | 02/18/2020 | 08/17/2021 | | |

| | | | | | | | | |
|---------------------|--|-------------------|-----------|---------------------|------------|------------|---------|------------|
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Canada | Pending | 3126615 | 02/18/2020 | 07/13/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Brazil | Pending | BR 11 2021 014985 6 | 02/18/2020 | 08/10/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | New Zealand | Published | 776600 | 11/28/2019 | 05/27/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Republic of Korea | Pending | 10-2021-7020174 | 11/28/2019 | 06/28/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Japan | Published | 2021-530989 | 11/28/2019 | 05/28/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Canada | Published | 3121230 | 11/28/2019 | 05/27/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Brazil | Published | BR1120210104054 | 11/28/2019 | 06/08/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Israel | Pending | 276217 | 01/22/2019 | 07/22/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Mexico | Issued | MX/A/2020/007784 | 01/22/2019 | 07/22/2020 | 408267 | 11/22/2023 |
| GW Research Limited | Use of cannabinoids in the treatment of epilepsy | Republic of Korea | Pending | 10-2020-7023811 | 01/22/2019 | 08/18/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Japan | Published | 2020-540552 | 01/22/2019 | 07/22/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Hong Kong | Published | 62021029645.0 | 04/21/2021 | 04/21/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | China | Published | 201980010033.5 | 01/22/2019 | 07/24/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Canada | Published | 3089404 | 01/22/2019 | 07/22/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Australia | Pending | 2019211224 | 01/22/2019 | 07/24/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Republic of Korea | Pending | 10-2020-7017717 | 11/30/2018 | 06/18/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | South Africa | Pending | 2020/02964 | 11/30/2018 | 05/20/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | New Zealand | Pending | 764587 | 11/30/2018 | 05/20/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Mexico | Issued | MX/A/2020/005719 | 11/30/2018 | 07/13/2020 | 408268 | 11/22/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Japan | Issued | 2020-529428 | 11/30/2018 | 05/29/2020 | 7256186 | 04/03/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Israel | Pending | 274769 | 11/30/2018 | 05/19/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Hong Kong | Published | 62021027906.8 | 11/30/2018 | 03/23/2021 | | |
| GW Research Limited | Use of cannabinoids in the treatment of epilepsy | US | Issued | 15/284,766 | 10/04/2016 | 10/04/2016 | 9949936 | 04/24/2018 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | China | Published | 201880076141.8 | 11/30/2018 | 05/25/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Canada | Published | 3,083,144 | 11/30/2018 | 05/21/2020 | | |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|---------------------|------------|------------|------------|------------|
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Brazil | Pending | BR112020010161 3 | 11/30/2018 | 10/06/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Australia | Pending | 2018374550 | 11/30/2018 | 05/20/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Republic of Korea | Pending | 10-2020-7015573 | 11/15/2018 | 05/29/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Israel | Pending | 274633 | 11/15/2018 | 05/13/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Hong Kong | Published | 62021026961.4 | 11/15/2018 | 03/10/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Canada | Pending | 3082433 | 11/15/2018 | 05/12/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Brazil | Pending | BR 11 2020 009508.7 | 11/15/2018 | 09/29/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Australia | Pending | 2018366443 | 11/15/2018 | 05/20/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | United Kingdom | Issued | 1718862.4 | 11/15/2017 | 11/15/2017 | 2568471 | 04/13/2022 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Japan | Issued | 2020-517999 | 10/01/2018 | 03/27/2020 | 7359757 | 10/02/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Israel | Pending | 273583 | 10/01/2018 | 03/25/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Hong Kong | Pending | 62020022136.9 | 12/15/2020 | 12/15/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | United Kingdom | Issued | 1816037.4 | 10/01/2018 | 10/01/2018 | 2568809 | 04/27/2022 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Hong Kong | Published | HK19126535.4 | 07/09/2019 | 07/09/2019 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Canada | Issued | 2992802 | 07/29/2016 | 01/17/2018 | 2992802 | 09/19/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF MENTAL DISORDERS | European Patent Office | Issued | 16766051.3 | 09/08/2016 | 09/08/2016 | EP3346999 | 06/19/2019 |
| GW Research Limited | Use of cannabinoids in the treatment of epilepsy | Australia | Allowed | 2021269374 | 06/16/2016 | 11/17/2021 | | |
| GW Research Limited | Use of cannabinoids in the treatment of epilepsy | Australia | Issued | 2016278088 | 06/16/2016 | 12/19/2017 | 2016278088 | 12/02/2021 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Mexico | Issued | MX/A/2021/003331 | 06/16/2016 | 03/19/2021 | 397850 | 11/28/2022 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Japan | Published | 2021-189417 | 06/16/2016 | 11/22/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Canada | Published | 2,989,779 | 06/16/2016 | 12/15/2017 | | |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | European Patent Office | Issued | 20182674.0 | 07/29/2016 | 06/26/2020 | 3769755 | 05/24/2023 |
| GW Research Limited | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | European Patent Office | Issued | 16747593.8 | 07/29/2016 | 07/29/2016 | EP3334422 | 07/01/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 15/751,563 | 07/29/2016 | 02/09/2018 | 11147783 | 10/19/2021 |
| GW Research Limited | USE OF CANNABIDIOL FOR THE TREATMENT OF FOCAL SEIZURES IN DRAVET SYNDROME | European Patent Office | Published | 21203376.5 | 06/16/2016 | 10/19/2021 | | |

| | | | | | | | | |
|---------------------|--|------------------------|-----------|------------------|------------|------------|------------|------------|
| GW Research Limited | Use of cannabinoids in the treatment of epilepsy | US | Issued | 15/183,947 | 06/16/2016 | 06/16/2016 | 10709671 | 07/14/2020 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF AICARDI SYNDROME | European Patent Office | Issued | 15784112.3 | 10/14/2015 | 10/14/2015 | 3206679 | 11/30/2022 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Mexico | Issued | MX/A/2020/006951 | 10/14/2015 | 06/30/2020 | 401171 | 03/23/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Japan | Issued | 2017-520530 | 10/14/2015 | 04/13/2017 | 6656241 | 02/06/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Hong Kong | Published | 42021029621.6 | 04/20/2021 | 04/20/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Hong Kong | Issued | 18101307.6 | 01/26/2018 | 01/26/2018 | 1241740 B | 12/03/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | US | Issued | 15/519,233 | 10/14/2015 | 04/14/2017 | 10765643 | 09/08/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Canada | Published | 2963208 | 10/14/2015 | 03/30/2017 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Australia | Allowed | 2021204353 | 10/14/2015 | 06/25/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Australia | Issued | 2015332212 | 10/14/2015 | 03/31/2017 | 2015332212 | 07/29/2021 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Australia | Published | 2022202119 | 06/17/2015 | 03/29/2022 | | |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING | European Patent Office | Issued | 15784113.1 | 10/14/2015 | 10/14/2015 | EP3206680 | 04/21/2021 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH DOOSE SYNDROME | European Patent Office | Published | 21166413.1 | 10/14/2015 | 03/31/2021 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME | European Patent Office | Issued | 15784111.5 | 10/14/2015 | 10/14/2015 | EP3206716 | 07/29/2020 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | US | Issued | 15/518,297 | 10/14/2015 | 04/11/2017 | US10226433 | 03/12/2019 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES | European Patent Office | Issued | 15784121.4 | 10/14/2015 | 10/14/2015 | EP3206681 | 04/10/2019 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY. | Mexico | Issued | MX/A/2017/016212 | 06/16/2016 | 12/13/2017 | 381089 | 03/31/2021 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS | Canada | Published | 2995927 | 09/08/2016 | 02/16/2018 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS | Australia | Issued | 2016320505 | 09/08/2016 | 02/15/2018 | 2016320505 | 07/14/2022 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | European Patent Office | Published | 20182071.9 | 10/14/2015 | 06/24/2020 | | |
| GW Research Limited | Use of cannabinoids in the treatment of seizures associated with Lennox-Gastaut syndrome | New Zealand | Pending | 805425 | 11/15/2018 | 11/13/2023 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME | Japan | Pending | 2023-170155 | 11/15/2018 | 09/29/2023 | | |

| | | | | | | | | |
|---------------------|---|------------------------|-----------|------------------|------------|------------|------------------|------------|
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME | South Africa | Pending | 2020/02768 | 11/15/2018 | 05/14/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME | New Zealand | Published | 764569 | 11/15/2018 | 05/20/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME | Mexico | Issued | MX/A/2020/005147 | 11/15/2018 | 05/15/2020 | 407298 | 10/19/2023 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME | Japan | Issued | 2020-526576 | 11/15/2018 | 05/14/2020 | 7391019 | 11/24/2023 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | US | Issued | 14/881,954 | 10/13/2015 | | 10918608 | 02/16/2021 |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME | China | Published | 201880080175.4 | 11/15/2018 | 06/11/2020 | | |
| GW Research Limited | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | US | Issued | 14/881,969 | 10/13/2015 | | 10111840 | 10/30/2018 |
| GW Research Limited | Use of combination of cannabidiol and 5-HT2B receptor agonist amphetamine for treating epilepsy | China | Issued | 201880063826.9 | 10/01/2018 | 03/30/2020 | ZL201880063826.9 | 11/22/2022 |
| GW Research Limited | USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER | Italy | Issued | 14732613.6 | 06/19/2014 | 06/19/2014 | EP3010497 | 04/10/2019 |
| GW Research Limited | USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER | United Kingdom | Issued | 14732613.6 | 06/19/2014 | 06/19/2014 | EP3010497 | 04/10/2019 |
| GW Research Limited | USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER | France | Issued | 14732613.6 | 06/19/2014 | 06/19/2014 | EP3010497 | 04/10/2019 |
| GW Research Limited | USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER | Spain | Issued | 14732613.6 | 06/19/2014 | 06/19/2014 | EP3010497 | 04/10/2019 |
| GW Research Limited | USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER | Germany | Issued | 14732613.6 | 06/19/2014 | 06/19/2014 | EP3010497 | 04/10/2019 |
| GW Research Limited | Use of the cannabinoids in the treatment of an epilepsy | Japan | Issued | 2017-565998 | 06/16/2016 | 12/14/2017 | 6983076 | 11/25/2021 |
| GW Research Limited | Use of the cannabinoids in the treatment of epilepsy | Japan | Issued | 2019-211265 | 06/17/2015 | 11/22/2019 | 7010915 | 01/17/2022 |
| GW Research Limited | NOVEL COMPOUNDS | Australia | Pending | 2022273928 | 05/11/2022 | 10/20/2023 | | |
| GW Research Limited | 7-HYDROXY-CANNABIDIVARIN (7-OH-CBDV) FOR USE IN THE TREATMENT OF EPILEPSY | European Patent Office | Issued | 15733514.2 | 06/29/2015 | 06/29/2015 | EP3160457 | 11/20/2019 |
| GW Research Limited | 7-OH-CBD DIABETES | US | Issued | 15/321,778 | 06/29/2015 | 12/23/2016 | 10039724 | 08/07/2018 |
| GW Research Limited | ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER | US | Issued | 15/321,766 | 06/26/2015 | 12/23/2016 | 9962341 | 05/08/2018 |

| | | | | | | | | |
|---------------------|--|------------------------|-----------|------------|------------|------------|------------|------------|
| GW Research Limited | ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER | European Patent Office | Issued | 15733502.7 | 06/26/2015 | 06/26/2015 | EP3160455 | 05/12/2021 |
| GW Research Limited | ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER | European Patent Office | Published | 21173064.3 | 06/26/2015 | 05/10/2021 | | |
| GW Research Limited | Absence Seizures | US | Issued | 14/741,829 | 06/17/2015 | | 11311498 | 04/26/2022 |
| GW Research Limited | USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY | European Patent Office | Issued | 15732886.5 | 06/17/2015 | 06/17/2015 | 3157511 | 04/25/2018 |
| GW Research Limited | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | European Patent Office | Issued | 15732887.3 | 06/17/2015 | 06/17/2015 | EP3157512 | 04/25/2018 |
| GW Research Limited | Use of cannabinoids in the treatment of epilepsy | US | Issued | 14/741,783 | 06/17/2015 | | 9474726 | 10/25/2016 |
| GW Research Limited | A COMBINATION OF TETRAHYDROCANNABINOL AND CANNABIDIOL FOR USE FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF A BRAIN TUMOUR | European Patent Office | Issued | 14732613.6 | 06/19/2014 | 06/19/2014 | EP3010497 | 04/10/2019 |
| GW Research Limited | COMBINATION OF CBD AND CBG IN THE TREATMENT OF OVARIAN CARCINOMA | European Patent Office | Issued | 14732614.4 | 06/19/2014 | 06/19/2014 | EP3010498 | 03/04/2020 |
| GW Research Limited | THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA | US | Issued | 14/899,613 | 06/19/2014 | 12/18/2015 | US10098867 | 10/16/2018 |
| GW Research Limited | TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING | US | Issued | 14/785,055 | 04/14/2014 | 10/16/2015 | 9675579 | 06/13/2017 |
| GW Research Limited | TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING | European Patent Office | Issued | 14717843.8 | 04/14/2014 | 04/14/2014 | EP2986289 | 10/31/2018 |
| GW Research Limited | Cannabinoid-containing plant extracts as neuroprotective agents | US | Issued | 14/163,019 | 01/24/2014 | 01/24/2014 | 9205063 | 12/08/2015 |
| GW Research Limited | SYNERGISTIC THERAPIES FOR NEUROPROTECTION | US | Issued | 14/405,950 | 06/10/2013 | 12/05/2014 | 10220005 | 03/05/2019 |
| GW Research Limited | Method for the treatment of constipation | US | Issued | 13/093,911 | 04/26/2011 | | 8771760 | 07/08/2014 |
| GW Research Limited | Cannabinoid-containing plant extracts as neuroprotective agents | US | Issued | 12/087,847 | 01/17/2007 | 01/17/2007 | 8673368 | 03/18/2014 |
| GW Research Limited | Pharmaceutical compositions for the treatment of pain | US | Issued | 11/115,983 | 04/27/2005 | 04/27/2005 | 7968594 | 06/28/2011 |

PART 6
INSURANCE POLICIES

| Chargor | Insurer | Policy Number | Type of Risk Insured |
|--|-------------------------------------|--|---|
| Jazz Pharmaceuticals UK Holdings Limited | Travelers Insurance Company Limited | ██████████6181 | Local-Admitted Insurance in UK—General and Employer's Liability |
| Jazz Pharmaceuticals Research UK Limited (formerly GW Research Limited) | Lloyd's of London | ██████████3321 ██████████3179 ██████████2083 ██████████2072 ██████████0047 ██████████0049 ██████████0076 | Clinical Trials |
| Jazz Pharmaceuticals Research UK Limited (formerly GW Research Limited) | Allianz Insurance | ██████████3211 | Clinical Trials |
| GW Pharma Limited | Lloyd's of London | ██████████2042 ██████████2043 ██████████2044 ██████████3078 ██████████3079 | Clinical Trials |

PART 7

INTRA-GROUP RECEIVABLES

None at the date of this Deed.

PART 8

TRADE RECEIVABLES

None at the date of this Deed.

SIGNATORIES

The Chargors

EXECUTED as a **DEED** by)
JAZZ PHARMACEUTICALS UK)
HOLDINGS LIMITED)
acting by)

By:

Name:

Title:

By:

Name: Luca Giacomo Marchetti

Title: Director

SIGNATORIES

The Chargors

EXECUTED as a DEED by)
JAZZ PHARMACEUTICALS UK)
HOLDINGS LIMITED)
acting by)

By:

Name:

Title:

By: 

Name: AISLINN DOODY

Title: company secretary

EXECUTED as a **DEED** by)
GW PHARMACEUTICALS LIMITED)
acting by)
)

By: ...

Name: Nelly Armissoglio Lepelletier

Title: Director

By:

Name:

Title:

EXECUTED as a DEED by)
GW PHARMACEUTICALS LIMITED)
acting by)
)

By:

Name:

Title:

By:



Name: AISLIN DOODY

Title: company secretary


EXECUTED as a DEED by)
GW GLOBAL SERVICES)
(INTERNATIONAL) LIMITED)
acting by)

By: 

Name: AISLINN DOODY

Title: Director

in the presence of:

Witness's signature: 

Name: AILISH HAMILL

Address: 

EXECUTED as a **DEED** by)
JAZZ PHARMACEUTICALS RESEARCH)
UK LIMITED)
acting by)

By:

Name:

Title:

By



Name: Luca Giacomo Marchetti

Title: Director

EXECUTED as a DEED by)
JAZZ PHARMACEUTICALS RESEARCH)
UK LIMITED)
acting by)

By:

Name:

Title:

By:



Name: AISLINN DOODY

Title: company secretary

EXECUTED as a **DEED** by)
GW PHARMA LIMITED)
acting by)
)

By:

Name:

Title:

By:



Name: Luca Giacomo Marchetti

Title: Director

EXECUTED as a DEED by)
GW PHARMA LIMITED)
acting by)
)

By:

Name:


Title:

By: 

Name: AISLINN DOODY

Title: company secretary

EXECUTED as a DEED by)
GW UK SERVICES LIMITED)
acting by)
)

By: 

Name: AISLINN DOODY
Title: COMPANY SECRETARY

By:

Name:

Title:

EXECUTED as a DEED by
GW UK SERVICES LIMITED
acting by

)
)
)
)

By:

Name:

Title:

By: ..

Name: David Spackman

Title: Director

Collateral Trustee

**U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS
SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION**



Name: Christopher J. Grell

Title: Vice President